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3Abstract
The assembly of enveloped viruses requires the correct trafficking of the viral 
envelope or membrane proteins to the site of virus assembly. To understand 
the molecular and cellular mechanisms in human immunodeficiency virus 
envelope protein (Env) trafficking, I analysed the activities of putative 
endocytosis signals in the cytoplasmic domain of Env. Morphological and 
biochemical analysis of HxB2 Env as well as CD4-Env chimeras revealed two 
functional endocytosis motifs, the membrane proximal GY712xx0  motif and the 
C-terminal dileucine motif. Both of these motifs work with equivalent efficiency 
and show no obvious additive effect. RNAi knock down experiments show that 
endocytosis mediated by both signals is at least partly dependent on the 
clathrin pathway and the clathrin adaptor AP-2.
Motifs of the Yxx0 type have been implicated in transport to the late 
endosome and HIV has been reported to assemble on membranes of this 
compartment. I studied the intracellular itineraries of HIV Env and found clear 
evidence of trafficking through early endosomes. However, no obvious 
colocalisation with CD63 or LAMP-1 was observed. Further analysis 
suggested that Env is transported to an endosomal compartment positive for 
the tetraspanin CD81, a compartment that has recently been recognised as 
the site of HIV assembly in macrophages. Env was targeted to this 
compartment independently of other viral components in HeLa cells as well as 
in macrophages.
In order to identify other cellular components interacting with Env and the 
machinery responsible for Env incorporation into virions I performed yeasty- 
hybrid assays. I found that Vps37B, a component of ESCRT-I, which is 
required for HIV assembly, can interact with both HIV and SIV Env cytoplasmic 
tails, and that the ubiquitin E3-ligase WWP2 binds SIV Env. These findings 
may enable us to establish a molecular mechanism for the incorporation of 
Env into budding HIV particles.
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1. Introduction
Despite more than 20 years of research into the pathogenesis of human 
immunodeficiency virus-1 (HIV-1) infection, many aspects of the biology of this 
virus are still poorly understood. HIV-1 targets cells of the human immune 
system, subverts their functions for efficient virus replication and the creation 
of viral reservoirs and ultimately kills them. HIV envelope glycoproteins (Env) 
are crucial for the infection process as they are required for binding to 
receptors on the host cell and fusion of the viral membrane with the host cell 
membrane. It is therefore essential that Env is incorporated into new virus 
particles during virus assembly. However, little is known about this process. In 
T cells, HIV assembly predominantly occurs at the plasma membrane (Barre- 
Sinoussi et al. 1983; Gallo et al. 1984); it has been suggested that Env can 
direct HIV assembly to certain sites in the host cell plasma membrane and 
amino acid motifs responsible for polarised Env targeting have been 
discovered (Owens et al. 1991; LaBranche et al. 1995; Rowell et al. 1995; 
Sauter et al. 1996; Lodge et al. 1997). But at steady state little Env is found at 
the plasma membrane, because it is rapidly internalised (LaBranche et al. 
1995; Rowell et al. 1995; Bowers et al. 2000; Wyss et al. 2001). Another 
puzzle is presented by the finding that in macrophages, which are also a major 
target for HIV infection, virus assembly occurs almost exclusively on 
intracellular membranes (Gendelman et al. 1988; Orenstein et al. 1988; 
Raposo et al. 2002; Pelchen-Matthews et al. 2003), but it is not known how 
Env is targeted to this compartment. The work described in this thesis aims to 
identify intracellular trafficking routes taken by HIV Env and examines the 
cellular machinery and amino acid sequences in Env required for targeting, in 
order to understand how Env is brought to the site of virus assembly. The 
second part, investigating Env interacting proteins, should provide insights into 
potential mechanisms for Env incorporation into budding virions. This 
introduction will give a general overview of HIV (sections 1.1 and 1.2). 
Subsequently, Env and Env trafficking will be discussed in detail (sections 1.3. 
and 1.4) and the machinery for retrovirus assembly described (section 1.5).
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1.1 Human immunodeficiency virus
1.1.1. Phylogeny and taxonomy of primate immunodeficiency viruses
The human immunodeficiency viruses (HIV-1 and -2) and the simian 
immunodeficiency virus (SIV) are members of the genus Lentiviridae, which is 
one of seven genera currently known in the family of the Retroviridae (Table 
1.1). Apart from HIV and SIV, this genus also includes some non-primate 
viruses like the ovine Visna/maedi virus (VISNA), equine infectious anaemia 
virus (EIAV), feline immunodeficiency virus (FIV) and caprine arthritis 
encephalitis virus (CAEV). Retroviruses are characterised by their unique life 
cycle, differentiating them sharply from other viruses. The viral particles 
contain genomic RNA, which upon entry into the host cell is reverse 
transcribed into DNA that can be integrated into the host cell genome. The 
integrated viral DNA, the provirus, serves as a template for the formation of 
viral RNAs and proteins that assemble progeny virions. These features allow 
the viruses to maintain a persistent infection evading host immune responses 
(summarised in Freed and Martin 2001).
To date two types of HIV are known, HIV-1 and HIV-2 (Barre-Sinoussi et al. 
1983; Clavel et al. 1986). Both types evolved in humans after zoonotic 
transmission of SIV, albeit from different simian species. HIV-1 is most closely 
related to chimpanzee Pan troglodytes troglodytes-derived viruses, while HIV- 
2 has originated from sooty mangabeys (Gao et al. 1999). HIV-2 appears to be 
immunologically distinct and less pathogenic than HIV-1, and it was primarily 
recovered from individuals residing in west African countries (Clavel et al. 
1986).
Based on sequence variations, genetic subtypes or clades of HIV-1 were 
defined and classified into three groups designated M (major), O (outlier) and 
N (new or non-M/non-O). The M group includes more than over 95% of the 
global virus isolates and has been further subdivided into nine discrete clades 
(A, B, C, D, F, G, H, J and K). It has become apparent that a significant 
fraction of the group M viruses now include interclade viral recombinants,
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which have arisen through superinfection of the same individual by viruses 
from different clades. An overview of the distribution of different HIV clades 
over different geographical regions can be found in Fields Virology 4th Edition 
(Freed and Martin 2001).
Genus Virus Species
Alpha Avian leucosis virus (ALV) 
Rous sarcoma virus (RSV)
Beta Mason-Pfitzer monekey virus (MPMV) 
Mouse mammary tumor virus (MMTV)
Gamma Feline leukaemia virus (FLV) 
Murine leukaemia virus (MLV)
Delta Primate T-lymphotropic virus-1, -2 (PTLV) 
Human T-lymphotropic virus-1, -2 (HTLV)
Epsilon Walleye dermal sarcoma virus (WDSW)
Walleye epidermal hyperplasia virus type 1, -2 (WEHV-1, -2)
Lentiviruses Equine infectious anemia virus (EIAV) 
Visna/maedi virus (VISNA)
Human immunodeficiency virus-1, -2 (HIV) 
Simian immunodeficiency virus (SIV) 
Caprine arthritis encephalitis virus (CAEV) 
Feline immunodeficiency virus (FIV)
Spumaviruses Simian foamy virus-1 (SFV-1) 
Bovine foamy virus (BFV) 
Chimpanzee foamy virus (CFV)
Table 1.1. The Retrovirus family. The different genera of the retrovirus family and examples 
of their members are shown. Adapted from (Freed and Martin 2001).
1.1.2. Structure and genome
As with all retroviruses, the lentiviruses are enveloped and characterised by 
their cylindrical or conical cores. A mature HIV particle measures 
approximately 145 nm in diameter (Briggs et al. 2003) and contains the 
structural proteins Env, MA, CA and NC (see Figure 1.1.). The viral envelope 
contains two envelope glycoproteins (Env), the transmembrane glycoprotein 
gp41 (TM) and the surface unit glycoprotein gp120 (SU). The TM and SU 
subunits are non-covalently linked to a heterodimer, which is then integrated
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into the viral envelope as a trimer. It is currently believed that one T cell- 
derived HIV virion contains on average 8-10 trimers (Zhu et al. 2003). Apart 
from the viral glycoproteins, the viral envelope can also contain cellular 
transmembrane proteins, which are incorporated into the viral envelope during 
budding. Among these are MHCII and the tetraspanins CD63 and CD81 (Ott 
2002; Pelchen-Matthews et al. 2003). The inner surface of the viral envelope is 
lined by approximately 1250 - 2100 copies of the matrix protein (MA, p17), and 
the conical capsid core, comprising ca. 1250 - 2100 copies of the capsid 
protein (CA, p24) (Briggs et al. 2003), is located in the centre of the virus. 
However, it has been suggested that up to 5000 unprocessed Gag proteins 
can be incorporated into immature virions (Briggs et al. 2004; Benjamin et al. 
2005) and that 5000 MA proteins may be spread over the inner membrane, 
though only 2000 CA are integrated into the viral capsid (Briggs et al. 2006). 
The capsid contains two identical copies of the unspliced viral genomic RNA, 
which is stabilised as a ribonucleoprotein complex with the nucleocapsid 
protein (NC, p7), and also contains three essential virally encoded enzymes, 
protease (PR), reverse transcriptase (RT) and integrase (IN).
viral membrane
Matrix (p17, MA)
RNA genome
Integrase (p19, IN)
,gp120 (SU)
Nucleocapsid (p7, NC]
Reverse transcriptase 
(p66/p51, RT)
Capsid (p24, CA) Protease (p11, PR)
Figure 1.1. Mature HIV-1 particle. Viral proteins, the viral RNA and the viral membrane are 
indicated.
23
The viral genome (see Figure 1.2.) is a single stranded 9.7 kb RNA molecule 
and contains open reading frames (ORFs) for the group associated antigen 
(gag), the polymerase (pol) and envelope (env), which are conserved in all 
retroviruses. In addition HIV contains several overlapping ORFs encoding a 
number of regulatory and accessory proteins, which are the viral infectivity 
factor (Vif), the viral protein R (Vpr), viral protein U (Vpu), the transactivator of 
transcription (Tat), the regulatory viral protein (Rev) and the negative factor 
(Nef). These genes control transcription, RNA processing, virion assembly, 
host gene expression and a number of other replication functions (Cullen and 
Greene 1990). The only genomic difference between HIV-1 and HIV-2 can be 
seen in the accessory proteins, HIV-2 contains viral protein X (Vpx) instead of 
Vpu.
'R ev '
ReV I
CA [p2j NC |pl| p6 vsr I r — * f * |I. J ■  Tat Vpu T 7  BN
PR RT IN Vpr SU TM
Pol Env
Figure 1.2. The HIV genome. Names of the precursor proteins encoded by the different parts 
of the genome are indicated below the boxes and names for the cleaved protein products (or 
in the case of Tat and Rev spliced products) are given within. The LTRs are regulatory 
elements and do not code for proteins. Abbreviations are explained in the text.
The three primary translation products are initially synthesised as polyprotein 
precursors, which are subsequently processed by viral or cellular proteases 
into mature particle-associated proteins. The 55kD Gag precursor (55Gag) is 
cleaved by the viral protease (PR) into the matrix (MA, p17), the capsid (CA, 
p24), the nucleocapsid (NC, p7) and the p6 protein after incorporation of Gag 
into immature virions. CA/NC and NC/p6 are separated in the genome by two 
linker peptides termed p2 and p1, respectively. A frameshift during Gag 
translation leads to the generation of the Gag-Pol precursor (p160), which 
gives rise to the viral enzymes, protease (PR), the reverse transcriptase (RT) 
and the integrase (IN) upon autocatalysis. The third precursor protein Env 
(gp160) is cleaved by a cellular protease into the glycoproteins gp120 and 
gp41 (see chapter 1.3.).
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On both sides of the genome long terminal repeats (LTR) contain a repeat 
region (R) and the unique regions U5 and U3. These regions do not code for 
any proteins.
1.1.3. The HIV life cycle
The HIV replication cycle can be divided into two phases. The early phase 
begins with the recognition of the target cell by a mature virion and involves all 
processes leading to and including integration of the viral genomic DNA into 
the chromosome of the host cell. The late phase begins with the expression of 
the proviral genome and involves the processes up to virus assembly, budding 
and maturation. A schematic depiction of the viral life cycle in T cells can be 
found in Figure 1.3.
Nucleus
CCR5/CXCR4
Virion
RNA
New Viral 
proteins—
Double 
Stranded 
DNA New Virion 
RNA
Figure 1.3. HIV life cycle in T cells. Viral proteins are depicted in dark red, viral DNA in red. 
The viral RNA is shown in green. Steps in the viral life cycle are numbered as follows: 1. 
Binding to cellular receptors; 2. Fusion with host cell membrane; 3. Reverse transcription; 4. 
Nuclear import; 5. Integration into host genome; 6. Transcription; 7. Translation; 8. Assembly; 
9. Budding and maturation.
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1.1.3.1. Early phase of HIV replication
The HIV envelope protein (Env) mediates virus entry into target cells. First, the 
viral gp120 binds to the virus receptor CD4 on the host cell. This causes 
conformational changes in gp120, which lead to the exposure of the 
coreceptor binding sites. Depending on the viral tropism CCR5 or CXCR4 
cellular coreceptors are engaged and fusion pore formation begins (Markosyan 
et al. 2003). A subsequent conformational change in gp41 leads to the 
formation of a six-helix bundle structure completing the fusion process of the 
two membranes and allowing the viral core to enter the target cell (Melikyan et 
al. 2000). Once in the cytoplasm, reverse transcription of the viral RNA to 
cDNA occurs mediated by the viral reverse transcriptase (RT), which also 
possesses RNase H activity to digest the genomic RNA. The reverse 
transcription process is complex and also involves the viral proteins Vif and NC 
(Goff 1990; Katz and Skalka 1994). Once synthesised, HIV cores then may 
use microtubules to transport their genome towards the nucleus (McDonald et 
al. 2002). The viral DNA is transported as a part of a preintegration complex 
that includes the IN, MA, RT and Vpr proteins (Miller et al. 1997). The Vpr 
protein directs nuclear localisation and is also able to interfere with the cell 
cycle and arrest infected cells in the G2 phase. After transport to the nucleus, 
the viral integrase covalently integrates the viral DNA into the host genome. 
Integrated viral DNA can stay in the nucleus of a host cell for a long time 
during the late phase of HIV infection. During the early stages of infection 
retroviruses are particularly vulnerable to cellular restriction factors, so called 
intrinsic immunity. Factors as such are Trim5a, which targets the incoming 
viral capsid, and APOBEC3G, a cytidine deaminase. APOBEC3G acts on 
single DNA strands generated during reverse transcription, changing cytidine 
to uracil that can either be replicated to an A residue and generate a mutation 
during replication, or generate a target site for endonucleases and be 
degraded before insertion into the host genome (Bieniasz 2004; Rose et al. 
2004).
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1.1.3.2. Late phase of HIV replication
The formation of new infectious HIV particles requires the synthesis of viral 
Gag and Env proteins and their transport to the site of viral assembly in the 
cell. For efficient assembly of virions, the proteins are required to colocalise in 
a spatial and temporal manner at this site. Trafficking of these components will 
be discussed in detail in section 1.4.2 and is also subject of chapters 3 and 4 
of this thesis.
The late phase of viral replication is initiated by the synthesis of viral mRNAs, 
which are transported to the cytoplasm for translation. First, short spliced 
RNAs are synthesised, encoding the regulatory proteins Tat, Rev and Nef. Tat 
is needed as a transcriptional activator. Later, the nuclear export of singly 
spliced and full-length mRNAs needed for the synthesis of Gag and Gag-Pol in 
the cytoplasm is mediated by Rev, which acts as a switch between early and 
late mRNA synthesis. The Env precursor polyprotein gp160 is synthesised in 
the rough endoplasmic reticulum (rER) (see chapter 1.3.1. for a detailed 
discussion; reviewed in Turner and Summers 1999).
Membrane enclosed HIV particles are generated in two steps, assembly and 
budding. The key component that drives retrovirus assembly is Gag. Virus-like 
particles (VLPs) can be formed in many cell types when Gag is expressed with 
or without other viral components. Gag has been reported to be targeted 
directly to the plasma membrane and in some cases to associate with 
detergent insoluble microdomains (Lindwasser and Resh 2001; Ono and 
Freed 2001; Suomalainen 2002; Rudner et al. 2005). Although in many cell 
systems e.g. T cells, HIV particles and VLPs bud from the plasma membrane, 
in some cells, e.g. macrophages, the majority of particles assemble on 
membranes of endocytic compartments similar to MVBs (Raposo et al. 2002; 
Pelchen-Matthews et al. 2003). These compartments have been found to 
contain MHC class II molecules (Raposo et al. 2002) and are positive for the 
tetraspanins CD63 and CD81 (Pelchen-Matthews et al. 2003). How exactly 
Gag is targeted to these internal membranes is unclear. One possibility is that 
Gag may interact with AP-2 and be carried from the plasma membrane on
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endocytic vesicles (Batonick et al. 2003). Alternatively, Gag may be targeted 
directly to endosomal membranes. It has recently been shown that Gag can 
directly interact with AP-3 and that this interaction is crucial for Gag targeting 
to late endosomes and particle formation (Dong et al. 2005). Perturbation of 
these endocytic membranes by overexpressing a dominant negative form of 
Vps4, an AAA ATPase involved in ESCRT recycling (see chapter 1.5.1.2.), can 
increase Gag association with endosomal compartments (von Schwedler et al. 
2003), as can modulation of phosphatidyl inositol phosphate distribution (Ono 
et al. 2004).
The HIV-1 Gag protein contains three domains, which are important for viral 
assembly, the membrane targeting (M), interaction (I) and late (L) domains. 
The M domain found in the MA region is myristoylated at its N-terminus and is 
required for membrane association. The I domain is located within NC and is 
required for monomer interaction. The L domain is required for scission of the 
assembled viral particle via interaction with the ESCRT complex (see chapter
1.5.2.2.). After budding, the Gag polyprotein is processed by the viral protease 
(PR) into the structural proteins MA, CA and NC and the p6 domain (reviewed 
in Gomez and Hope 2005).
In the case of budding at the plasma membrane, free virus is thought to be 
released from lipid raft like regions in the plasma membrane directly to the 
extracellular space. Lipid rafts are membrane domains rich in sphingolipids, 
cholesterol and GPI-linked proteins and appear to be important for several 
functions. Disruption of these membrane domains can reduce virus production 
(Nguyen and Hildreth 2000). In the case of intracellular budding in 
macrophages, it has been shown that infectious virus can be released 
efficiently from cells (Pelchen-Matthews et al. 2003). However the mechanism 
of release remains unclear. It has been suggested that HIV may hijack a pre­
existing pathway for exosome exchange, and the mechanism of internal HIV 
assembly bears similarities to exosome formation. In this so-called Trojan 
exosome hypothesis a multivesicular body filled with virus would move to the
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plasma membrane and release its content by membrane fusion (Gould et al. 
2003).
It has also recently become apparent that HIV release from infected cells might 
not be random, and virus can be targeted specifically to sites of cell-cell 
contact in infected T cells. It was further demonstrated that HIV-1 Gag and Env 
are able to accumulate at sites of cell contact, the so-called infectious 
synapse, where controlled virus release occurs (Jolly et al. 2004).
1.2. Viral pathogenesis and AIDS
HIV was discovered to be the cause of the acquired human immunodeficiency 
syndrome (AIDS) (Barre-Sinoussi et al. 1983). To date, the epidemic is most 
severe in Sub-Saharan Africa, but it is also increasingly spreading in Latin 
America and South-East Asia as well as Eastern Europe. In western countries 
the disease was initially found mainly in homosexual men and drug users, but 
it is now equally found in heterosexuals and among different groups of people. 
The AIDS epidemic has resulted in more than 25 million deaths since its 
identification in the early 1980s. Currently, an estimate of 40 million people, 
including 2.3 million children, lives with HIV or AIDS. In 2005 alone, 4.9 million 
people were newly infected and 3.1 million died from AIDS (UNAIDS/WHO  
statistics 2005).
1.2.1. Cellular targets for HIV
The main cellular targets for HIV are cells of the immune system expressing 
the HIV receptor CD4 and its co-receptors: The CD4+ T-helper/inducer subset 
of lymphocytes, responsible for stimulation of the cellular and humoral immune 
response by the secretion of cytokines, and CD4+ cells of the monocyte 
lineage, including macrophages and some subpopulations of dendritic cells 
(DC). Macrophages and DCs are antigen-presenting cells (APC) that can 
activate CD4+ T cells through the presentation of processed antigens on 
MHCII molecules. During antigen presentation APCs come into close contact 
with T cells, possibly facilitating transmission of HIV. Other haematopoietic 
cells have also been reported to be infected with HIV in vivo, such as CD8+ T 
cells (Livingstone et al. 1996; Saha et al. 2001) and natural killer cells (Valentin
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et al. 2002), but the relevance of this infection for pathogenesis is unclear. In 
vitro cell lines can be rendered susceptible for HIV infection when engineered 
to express the HIV receptors (Berg et al. 1991). The discovery of the viral co­
receptors, the chemokine receptors CXCR4 and CCR5 (Choe et al. 1996; 
Deng et al. 1996; Feng et al. 1996) lead to the classification of viruses into two 
groups, X4 and R5 tropic. The majority of X4 viruses are T-cell tropic, while the 
R5 viruses are predominately macrophage tropic.
The infection of T cells was first discovered by the observation that AIDS 
patients suffered from a severe decline in T-helper cell numbers (Stahl et al. 
1982; Dalgleish et al. 1984). Later it was shown that different subsets of T cells 
can be infected by different types of HIV-1. While X4 tropic strains infect naive 
T cells, R5 tropic strains show a preference for resting memory T cells. 
However, resting T cells are not able to integrate the HIV DNA into the host 
genome, the DNA remains extrachromosomal and is only integrated upon cell 
activation (Stevenson et al. 1990; Zack et al. 1990). When an activated T cell 
is infected with HIV but then converts to a resting memory state, it may carry 
the HIV genome without producing virus, and viral gene expression is only 
induced upon stimulation of the cell. This ability to hide in a latent state 
presents a significant problem for therapy. Infection of activated T cells, and 
virus production in these cells, leads to cytopathic effects such as syncytia 
formation and apoptosis in vivo, which is responsible for the observed decline 
in T cell numbers.
Other targets for HIV are tissue macrophages. Infected macrophages can be 
found in lymphoid tissue, lung (alveolar macrophages) and brain (microglia) 
(Stevenson and Gendelman 1994) as well as in the cervical and 
gastrointestinal mucosa (Pomerantz et al. 1988; Nuovo et al. 1993; Smith et al.
1997) and the peritoneum (Olafsson et al. 1991). Macrophages are primarily 
infected by R5 tropic strains, which are predominant in the early stages of 
infection and the pre-AIDS state (van't Wout et al. 1994). In contrast to T cells, 
macrophages show a low susceptibility to cytopathic effects and therefore 
have a longer half-life after infection. Infected tissue macrophages in patients
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survive for up to two weeks, while monocyte-derived macrophages in culture 
have a half-life of several weeks. It was suggested that a slower viral life cycle 
(Collin and Gordon 1994; O'Brien et al. 1994) or upregulation of anti apoptotic 
genes (Zhang et al. 2002) might be responsible for this effect. The ability of 
macrophages to attract and activate T cells is assumed to facilitate 
transmission of HIV between these cell types, and may therefore contribute to 
the decline in T cell numbers and HIV pathogenesis. While macrophages 
account for around 10% of infected cells during the first 2 weeks of infection 
(Zhang et al. 1999), the proportion of infected macrophages seems to increase 
with the onset of opportunistic infections (see below). Macrophages in lymph 
nodes and in tissue culture were found to harbour mature virus particles inside 
intracellular structures, which were identified as MHCII containing 
compartments positive for the tetraspanins CD81, CD9, CD63 and CD53 
(Raposo et al. 2002; Pelchen-Matthews et al. 2003). It was proposed that 
these cells act as virus reservoirs and release virus in a regulated manner.
Dendritic cells (DC) are further targets for HIV; they are important players of 
the host immune response and are involved in both adaptive and innate 
immunity. They consist of a range of subpopulations such as Langerhans cells 
in the skin and follicular DCs in germinal centres of the lymph nodes. Immature 
DCs in the skin and mucosa act as sentinels and are efficient at capturing 
antigens. They then migrate to the lymph nodes, where they are found as 
mature DCs in the T cell areas and function in inducing immunity against the 
captured antigen (Banchereau and Steinman 1998). Immature DCs residing in 
the epithelial and subepithelial surfaces are believed to be a primary target for 
HIV after mucosal exposure (reviewed in Larsson 2005). However, in culture, 
the levels of virus produced by DCs are low and it has been proposed that they 
may not contribute to virus dissemination through productive (c/'s-) infection, 
but rather through transfer of internalised virus particles (frans-infection) to 
uninfected cells, especially T cells during antigen presentation in the lymph 
node. It was shown that in addition to binding HIV by the classical HIV 
receptors, DCs can bind HIV particles by attachment to C-type lectins, e.g. 
DC-SIGN, Langerin and mannose receptor in vitro (Turville et al. 2002).
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Binding to DC-SIGN can initiate HIV internalisation into a low pH, non- 
lysosomal compartment, where the virus can survive for several days prior to 
transfer to T cells (Kwon et al. 2002), whether this pathway is relevant in vivo 
remains to be established. The contact between the DC and the T cell can 
mediate the recruitment of virus to the site of cellular interaction and facilitate 
its transfer (McDonald et al. 2003) and has therefore been termed an 
infectious synapse. The compartment where HIV is stored in DCs has 
similarities with the HIV budding compartment in macrophages and is enriched 
for the tetraspanin CD81, which seems to facilitate formation of the infectious 
synapse and enhance virus transfer (McDonald and Hope 2004; Garcia et al. 
2005).
1.2.2. Course of infection and AIDS
Transmission of HIV occurs via the sexual or parenteral route (e.g. blood 
transfusions and the sharing of needles). Virus transmission is also possible 
from mother to child with the greatest risk during birth.
One of the most prominent and earliest recognised clinical features of AIDS is 
the selective depletion of CD4+ T cells (Ho et al. 1995). AIDS is usually 
diagnosed by these low T cell counts (less than 200 cells/mm3 blood) in 
combination with detection of virus or antiviral antibodies in blood, impaired or 
absent delayed-hypersensitivity reactions and the occurrence of opportunistic 
infections. Infection with HIV is characterised by an initial phase of high level 
viremia, when large amounts of virus are produced, the so-called acute phase 
in weeks 1-9 after infection. In this primary phase the majority of infected cells 
are activated CD4+ T cells. T cell numbers keep decreasing until the host 
immune response exerts some control over virus replication (Clark et al. 1991). 
The acute phase is followed by an asymptomatic phase of persistent viral 
replication that can last from months to years. The presence of anti-HIV 
antibodies is observed after seroconversion, which occurs within a few months 
of infection, and is characteristic for the asymptomatic phase. This 
asymptomatic phase is a result of a dynamic interplay between the virus and 
the immune system. During the initial infection virus is disseminated to 
lymphoid organs and a strong immune response with a combination of anti-
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HIV antibodies and HIV specific cytotoxic T cells is established (Fauci et al. 
1996). But even when the level of virus in the circulation is stable, at least 109 
new cells are infected per day (Coffin 1995).
Clinical symptoms indicative of AIDS generally do not appear for at least 8 
years after infection, but this interval is variable. The onset of clinical AIDS is 
characterised by a decrease in T cell numbers and a new increase in viral load 
(Fauci et al. 1996). First symptoms often include opportunistic infections with 
Candida albicans or P. Carinii and in women vulvovaginal yeast infections. 
Later, the indicator diseases of AIDS range from Herpes zoster and Herpes 
simplex symptoms to cancerous diseases like Karposi’s sarcoma and different 
types of lymphoma. Eventually, the patient’s immune system collapses and 
s/he dies of one of the diseases mentioned above.
Anti-retroviral treatment aims to decrease the viral load allowing CD4+ T cell 
numbers to increase. A number of drugs are currently available that interfere 
with the viral lifecycle by inhibiting either the viral reverse transcriptase or the 
viral protease (see below). The prototype of drugs that interfere with reverse 
transcription is zidovudine or AZT. AZT is a nucleoside analog, that when 
introduced into the growing cDNA chain during reverse transcription causes 
chain termination. In most cases treatment for AIDS is a combination therapy, 
using regimens designated HAART (highly active anti-retroviral therapy). This 
combines the use of two nucleoside analogs and one protease inhibitor. But 
even though HAART is very effective at controlling virus levels, it cannot clear 
the virus. As soon as the therapy is stopped the virus levels rise again. Current 
strategies on drug targets for anti-retroviral therapy are (reviewed in Reeves 
and Piefer 2005).
1.3. Lentiviral envelope proteins
1.3.1. Biogenesis
Retroviruses encode a single envelope glycoprotein (Env). In the case of HIV 
and SIV, Env is a type 1 integral membrane protein, which is synthesised as a 
160kD precursor protein and then proteolytically processed to form the gp120
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surface unit (SU) and the gp41 transmembrane subunit (TM) (summarised in 
Figure 1.4). Viral membrane proteins hijack the cellular folding machinery and 
exocytic pathway for their synthesis, and a detailed review of viral glycoprotein 
folding can be found in (Braakman and van Anken 2000). In the case of HIV, 
the 845-870 aa (depending on the strain) precursor is synthesised by ER- 
bound polysomes and co-translationally translocated into the ER lumen. The 
folding of secondary structure (beta sheets and alpha helices) starts co- 
translationally, as soon as the relevant amino acids emerge into the ER lumen. 
Native and non-native disulfide bridges are formed during the folding process, 
catalysed by the cellular disulfide isomerases in the ER. In HIV Env there are
SU gp120
TM gp41
gp160:
ER Trans-Golgi
Figure 1.4. Folding and maturation of the HIV envelope protein. Gp160 is synthesised and 
cotranslationally inserted into the ER membrane. The protein is then folded and extensively 
glycosylated in the ER (glycan moieties are indicated as red dots). Upon transport through the 
Golgi apparatus gp160 is cleaved into its subunits SU (gp120) and TM (gp41) and the glycans 
are modified (red squares). The SU subunit is depicted in red and TM in green. The fusion 
peptide of TM is shown in blue. The movement of the TM N-terminus is assumed - based on 
the structure of Influenza HA.
10 native disulfide bonds, 9 in gp120 and 1 in gp41. N-linked glycan chains are 
co-translationally added to asparagine residues in the consensus glycosylation 
sequences. HIV Env contains around 30 potential glycosylation sites, most of 
which are used (Leonard et al. 1990), thus the final weight of the protein 
(160kD) is nearly 50% carbohydrates. The number and location of these 
glycosylation sites is fairly conserved among different virus strains and the
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addition of glycans is required for proper folding of the protein. It has been 
shown that deletion of certain single glycosylation sites can lead to ER 
retention (Fenouillet and Jones 1995). Folding and disulfide bond formation 
continue after release from the translocon. Folding is assisted by cellular 
chaperones, like the lectins calnexin and calreticulin that bind mono- 
glucosylated N-linked glycans, and chaperones such as hsp70 and BiP that 
bind hydrophobic sequences found in unfolded or misfolded proteins.
Proteins that are synthesised in the ER contain a signal peptide or signal 
anchor sequence that directs ribosomes to the ER membrane. For most types 
of proteins this signal is cleaved off directly after translocation into the ER 
lumen. HIV gp160 is an exception with this regard, it stays attached to the 
membrane via its signal peptide for at least 15 min after synthesis is 
completed. The timing of the cleavage appears to be dependent on folding and 
may help to ensure a proper outcome of the folding process (reviewed in Land 
and Braakman 2001). Completed folding of gp160 can be assessed by its 
ability to bind CD4. This already happens in the ER and leads to down- 
regulation of cell surface CD4 expression (Fennie and Lasky 1989; Kawamura 
et al. 1989; Earl et al. 1991). In general gp160 folding kinetics in the ER are 
slow compared to other proteins, and it has been shown that the long time 
spent in the ER by this protein is mainly due to extensive isomerisation of 
disulfide bonds, the high glycosylation and the late cleavage of the signal 
peptide (Land et al. 2003).
Lentiviral Env assembles into trimers during the folding process in the ER 
(Weiss et al. 1990; Earl et al. 1991; Chan et al. 1997). The ectodomain of gp41 
is crucial for the trimerisation process (Earl et al. 1991) and it has been shown 
that the half time for trimerisation varies considerably between virus strains 
(Land and Braakman 2001). When folding and trimerisation are completed the 
oligomers are exported from the ER to the Golgi apparatus, where the 
carbohydrates on gp160 are modified by the addition of complex sugars 
(Leonard et al. 1990). In the trans-Golgi gp160 is cleaved into its subunits 
gp120 and gp41 at the N-terminus of the consensus sequence Arg-Glu-Lys-
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Arg (McCune et al. 1988). The subtilisin-like cellular endoproteases furin and 
PC7 are thought to be the cellular enzymes that mediate cleavage. Even 
though cleavage of gp160 is not a prerequisite for transport to the plasma 
membrane, uncleaved gp160 is not incorporated into virus particles (Moulard 
et al. 1999). Cleavage is also needed for the generation of functional envelope 
proteins that mediate cell to cell or virus to cell fusion (Bolmstedt et al. 1991). 
The gp120 and gp41 trimers are held together by non-covalent interactions 
between the gp41 ectodomain and discontinous structures at the gp120 bl­
and C-termini (Helseth et al. 1991). The fate of envelope proteins after arrival 
at the plasma membrane will be discussed in section 1.4.2.
The relatively complicated folding and maturation processes make it difficult to 
produce recombinant Env complexes for research on Env trafficking and 
function and for use as vaccines. It has been shown that cleavage of the 
gp160 precursor is inefficient when Env is expressed at high levels, and it is 
not known how well the native structure of gp120 is mimicked by uncleaved 
gp160 or how effectively these proteins can be used to generate neutralising 
antibodies. To achieve full cleavage of the precursor in Env transfected cells it 
is often necessary to coexpress furin, which in turn reduces the expression of 
Env. However, cleaved complexes often appear to be unstable because the 
interaction between the two subunits is weak and gp120 is shed. The 
association between gp41 and gp120 can be stabilised by the introduction of 
appropriately positioned cysteine residues that form inter chain disulfide bonds 
between gp120 and gp41 (Binley et al. 2000). While such covalently linked 
complexes are useful to mimic the structure of native Env and can be used to 
produce soluble gp140 Env for antibody production (the transmembrane and 
cytoplasmic domains of gp41 are removed), these gp140 proteins do not show 
fusion activity. The expression of fully cleaved Env can be improved when the 
consensus sequence for the protease is engineered to increase the affinity for 
co-expressed furin (Binley et al. 2002). However, effective expression of 
recombinant Env is highly dependent on the intended use, and there is a trade 
off between expression efficiency and correct processing.
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1.3.2. Structure and function
As discussed in the previous section, the lentiviral envelope proteins are 
hexamers consisting of the 3 transmembrane subunits gp41 (TM) and 3 
soluble subunit gp120 (SU). The structure of gp41 can be divided into three 
domains, a C-terminal cytoplasmic-, a transmembrane- and an N-terminal 
ectodomain. While for the most part retroviral Envs have short cytoplasmic 
domains, HIV and SIV are unusual in that their Env cytoplasmic domains vary 
from 150-200 amino acids for different strains of viruses. The cytoplasmic 
domain contains various consensus sequences required for correct sorting of 
the protein (see section 1.4.2.) and protein-protein interactions (see chapters 5 
and 6). Env incorporation into virions has largely been considered to be a 
function of the cytoplasmic domain of TM and its interaction with Gag (Cosson 
1996; Vincent et al. 1999) and the budding machinery (see this study), though 
little is known about this interaction.
The ectodomain of TM, located N-terminal of the short transmembrane domain 
shares several features with the fusion proteins from divers classes of 
enveloped viruses (e.g. Influenza HA) with regard to its domain organisation. 
These features include a hydrophobic stretch at the extreme N-terminus of 
gp41, termed the fusion peptide (FP), and two heptad repeat motifs (HR), 
termed N-HR and C-HR respectively, placed adjacent to hydrophobic domains. 
The HR motifs have a characteristic pattern of seven residues, where the 
alternate third and fourth residues contain bulky, hydrophobic side chains. 
These side chains stabilise coiled-coil structures as the HRs oligomerise in a 
helical configuration and form a six-helix bundle structure in the Env trimer 
during fusion. Between the HRs lies a five-amino acid hydrophilic loop, defined 
by two cysteine residues. This loop forms a protrusion, which allows packing 
into a cavity in the surface subunit (reviewed in Weiss 2003).
The Env surface subunit gp120 is extensively glycosylated and formed by five 
variable regions (V1-V5) interspersed with five conserved regions (Starcich et 
al. 1986). Intramolecular disulfide bonds result in the incorporation of the first 
four variable regions into loop like structures that are well exposed on the
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surface of the glycoprotein. The conserved structures form the core of gp120, 
composed of an inner and an outer domain and a four stranded bridging p- 
sheet, the inner domain makes contact with gp41. The contact between HIV 
and the host cell is initiated by gp120 binding to the virus receptor on the host 
cell, CD4. CD4 binds into a pocket in the gp120 core at the interface between 
the inner and the outer domain, making intensive contact by H-bonds. CD4 
then induces conformational changes in gp120 exposing the site for 
chemokine receptor binding (Wyatt and Sodroski 1998) (Turner and Summers 
1999). Viruses arising later in the course of infection use preferentially CXCR4. 
The gp120 V3 loop plays a role in determining which chemokine receptor is 
used as a co-receptor and can promote the co-receptor switch. It was 
observed that an R5 to X4 switch is often associated with an increase in the 
net positive charge on V3. However, it has recently become evident that V3 
may not be the only determinant on gp120 responsible for co-receptor usage, 
as sequence changes in the V1 or V2 loops or the CD4 binding site may also 
have an impact (Hartley et al. 2005).
Binding of the co-receptor may promote further conformational changes in 
gp120, which are transduced to gp41 and lead to the loosening of the 
association between the two subunits. This allows insertion of the fusion 
peptide, folding of the HR domains on gp41 into thermostable six helix bundles 
and the onset of contact between the two membranes (Weiss 2003). The HIV 
fusion process has recently become a prime target for the design of antiviral 
drugs. It was found that peptides corresponding to the HR domains of gp41 
block Env-mediated fusion and therefore HIV infection. The C-peptide inhibitor 
T20 (Enfuvirtide) has become the first licensed agent in a class of fusion 
inhibitor antiretrovirals (Kilby et al. 1998). The peptides can bind the gp41 HR 
and lead to the formation of mixed six-helix bundles, which prevent formation 
of the viral six-helix bundle required for fusion (reviewed in Weiss 2003).
Apart from being fusogens, the lentiviral Envs are also the prime targets on the 
virus for antibodies. The first antibody response in the early weeks of infection 
is usually elicited by the disassembly of the gp120/gp41 complex and the
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immunogenicity of their interaction sites. However, antibodies against these 
sites cannot recognise the native Env and are therefore not neutralising. 
Neutralising antibodies are produced much later, when the virus is firmly 
established in the host. They are often strain restricted and recognise primarily 
the V3 loop of gp120. This first set of neutralising antibodies often interferes 
with chemokine receptor binding of the virus. Later sets of neutralising 
antibodies recognise a wider range of HIV strains and they interfere with the 
binding between gp120 and CD4. Another conserved epitope for neutralisation 
on gp120 is recognised by the antibody 2G12 (used in this study). It binds to 
an outer domain of gp120 and recognises conserved carbohydrate structures. 
Binding of 2G12 does not seem to be affected by the variability in the amino 
acid sequence in gp120, probably because the carbohydrates and their high 
density remain the same (reviewed in Wyatt and Sodroski 1998). Neutralising 
antibodies have also been reported against the native conformation of the 
gp41 subunit, e.g. 2F5 (Muster et al. 1993).
The virus has developed several strategies to escape antibody responses. The 
co-receptor binding site on gp120 is not exposed and may not even exist on 
Env prior to CD4 binding, which renders it less sensitive to antibodies. Minor, 
naturally resistant variants of virus may expand to dominance, or the virus can 
introduce new mutations and create a variant that is inefficiently recognised 
while Env function is maintained. The V3 loop is particularly prone to mutations 
altering its antibody epitopes and therefore creating escape mutants (Hartley 
et al. 2005). It is also believed that the high extent of glycosylation can act as a 
type of protective shield against antibody recognition and that the virus may 
minimise the exposure of Env on infected host cells by internalising cell 
surface Env (see chapters 1.4.2 and 3).
1.4. Trafficking of viral envelope proteins
The final steps in the assembly of enveloped viruses occur in the context of a 
cellular membrane when the nascent particle undergoes a budding reaction 
that simultaneously generates the viral envelope and releases the free virion. 
The cellular membrane can be the plasma membrane, leading to virus release
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directly to the extracellular space, or an intracellular membrane (e.g. the ER, 
Golgi apparatus or endosomal system), in which case the virions are delivered 
into intracellular vacuoles from which they are subsequently released to the 
extracellular space by a secretory type mechanism. During the budding 
process membrane proteins are incorporated into the viral envelope. These 
can include integral membrane proteins and peripheral proteins, and both 
types can be virally encoded or of cellular origin. The number of envelope 
proteins varies greatly between different viral families. Genetically relatively 
simple viruses, such as rhabdoviruses, encode a single integral membrane 
glycoprotein that mediates the key entry functions of receptor recognition and 
membrane fusion. More complex viruses, such as herpesviruses encode up to 
60 putative membrane proteins, many of which can be found in the viral 
envelope (Spaete et al. 1994; Britt and Mach 1996).
To ensure that fully infectious virions are produced, the components of a 
mature virus must be brought together in infected cells in a temporally and 
spatially coordinated manner. The proteins must be synthesised at an 
appropriate time and transported to the membrane system where they will be 
incorporated into domains that will become viral envelopes. As discussed in 
Chapter 1.3.1, viral integral membrane proteins are synthesised on the ER and 
use cellular mechanisms to ensure correct folding, quality control and export to 
the Golgi apparatus. Subsequently these proteins must be transported, directly 
or indirectly, to sites in the cell where budding occurs. The transport events 
may require transit through specific cellular compartments where, for example, 
glycosylation is completed or proteolytic cleavage occurs (see section 1.3.1). 
For this transport, viruses exploit cellular trafficking machineries and use 
signals that frequently mimic those found in cellular proteins.
Although most studies have focussed on integral membrane proteins, similar 
types of processes must occur for viral peripheral membrane proteins, such as 
retroviral Gag polyproteins that associate with the cytoplasmic side of cellular 
membranes and are subsequently located on the interior of assembled virions. 
These proteins are synthesised on free polysomes and targeted to membranes
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by a N-terminal myristic acid moiety plus, in many cases, a second motif such 
as an adjacent stretch of basic amino acids (reviewed in Bijlmakers and Marsh
2003). For many peripheral membrane proteins association with a specific 
membrane system may be direct but, for others, targeting may involve 
vesicular transport. Currently little is known of the mechanisms involved in the 
trafficking of these peripheral proteins.
In addition to structural proteins of the virion, a number of viruses encode 
membrane proteins with other roles. These can include proteins that modify 
the cell surface expression of MHC antigens or clear chemokines or antibodies 
from the environment around infected cells, thereby modifying the efficacy of 
the host’s immune response to infection. Again, these proteins use host cell 
trafficking machineries and signals to effect their functions.
1.4.1. Cellular protein sorting and trafficking machinery
A considerable amount of information has recently emerged on the trafficking 
pathways in eukaryotic cells and the cellular and molecular mechanisms 
through which these pathways operate. The vacuolar apparatus can be 
considered as a series of functionally overlapping membrane-bound 
compartments:
• The ER/Golgi systems, in which glycoprotein synthesis, folding, 
oligomerisation, glycosylation, acylation and quality control occur.
• The TGN/endosomal systems, in which many of the sorting reactions 
that control constitutive and regulated secretion, polarity and 
endocytosis occur.
• The plasma membrane.
• The late endosomal/lysosomal systems, in which many receptors and 
their ligands, plus other membrane proteins and material internalised by 
endocytosis are degraded.
A network of trafficking pathways (see Figure 1.5.) mediates transport between 
the different compartments in a highly regulated manner (Bonifacino et al. 
1996; Hirst and Robinson 1998; Sorkin 2000; Pelkmans and Helenius 2002; 
Bonifacino and Glick 2004). Following synthesis, the default pathway for
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Figure 1.5. Endocytic and exocytic trafficking pathways in a cell. Arrows are depicting 
transport between different organelles and coat and adaptor proteins are indicated in boxes. 
The * is pointing at multivesicular body formation as an example of an outwardly directed 
vesiculation process.
secretory proteins leads them from the ER to the Golgi apparatus and then via 
the TGN to the plasma membrane. Many plasma membrane proteins follow a 
similar route. Some proteins, e.g. the cation-independent mannose-6- 
phosphate receptor (CI-M6PR), that carries lysosomal enzymes, are directed 
from the TGN to late endosomes via early endosomes (Kornfeld and Mellman 
1989; Trowbridge et al. 1993; Tikkanen et al. 2000). Proteins delivered to the 
plasma membrane can be re-internalised by clathrin-dependent or clathrin- 
independent/lipid raft-dependent pathways to endosomal organelles from 
where they may be recycled, targeted to lysosomes or sorted to other cellular 
compartments including the Golgi apparatus, ER or alternative plasma 
membrane domains. In polarised cells, membrane and secretory proteins can 
be targeted to either basolateral or apical domains and sorting to these 
domains can occur at the TGN or in endosomes. Some of the signals involved 
in these latter sorting steps are related to endocytosis signals and appear to be
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interpreted by similar machineries. These pathways may also exist in non­
polarised cells (Scheiffele et al. 1997), though epithelial-specific sorting 
reactions do occur (Sugimoto et al. 2002).
1.4.1.1. Sorting signals
The trafficking of membrane proteins in the vacuolar apparatus involves 
sorting signals and a set of cellular machineries to interpret the information in 
these signals. Very different molecular features can influence protein sorting, 
and the distribution of a protein is dependent on a cell’s ability to decipher 
multiple signals operating at different stations in the vacuolar system 
(Trowbridge et al. 1993; Bonifacino et al. 1996; Schmid 1997; Hirst and 
Robinson 1998; Sorkin 2000; Bonifacino and Traub 2003). Here I give only 
superficial coverage of a few examples that are particularly relevant to viral 
protein trafficking.
Aside from the sequences that specify ER translocation, protein folding and 
ER quality control (Maggioni and Braakman 2005), specific signals regulate 
protein export from the ER and transport through the stations of the vacuolar 
pathway. These signals act either as markers for transport or for retention. 
Signals for transport allow proteins to be incorporated into transport vesicles 
and move efficiently from one compartment to another. These signals often 
operate by binding the proteins in which they are located to coat proteins that 
form the vesicle, or by ensuring proteins are located in the membrane domains 
that are incorporated into vesicles. Retention signals operate in the opposite 
way. They prevent incorporation of proteins into transport vesicles and cause 
them to be retained in a specific membrane system. These signals may 
operate by linking membrane proteins to cytoskeletal elements, or keeping 
proteins in membrane domains that do not form vesicles. Note that the well 
characterised C-terminal KKxx (where x = any amino acid) retrieval signal, that 
prevents export of ER proteins, is in fact a transport signal that specifies 
incorporation of proteins into retrograde transport vesicles operating between 
the Golgi and the ER (Letourneur et al. 1994). Many proteins contain multiple 
signals, several of which may allow efficient transport between several 
compartments while others restrict transport once the protein has been
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delivered to a specific target destination. Proteins that lack signals are 
transported inefficiently between compartments through non-specific inclusion 
in transport vesicles.
The molecular features of sorting signals are varied and can include:
1. Short linear amino acid sequences. Best exemplified by the tyrosine- 
based signals that mediate endocytosis. Two types of Y-based motif 
have been identified. Yxx0 type signals (where 0  = a large hydrophobic 
amino acid) are found in the cytoplasmic domains (at least 7 residues 
from the transmembrane domain) of many cell surface receptors and 
other proteins that undergo endocytosis in clathrin-coated vesicles 
(CCVs). These motifs interact with the \l2 subunit of the CCV AP2 
adaptor complex (see below). A second Y-based motif, FxNPxY, is 
found in the low-density lipoprotein receptor and some other proteins 
that also undergo endocytosis in CCVs. However, other adaptors such 
as ARH or Numb may be involved in recruiting these proteins into CCVs 
(Aridor and Traub 2002; He et al. 2002). In addition to mediating sorting 
at the plasma membrane, Y-based motifs can also operate at the TGN 
and may influence sorting in polarised cells, delivery to endosomes and 
other specific transport steps. Motifs such as dileucine sequences, can 
also mediate endocytosis and TGN sorting. Motifs such as DxE appear 
to be required for efficient export of proteins from the ER (for detailed 
list of ER export signals see Bonifacino and Glick 2004). Others, such 
as acidic clusters with a pair of adjacent serines that can be 
phosphorylated by casein kinase II (CKII) (Molloy et al. 1994; Schafer et 
al. 1995; Takahashi et al. 1995) can specify other sorting steps (Aridor 
and Traub 2002). Examples of motifs involved in sorting are listed in 
Table 1.2.
2. Transmembrane domains. The number of amino acids in the 
transmembrane domain of a single pass integral membrane protein can 
influence its association with membrane sub-domains of different lipid 
composition. Due to the ability of cholesterol to render the acyl chains of
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sphingolipids more rigid, cholesterol rich membrane domains are a few 
A thicker. Proteins with transmembrane domains of approximately 22 aa 
show a propensity to associate with these cholesterol-rich domains, 
whereas proteins with a transmembrane domain of around 18 aa tend 
to be excluded (Bretscher and Munro 1993). Conserved residues in the 
transmembrane domains of some membrane proteins have also been 
linked to association with detergent insoluble membrane domains 
(DIMs) and apical sorting (Lin et al. 1998).
3. Lipid modifications. A number of cell surface proteins are linked to the 
plasma membrane by glycophosphatidyl inositol (GPI) moieties that are 
added to certain transmembrane proteins during their synthesis in the 
ER. The GPI moiety replaces the transmembrane domain. Other 
proteins are post-translationally modified by the addition of palmitic acid 
to cysteine residues in the cytoplasmic domain or the transmembrane 
domain/cytoplasmic domain junction. Myristoylated proteins can also be 
palmitoylated on cysteines close to the N-terminus. These lipid-modified 
proteins can all show some propensity to interact with cholesterol-rich 
microdomains, which may influence their distribution in the plasma 
membrane and other membrane systems.
4. Glvcosvlation. Carbohydrates have been proposed to act as apical 
targeting signals for some secretory and membrane proteins (see 
Scheiffele et al. 1995; Yeaman et al. 1997).
5. Oligomerisation and Cross-linking. Cross-linking or oligomerisation of 
membrane proteins can lead to a change of trafficking routes (see for 
example Ukkonen etal. 1986)
1.4.1.2. Transport vesicles and adaptors
Trafficking between membrane compartments is mediated by transport 
vesicles, many of which are transiently coated with protein complexes. Three 
distinct coats have been characterised to date. COP II coats are associated 
with vesicles that bud from the ER en route to the Golgi apparatus, COP I
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coats are associated with retrograde transport vesicles from the Golgi to the 
ER (Robinson 1987), and CCVs are associated with endocytosis, transport 
from the TGN and some pathways from endosomes. Additional coats have 
been implicated in other transport events but remain to be characterised in 
detail (Seaman and Williams 2002).
The sorting information contained within membrane and other proteins is 
interpreted by the cell’s transport and sorting machineries. The best 
understood of these machineries are the clathrin-associated adaptor 
complexes, and in particular AP-2, for which detailed structural information 
now exists (Collins et al. 2002). AP adaptors, of which 4 have been identified 
(AP-1-4), are heterotetrameric complexes composed of two large (a,p,y or 5), 
one medium p, (~50 kDa) and one small a  (~20 kDa) adaptin (Hirst and 
Robinson 1998). AP-2 is associated with endocytic CCVs (cf AP-1 and AP-3 
which are associated with TGN and/or endosomally-derived CCVs). The large 
adaptins contain a core domain and a so-called C terminal ear domain 
connected to the core by a flexible linker. The linker of the p subunits contains 
a ‘clathrin box’ sequence that binds the adaptor to the N-terminal p propeller 
domain of clathrin (ter Haar et al. 1998). The \i2 subunit is responsible for 
binding Yxx0 type signals. The hydrophobic side chains of the Tyr and Y+3 
residues bind into hydrophobic pockets located in the \i2 p sheet C-terminal 
domain. However, the binding site is only accessible after phosphorylation of 
threonine 156 by adaptor associated kinase 1 (AAK1), indicating that access is 
regulated (Conner and Schmid 2002; Ricotta et al. 2002). AAK1 activity is 
governed by clathrin (Conner et al. 2003; Jackson et al. 2003) linking 
recruitment of Yxx0-containing cargo to clathrin assembly at the plasma 
membrane. Dileucine motifs with an upstream acidic residue (e.g. ExxxLL), 
appear to bind the y and a1 subunits of AP-1 rather than the \i subunit (Janvier 
et al. 2003).
Similar modes of recognition, and perhaps regulation, may occur for other 
clathrin adaptor complexes (Ghosh and Kornfeld 2003). Whether the same 
applies for other adaptors, including GGA proteins (for review see Bonifacino
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2004), and coats that are now being identified remains to be established 
(Aridor and Traub 2002; Ghosh and Kornfeld 2003). How other types of sorting 
signals that do not rely on short peptide sequences are interpreted also awaits 
additional study.
1.4.2. Traffic of viral envelope proteins
Viruses, in particular enveloped viruses, have learned to exploit the cellular 
trafficking pathways to facilitate their replication. In some viruses the trafficking 
itineraries of the envelope proteins are relatively simple, and may lead to the 
proteins being exported from the ER and delivered to the cell surface. By 
contrast, for other viruses much more complex itineraries involving multiple 
signals have been identified. Viral proteins have adopted many of the sorting 
signals found in cellular proteins, and they exploit the cellular sorting 
machineries. In some cases viruses encode adaptors, e.g. HIV Nef, to couple 
proteins to trafficking machineries with which they do not normally interact, or 
interact in a different manner, thus sorting cellular proteins to different sites in 
infected cells. Here I will give examples of several different families of viruses 
and the trafficking properties of some of their membrane proteins, in order to 
give an overview of the possible mechanisms used. Relevant targeting motifs 
for viral proteins are outlined in Table 1.3.
1.4.2.1. HIV and SIV Env trafficking
HIV Env trafficking has been studied with respect to the formation of virions. 
Thus most models propose that Env must be transported to the cell surface, 
where in the main HIV assembly occurs. In many cell types HIV does bud from 
the plasma membrane, but the degree to which Env is incorporated into these 
partjcles is unclear. Early studies suggested that much of the newly 
synthesised HIV Env exported from the ER is transported to lysosomes (Willey 
et al. 1988). Recent work has suggested a complex itinerary for Env and that 
this trafficking activity is crucial for viral pathogenesis (Fultz et al. 2001; Blot et 
al. 2003).
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Retroviruses
HIV-1 Subtype B RVRQGYSPLSFQTHLPTPRGPDRPEGIEEEGGERDRDRSIRLVNGSLALIW DDLRSLCLFSY
HRLRDLLLIVTRIVELLGRRGW EALKYW W NLLQYW SQELKNSAVSLLNATAIAVAEGTDRVIEW
QGACRAIRHIPRRIRQGLERILL
SIV mac 239 KLRQGYRPVFSSPPSYFQQ THIQQ DPALPTREG KERDGGEG GGNSSW PW QIEYIHFLIRQLI
RLLTW LFSNCRTLLSRVYQILQPILQRLSATLQRIREVLRTELTYLQYGW SYFHEAVQAVW RSATE  
TLAG A W G DL W ETLRRGG RWI LA I PR RIRQG LE LTLL
HTLV-1 RH LPSRVRYPH Y SU KPES S L
HTLV-2 QALPQ RLQNRHNQYSLINPETM L
FIV DCIRNCIHKILGYTVIAM PEVEGEEIQPQM ELRRNGRQCGM SEKEEE
Herpesviruses
HSV-1 gB RYVM RLQSNPM KALYPLTTKELKNPTNPDASGEGEEGGDFDEAKLAEAREM IRYM ALVSA
M ERTEHKAKKKGTSALLSAKVTDMVMRKRRNTNYTQVPNKDGDADEDDL
HSV-2 gB RYVLQLQRN PMKALYPLTTKELKTSDPGGVGG EG EEGAEGGGF D EAKLAEAREMIRYMAL
VSAMERTEHKARKKGTSALLSSKVTNMVLRKRNKARYSPLHNEDEAGDEDEL
V ZV g B  YRYVLKLKTSPMKALYPLTTKGLKQLPEGM DPFAEKPNATDTPIEEIGDSQNTEPSVNSGFD
PDKFREAQEMIKYMTLVSAAERQESKARKKNKTSALLTSRLTGLALRNRRGYSRVRTENVT  
GV
HCM VgB  YTRQ RRLCTQPLQNLFPYLVSADGTTVTSG STKDTSLQAPPSYEESVYNSGRKGPGPPSS
DASTAAPPYTNEQAYQMLLALARLDAEQRAQQNGTDSLDG QTGTQDKGQKPNLLDRLR  
HRKNGYRHLKDSDEEENV
HSV-1 gE ACM TCW RRRAW RAVKSRASGKGPTYIRVADSELYADW SSDSEGERDQVPW LAPPERPDS
PSTNGSG FEILSPTAPSVYPRSDG HQ SRRQLTTFGSGRPDRRYSQASDSSVFW
V2V gE K RM R VK AYRVDKSPYNQSM YYAG LPVDDFEDSESTDTEEEFGNAIGG SHG GSSYTVYIDK
TR
VZV gH (W M LCGN)SRLREYNKIPLT
HSV-1 gH KVLRTSVPFFW RRE
Orthomyxovriuses
Influenza HA ...M G VYQ  |ILAIYATVAGSLSI_AIMMAGISFWMCS| NGSLQCRICI
Rhabdoviruses
VSV-G RVGIYLCIKLKHTKKRQIYTDIEMNRLGK
Poxviruses
Vaccinia B5R CSCDKNNDQYKFHKLLP
Table 1.3. Examples of viral membrane protein cytoplasmic domain sequences. Amino 
acid motifs that play a role in trafficking are highlighted. For Influenza HA, 5 aa of the luminal 
domain and the transmembrane domain (boxed) are given, in addition to the cytoplasmic 
domain sequences.
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All HIV and SIV Envs contain a conserved Yxx0 type signal close to the 
junction of the cytoplasmic and transmembrane domains (see Table 1.3.). This 
sequence functions as an endocytosis signal in HIV and SIV Env and in Env 
cytoplasmic domain reporter constructs (LaBranche et al. 1995; Rowell et al. 
1995; Bowers et al. 2000; Wyss et al. 2001), and as a basolateral sorting motif 
in polarised epithelial cells (Owens et al. 1991; Lodge et al. 1997). SIV Envs, 
with short cytoplasmic domains can spontaneously gain a Y->C mutation in the 
Yxx0 sequence when the virus is maintained in tissue culture (LaBranche et 
al. 1995). This mutation destroys the sorting information in the motif and the 
cell surface expression of Env is dramatically upregulated, arguing that 
endocytosis normally keeps cell surface Env levels low (LaBranche et al. 
1995). When SIV, containing an Env gene in which the same Tyr codon is 
deleted or replaced by that of another amino acid, is used to infect non-human 
primates the animals become infected, but do not develop AIDS unless the 
mutation reverts (Fultz et al. 2001). Thus, though not required for growth in 
tissue culture, the trafficking activity of the Yxx0 signal is required for 
pathogenesis in vivo. In addition, the bulk of the SIV cytoplasmic domain is not 
required for growth in tissue culture as the Env gene frequently gains a 
mutation that places a premature stop codon about 20 amino acids into the 
cytoplasmic domain of TM. However, these truncations revert when the viruses 
are introduced into primate hosts. The functional activities of the full-length 
cytoplasmic domain are unclear as, for SIV at least, truncated Envs can still be 
incorporated into virions. Thus the requirements for the full-length tail are 
intimately linked to the biology of these viruses in vivo and may involve key 
roles for trafficking.
Full length HIV and SIV Env, or Env cytoplasmic domain containing reporter 
constructs, in which the membrane proximal Yxx0 signal is inactivated by 
mutation of the Tyr, retain some capacity for endocytosis and AP-2 binding 
and show only modest increases in cell surface levels (Bowers et al. 2000; 
Wyss et al. 2001) but no longer show basolateral sorting (Lodge et al. 1994; 
Lodge et al. 1997). This indicates 1) that additional endocytosis information 
exists downstream of the membrane proximal signal and 2) that, the
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membrane proximal signal is the only component of Env responsible for 
polarised sorting. The nature of the additional endocytic activity is obscure. In 
HIV Env, a C-terminal dileucine has been implicated in AP-1 binding and 
mutation of this motif in conjunction with mutation of the membrane proximal 
Tyr have additive effects in increasing Env cell surface expression (Wyss et al. 
2001). Mutation of analogous sequences in SIV Env had no effect on cell 
surface expression or endocytosis (Bowers et al. 2000). However, truncation of 
SIVmac Env at residue 767 increased Env incorporation into virions even in 
the presence of an intact Yxx0 motif (Yuste and Desrosiers 2003). How this 
mutation affects the trafficking of Env remains to be established.
In addition to the endocytosis and basolateral sorting information, other sorting 
signals must exist in Env, and their identification is a subject of this thesis. A 
significant amount of HIV Env, or an Env cytoplasmic domain reporter protein, 
is located in the Golgi apparatus and /or the TGN (Berlioz-Torrent et al. 1999; 
Blot et al. 2003). Antibody feeding experiments show that at least some of this 
material is internalised from the cell surface and that Env cycles between the 
plasma membrane and the Golgi/TGN (Blot et al. 2003). EM observations of 
HIV infected macrophages also show prominent labelling for Env on viruses in 
late endosomes, where the majority of infectious virus assembles in these cells 
(Raposo et al. 2002). Thus HIV-Env trafficking may involve transit from the cell 
surface to early and late endosomes, from where it is directed to the Golgi 
apparatus or the TGN. From this site it is either returned to the cell surface or 
perhaps cycles to endosomes. Little is known of how HIV Env traffics to late 
endosomes, though the fact that the membrane proximal Tyr is preceded by a 
Gly (GYxx0) as in a number of late endosomal/lysosomal proteins may be 
relevant (Bonifacino and Traub 2003). A detailed analysis of Env trafficking in 
the endocytic pathway is found in chapter 4.
The cellular machinery responsible for the trafficking of Env has been identified 
to some extent. The membrane proximal GYxx0 in HIV and SIV Env can bind 
jj2 and the AP-2 complex in in vitro experiments (Bowers et al. 2000; Wyss et 
al. 2001). This signal may also bind AP-1 and AP-3 (Ohno et al. 1997;
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Bonifacino and Traub 2003). Binding to AP-1 appears to be weaker than to 
AP-2, and its functional relevance (and that of AP-3-binding) is unclear, though 
a role in sorting Env from the Golgi to endosomes and/or recycling internalised 
Env to the TGN is possible. The membrane proximal Tyr is crucial for both AP- 
2 and AP-1 binding. In addition, for AP-2 binding, the G at Y -1, P at Y+2 and 0  
at Y+3 all influence endocytosis (Sauter et al. 1996; Boge et al. 1998; Bowers 
et al. 2000). In this respect, the HIV/SIV membrane proximal signal conforms 
to a consensus \i chain binding motif (Bonifacino and Dell'Angelica 1999). 
Other possible Y-based motifs in HIV and SIV Envs have not been found to 
have a major role in sorting or endocytosis, though they may bind adaptors or 
adaptor components in vitro. TIP47 (tail interacting protein of 47kD), a protein 
that plays a role in recycling from late endosomes to the TGN and binds a 
diaromatic motif in M6PRs (Diaz and Pfeffer 1998), has also been implicated in 
sorting HIV and SIV Envs, where a similar motif (Y8o2 Wso3 in HIV-1 me) is 
conserved. This interaction has been suggested to be crucial for Env 
incorporation into virions (Blot et al. 2003).
1.4.2.2. Other retroviruses
The presence of endocytosis signals in the Env cytoplasmic domain is not 
uncommon in retroviruses. The human T cell leukaemia virus (HTLV-I), a 5- 
retrovirus, has been studied in some detail. HTLV-I Env is required for 
infectivity and cell-cell fusion, but is only expressed at low levels on the 
surfaces of infected cells and when Env is expressed in the absence of other 
viral components (Nagy et al. 1983; Delamarre et al. 1997; Derse et al. 2001; 
Jassal et al. 2001). The cytoplasmic domain of Env appears to play important 
roles in virus transmission as its truncation can increase cell-cell fusion activity 
(syncytium formation) and decrease cell-cell transmission of the virus (Pique et 
al. 1993; Kim et al. 2003). In common with many other retroviruses, the 
cytoplasmic domain of HTLV-I Env is short (28 aa), but it contains Tyr residues 
at positions 476 and 479, both of which are found in a Yxx0 context. Mutation 
of either, or both, Tyr residues leads to loss of basolateral targeting when this 
Env is expressed in polarised cells (Lodge et al. 1997). In the absence of other 
viral proteins, HTLV-I Env is located on intracellular membranes close to the 
nucleus as well as at the plasma membrane. Mutation of Y479, but not Y476,
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increases Env cell surface expression and the fusogenic activity of transfected 
cells. The HTLV-I Env cytoplasmic domain binds both AP-1 and AP-2 in pull­
down experiments, and interacts with the jx1 and \i2 subunits in yeast 2-hybrid 
assays. Significantly, the interaction with pi1 can be abolished by mutation of 
Y479 only, while binding of \x2 is affected by mutations in either or both 
tyrosines (Berlioz-Torrent et al. 1999).
Thus, as with HIV and SIV, a putative endocytosis signals appears to limit 
HTLV-I Env cell surface expression, but in other respects the trafficking 
information encoded in this protein is less complex than that of HIV/SIV Envs. 
The transfer of HTLV-I from infected to uninfected cells has suggested a role 
for a so-called ‘virological synapse’ (Bangham, 2003). In infected cells it 
appears that Gag is sorted to these regions of cell-cell interaction. It remains to 
be seen whether this Gag is associated with preassembled particles in 
membrane-bound compartments, or whether viral particles bud into the 
‘synapse’ or are transferred from one cell to another by another mechanism, 
perhaps involving cell-cell fusion (Igakura et al. 2003).
In addition to HIV/SIV and HTLV-I, Yxx0 sequences have been found in the 
Env proteins of, for example, the avian a  retrovirus, Rous sarcoma virus (RSV) 
and in Mason-Pfizer monkey virus (MPMV). In RSV Env the signal is 
functionally silent, but is activated in Env proteins that are deficient for 
palmitoylation or have modified transmembrane domain sequences 
(Ochsenbauer et al. 2000). When the signal is active, Env exhibits rapid 
endocytosis through CCVs. Whether this signal can be modulated in infected 
cells at different stages of the virus life cycle is unclear. p-Retroviruses such as 
MPMV differ from other retroviruses in that their capsid assembly occurs in the 
cytoplasm of infected cells prior to Gag membrane-association. A motif has 
been identified in the MPMV Gag that targets the newly synthesised protein to 
the area of the cell around the microtubule organising centre (MTOC), where 
core assembly appears to occur (Sfakianos and Hunter 2003). Subsequently, 
assembled cores traffic to the plasma membrane for envelopment, budding 
and release. A Yxx0 type motif in MPMV Env is required for these events and
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suggests that trafficking of Env through the recycling endosome compartment 
is required to bring the core particles to the plasma membrane (Sfakianos et 
al. 2003). Whether the core particles interact with Env in recycling endosomes 
and traffic to the cell surface on recycling vesicles is unclear.
1.4.2.3. Herpesviruses
Herpesviruses express multiple envelope glycoproteins. Alpha-herpesviruses, 
such as Herpes simplex virus (HSV), carry -1 2  envelope glycoproteins, while 
p-herpesviruses, such as human cytomegalovirus (HCMV), encode -6 0  
putative glycoproteins, many of which may be carried in the viral envelope. 
Some glycoproteins, e.g. gB, gH and gL are essential for viral entry and are 
thought to be conserved in all herpesviruses. Others appear to be included to 
facilitate the infection and replication of specific viruses. These may encode 
additional receptor binding molecules, to broaden the range of susceptible 
cells, or proteins that have been implicated in the signalling events occurring 
early after fusion that prime cells for replicating the incoming virus (Kledal et al.
1998).
Glycoproteins B (aB) are type I integral membrane proteins that are essential 
for the attachment and fusion of herpesviruses with their host cells (Spear and 
Longnecker 2003). The proteins form homodimers or trimers in some 
herpesviruses and, in HCMV, are proteolytically cleaved to generate two 
associated polypeptides. GB, like HIV Env, shows low levels of surface 
expression, which is linked to the presence of a YxxL motif that is conserved in 
the COOH-terminal cytoplasmic domain of all sequenced gBs (see Table 1.3) 
(with the exception of Epstein Barr virus gB) (Radsak et al. 1996; Tirabassi 
and Enquist 1998; Tugizov et al. 1999; Nixdorf et al. 2000; Heineman and Hall 
2001). Other potential trafficking motifs can also be identified, e.g. HSV gB has 
a second Yxx0 motif closer to the transmembrane domain, as well as a 
dileucine signal in between the two Y-containing motifs, but they do not appear 
to be functional. Similar motifs were found in varicella zoster virus (VZV).
HCMV gB undergoes endocytosis and recycling in fibroblasts and epithelial 
cells. Internalisation is believed to be clathrin dependent (Tugizov et al. 1999)
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and the internalised protein is seen to co-localise with p-COP, Rab4, Rab5, 
Rab11, AP1, VIP-21 and TGN46, suggesting it may traffic through early and 
recycling endosomes and the TGN (Tugizov et al. 1998; Jarvis et al. 2002). 
The cytosolic domain of gB contains several potential signals for sorting to 
endocytic vesicles, including tyrosine- and dileucine based motifs as well as a 
cluster of acidic residues (Tugizov et al. 1999). HCMV gB is transported to 
apical membranes in epithelial cells independently of other viral glycoproteins 
(Tugizov et al. 1998). Apical transport is abolished by partial deletion of the 20 
aa transmembrane domain of gB and stretches of large hydrophobic amino 
acids in this domain have been implicated in raft-dependent gB sorting 
(Tugizov et al. 1998). In addition, a deletion of the acidic cluster in the 
cytoplasmic domain leads to missorting of the protein to basolateral 
membranes in polarised cells (Tugizov et al. 1998). However, the cytoplasmic 
domain of gB might be involved in other functions in certain cell types. In U373 
cells, gB induces syncytium formation that is regulated by its cytoplasmic 
domain. It appears to be dependent on rapid concentration of gB into 
endocytic vesicles at the plasma membrane (Tugizov et al. 1994; Tugizov et 
al. 1995). Whether this indicates a need to generate regions of concentrated 
gB for fusion complex formation is unclear. Endocytic trafficking of gB may 
also play an important role in virus assembly. The gB incorporated into virions 
appeared to have trafficked over the plasma membrane (Radsak et al. 1996) 
and envelopment of the virus has been proposed to occur in endocytic 
organelles (Radsak et al. 1996; Fraile-Ramos et al. 2002; Jarvis et al. 2002). 
Thus endocytosis of gB may be crucial for targeting the protein to sites of virus 
assembly.
Glycoprotein E (gE) is found in a number of herpesviruses. Together with gl, 
gEs form a high affinity receptor for immunoglobulin Fc domains (Johnson and 
Feenstra 1987). In HSV infected epithelial cells, the gE/gl complex is crucial 
for virus spreading (Dingwell and Johnson 1998; Wisner et al. 2000; Johnson 
et al. 2001; McMillan and Johnson 2001).
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HSV gE cycles between the TGN and the cell surface. In the early stages of 
infection, the bulk of the protein is in the TGN and only small amounts are 
found at the plasma membrane (Alconada et al. 1999). The cytoplasmic 
domains of gEs in herpesviruses contain four potential trafficking motifs: a 
Yxx0 motif and an acidic cluster are highly conserved and a further Tyr 
containing motif and an aromatic residue may also contribute to trafficking. The 
acidic cluster contains one or more potential CKII phosphorylation sites 
(Alconada et al. 1996; Zhu et al. 1996; Alconada et al. 1999). Truncation of the 
acidic cluster in HSV gE leads to its partial mislocalisation to the plasma 
membrane, but a role for phosphorylation has not yet been found. Mutation of 
the Tyr in the Yxx0 motif also leads to partial missorting, and truncation of all 
four putative signals leads to exclusive surface localisation (Jones et al. 1995; 
Takahashi et al. 1995; Alconada et al. 1999). The association of gE with gl 
appears to important in later stages of infection, when the gE/gl complex is 
transported to lateral surfaces in epithelial cells. Transport to the surface is 
abrogated in gl negative HSV mutants, suggesting that although gE possesses 
information necessary for internalisation and recycling, transport to cell 
junctions is dependent on information in gl (McMillan and Johnson 2001). 
Thus, while the intracellular accumulation of gE/gl may be associated with 
virus assembly, transport of gE/gl to junctional domains may facilitate cell-cell 
spread of the virus (McMillan and Johnson 2001). Similar mechanisms exist for 
the VZV gE and gl proteins.
Glycoprotein H (gH) is the third most abundant envelope protein in VZV after 
gE and gB. It is required for membrane fusion and forms heterodimeric 
complexes with gL. Formation of this complex is essential for maturation and 
cell surface expression of gH (Montalvo and Grose 1986; Hutchinson et al. 
1992; Rodriguez et al. 1993; Forghani et al. 1994). gH is also efficiently 
internalised from the surface of VZV infected cells and localises to the TGN. 
Co-expression of recombinant gH and its chaperone gL showed that 
internalisation is independent of other viral glycoproteins, suggesting that gH 
contains its own sorting information (Pasieka et al. 2003). The cytoplasmic 
domain of VZV gH is only 12-14 aa long. Nevertheless, gH internalisation is
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clathrin-mediated and involves a Yxx0 motif (Pasieka et al. 2003). Little is 
known about the trafficking of gH’s chaperone gL.
How exactly trafficking information is co-ordinated in herpesviruses to allow the 
components of these complex viral membranes to be bought together at the 
sites of viral budding remains to be established. Proteins that may shepherd 
key viral membrane proteins to assembly sites have been proposed, e.g. U6 in 
HSV (see Newcomb et al. 2003), but analogous proteins have yet to be 
identified in viruses such as HCMV.
1.4.2.4. Orthomyxoviruses
Influenza A viruses are the prototype viruses of the orthomyxovirus sub-family. 
These viruses contain two main surface glycoproteins, haemagglutinin (HA) 
and neuraminidase (NA). HA has been widely used as a model for studies of 
protein folding, protein quality control and membrane fusion. It is a non- 
covalently linked homotrimer, each monomer of which has a short 10 amino 
acid COOH-terminal cytoplasmic domain containing three cysteines, each of 
which can be palmitoylated. By contrast, NA is a homotetramer of a type II 
membrane protein.
A primary site for influenza infection is the epithelium of the respiratory tract. In 
infected polarised epithelial cells, both HA and NA are expressed on the apical 
surface where they are associated with lipid rafts (Scheiffele et al. 1997). The 
transmembrane domain of HA and NA can specify apical targeting through 
association with detergent insoluble membrane domains (DIMs). Detailed 
mutational analysis of the HA transmembrane domain indicates that although 
partitioning into DIMs is required for apical sorting it is not sufficient, and that 
certain conserved residues within the transmembrane domain are required for 
interaction with the DIM-associated apical sorting machinery (Lin et al. 1998). 
No internalisation or recycling activity has been detected for HA.
1.4.2.5. Rhabdoviruses
Vesicular stomatitis virus (VSV), the prototype rhabdovirus, encodes a single 
type I integral envelope glycoprotein G. G has been used extensively to study
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protein export from the ER and transit through the Golgi. Truncation of the 
cytoplasmic domain leads to slower export without affecting folding or 
trimerisation of the protein, suggesting the presence of export signals (Dorns et 
al. 1988). Mutation of a six residue sequence (YTDIEM, position 19 to 24 in the 
cytoplasmic domain) (see Table 1.3) inhibits efficient export (Nishimura and 
Balch 1997).
In epithelial cells, G is targeted to basolateral surfaces, from where the virus 
buds (Boulan and Pendergast 1980). G also localises to coated pits in these 
domains through which it is internalised (Matlin et al. 1983). A Yxx0 motif in 
the G cytoplasmic domain has been implicated in basolateral targeting as 
mutation of the single tyrosine (Y501) and/or I504 (positions 19 and 22 in the 
cytoplasmic domain respectively) cause the protein to appear on both the 
apical and basolateral surfaces (Thomas et al. 1993). G also undergoes 
endocytosis, though the rate is slower than that observed for other proteins 
using Y-based signals. The VSV Tyr motif does not play a role in 
internalisation and the endocytosis signal remains unclear (Thomas et al. 
1993).
1.4.2.6. Pox viruses
Vaccinia virus (W )  is the prototype member of the poxvirus family. The 
formation of W  particles is complex and they can exist in several different 
forms until they are released as extracellular enveloped virions (EEV) 
(reviewed in Smith et al. 2002). W  contains two glycoproteins that appear to 
be required for envelopment and high level production of EEV (Blasco and 
Moss 1991): F13L (Blasco and Moss 1991) and B5R (Engelstad and Smith 
1993; Wolffe et al. 1993). B5R, a 42 kDa glycoprotein, has also been 
implicated in cell entry, because antibodies against its extracellular domain can 
neutralise the virus (Galmiche et al. 1999). In infected cells both F13L and B5R 
concentrate in the membranes of the TGN (Schmelz et al. 1994); F13L is a 
cytosolic peripheral protein that requires acylation for membrane association 
when expressed alone. B5R is a type I membrane protein (Isaacs et al. 1992) 
that is believed to contain its own sorting information. These sorting signals 
reside in the transmembrane and/or cytoplasmic domains of the protein (Katz
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et al. 1997). Studies with chimeric proteins also indicate that the B5R 
cytoplasmic domain prevents accumulation of the protein in the plasma 
membrane, either by Golgi retention or endocytic retrieval (Ward and Moss 
2000). This domain displays two motifs that might regulate surface expression, 
a tyrosine at position 310 and a dileucine signal at positions 315/316 (see 
Table 1.3). Mutation of either or both of these motifs increases the levels of 
B5R on the plasma membrane. B5R is cycling from the Golgi apparatus to the 
plasma membrane and back with the stage of transit through the TGN being 
the slowest part of the cycle. Mutations of Y310 or the dileucine motif impaired 
retrograde transport, while a double mutation abrogated it (Ward and Moss
2000). However, the exact contribution of each signal and the mechanism of 
transport, remain to be fully established.
1.5. Viral budding and the ESCRT machinery
As discussed earlier, assembly of new viruses requires the temporally and 
spatially coordinated co-localisation of all the structural components required 
to form an infectious virus. For most enveloped viruses, assembly is often 
seen as a budding process in which the assembling virion progressively 
deforms the cellular membrane into a bud that eventually pinches off as a free 
virus particle. For viruses with rapid replication cycles, these events often 
occur at the cell surface, but for viruses that establish long term sustained 
infection, assembly must be balanced to ensure the survival of infected cells. 
In this case a high cell surface expression of viral proteins is likely to attract the 
attention of the immune system and alternative routes for assembly may be 
taken by the virus (for a discussion see Pelchen-Matthews et al. 2004).
In many cases the localisation of envelope proteins appears to determine the 
site of virus assembly. For other viruses the process is more complex. For 
example, it has long been believed that HIV and other retroviruses bud 
exclusively from the plasma membrane. However, HIV Env is internalised 
efficiently from the surface, requiring that either Env must be relocated during 
assembly or suggesting that not all assembly occurs at the cell surface. It is 
possible that Gag might mask the internalisation motifs on Env, and allow Envs
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to accumulate at the cell surface, but in some cells at least infectious HIV is 
assembled intracellularly (Pelchen-Matthews et al., 2003).
It has recently become clear that cellular components are required to facilitate 
the assembly and release of many enveloped viruses. One of the most 
extensively characterised of these machineries, which also appears to be 
involved in retrovirus budding, is the Endosomal Sorting Complex Required for 
Transport (ESCRT) (Katzmann et al. 2002), a set of protein complexes 
involved in sorting membrane proteins destined for degradation in the 
lysosome to multivesicular bodies.
1.5.1. The Multivesicular body sorting machinery
1.5.1.1. Multivesicular bodies
Vesicular transport between the plasma membrane and the 
lysosomal/vacuolar organelles is coordinated by a set of heterogeneous 
compartments referred to as endosomes. Endosomes are generally classified 
as early or late depending on the kinetics with which the compartments are 
loaded with endocytosed material. The tubular and vesicular early endosomes 
are usually found closer to the plasma membrane while late endosomes are 
closer to the nucleus (reviewed in Mellman 1996; reviewed in Gruenberg
2001). Some endosomes appear multivesicular, i.e. they contain internal 
membranes and are therefore referred to as multivesicular bodies (MVB). 
MVBs were first discovered by electron microscopy more than 50 years ago 
and described as organelles with a limiting membrane and 40-90 nm diameter 
internal vesicles (Palade 1955). These internal vesicles were observed to have 
arisen by invagination of the limiting membrane of the endosome into the 
lumen reviewed in (Katzmann et al. 2002). Later it was shown that MVBs 
contain molecules that have been endocytosed from the plasma membrane 
and are therefore part of the endocytic pathway (Hopkins 1980; Ukkonen et al. 
1986). It is believed that MVBs are formed from sorting early endosomes and 
can then fuse with later endosomal compartments and lysosomes. The 
process required to generate MVBs from early endosomes has been linked to 
a protein called annexin II. Annexin II forms cholesterol-rich platforms that
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organise the membrane of early endosomes, and it has been shown that 
annexin downregulation leads to multivesicular regions in early endosomes 
that do not pinch off (reviewed in Gruenberg and Stenmark 2004).
The physiological significance of MVBs was first discovered in studies of the 
degradation of the epidermal growth factor receptor (EGFR). To regulate 
signalling via EGF, a peptide stimulating cell growth, cells use several 
mechanisms, one of which is the degradation of the EGF-EGFR complex 
following endocytosis and delivery to the lysosome (Gorden et al. 1978). 
EGFR has been detected by EM on the membrane of internal vesicles of 
MVBs (Miller et al. 1986; Futter et al. 1996). These vesicles and their content 
are then delivered to the lumen of the lysosomes, upon fusion of the limiting 
membrane with the lysosomes, and the cargo is degraded. With this 
mechanism cells are able to degrade entire transmembrane proteins as well as 
lipids sitting on the internal vesicles. Apart from EGFR degradation, the MVB 
pathway is important for several other aspects of cellular physiology in different 
organisms. In Drosophila and C.elegans, MVBs play a role in the Notch 
signalling pathway that acts at various developmental stages. Proteins that are 
retained in the limiting membrane of the MVB are spared this destiny, they are 
either recycled to the TGN or the plasma membrane or are delivered to the 
limiting membrane of the lysosome. Thus the MVB can also provide a means 
for delivering lysosomal proteins and lipid components (reviewed in Katzmann 
et al. 2002; Raiborg et al. 2003; Babst 2005; Hurley and Emr 2006).
Apart from transport to the lysosomes, MVBs can have a variety of other 
specialised functions. The intralumenal vesicles can provide storage for 
proteins that are to be released from the cell in a regulated manner by fusion 
of the MVB with the plasma membrane. In certain cell types, like melanocytes 
and haematopoietic cells, the MVBs can act as intermediates in the formation 
of secretory lysosomes, or melanosomes, MHCIl compartments or lytic 
granules (reviewed in Blott and Griffiths 2002). The contents of these 
specialised organelles can be released to the outer cellular space when the
61
cell is triggered with a stimulus. In the case of APCs the release of such 
internal vesicles is a form of exocytosis and the vesicles are called exosomes.
Compared to early endosomes, late endosomes and MVBs have a 
considerably different lipid composition. While early endosomes contain many 
of the same lipids as the plasma membrane, i.e. high levels of 
glycosphingolipids and cholesterol, late endosomes are enriched in neutral 
phospholipids. Certain lipids also appear to be concentrated in the 
intralumenal vesicles of MVBs, Ptdlns(3)P is sorted into the MVB and targeted 
for degradation (Wurmser and Emr 1998). Ptdlns(3)P also appears to have a 
crucial role in sorting of cargo protein to the MVB and the formation of 
intralumenal vesicles (see detailed discussion in chapter 1.5.1.3.). An unusual 
phospholipid, lyso-b/sphosphatidic acid (LBPA) has been found exclusively on 
late endosomes and particularly in the membranes of the lumenal vesicles 
(Kobayashi et al. 1998). Because of its unusual structure, LBPA is inefficiently 
degraded by lipases and therefore accumulates in MVBs. LBPA has been 
implicated in mediating inwards invagination and the formation of lumenal 
vesicles, and it was observed that antibodies against LBPA can inhibit the 
formation and function of MVBs. This function might be due to the particular 
inverted cone shape of the lipid. LBPA specific antibodies also result in the 
accumulation of cholesterol in lumenal vesicles of MVBs, indicating a role for 
LBPA in cholesterol sorting (reviewed in Katzmann et al. 2002; reviewed in 
Raiborg et al. 2003; Babst 2005). However, it has to be mentioned that LBPA 
is only found in mammalian cells and not in yeast, even though the vacuolar 
sorting in yeast is homologous to MVB sorting and the machinery seems to be 
highly conserved from yeast to humans. Thus LBPA is not required for the 
formation of lumenal vesicles.
Apart from their specific lipid composition the lumenal vesicles of MVBs also 
appear to be enriched in certain types of proteins, which are not obviously 
targeted for degradation, in particular tetraspanins and glycosyl 
phosphatidylinositol - (GPI-) linked proteins. The tetraspanins include CD63, 
CD81 and CD9 (Pelchen-Matthews et al. 2003), which are proteins with
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multiple functions in immune regulation and cell-cell fusion processes 
(reviewed in Hemler 2005).
1.5.1.2. Class E proteins and ESCRT complexes
By contrast to the inwardly directed formation of membrane transport vesicles, 
such as CCVs, which, regardless of the compartment on which they are 
formed, are released into the cytoplasm of the cell, the formation of lumenal 
vesicles in MVBs requires an outwardly driven budding process. Recently, it 
has become apparent that cells have a highly conserved machinery for 
outward vesiculation (reviewed in Katzmann et al. 2002). In the yeast 
Saccharomyces cerevisiae a group of 18 proteins was identified as class E 
Vps proteins in a vacuolar protein sorting screen (Raymond et al. 1992; 
Cereghino et al. 1995) (reviewed in Katzmann et al. 2002; Babst 2005; Hurley 
and Emr 2006). Single deletions of each of the class E VPS genes in yeast 
results in the missorting of transmembrane proteins to the limiting membrane 
of the vacuole and the perturbance of a prelysosomal compartment (the so- 
called class E compartment), which is analogous to the MVB (Rieder et al. 
1996; Odorizzi et al. 1998). These class E proteins are highly conserved in 
eukaryotic cells and the phenotypes of their deletion are similar to the class E 
phenotypes in yeast suggesting that the function of class E proteins in MVB 
sorting is conserved from yeast to mammals (reviewed in Katzmann et al. 
2002; Babst 2005; Hurley and Emr 2006). For each of the yeast class E Vps 
proteins there are at least one or more mammalian homologs. For a Table of 
all class E Vps components see Table 1.4.
The majority of the class E Vps proteins are organised into four separate 
protein complexes termed ESCRT-0, ESCRT-I, ESCRT-II and ESCRT-III. 
These complexes appear to function in a sequential way and are recruited 
from the cytoplasm to the endosomal membranes. In yeast, ESCRT-0 is the 
first complex to interact with cargo (frequently mono-ubiquitinated membrane 
proteins) and recruits ESCRT-I that recruits ESCRT-II until ESCRT-III finally 
sorts the cargo into the lumenal vesicles. In the following detailed discussion of 
ESCRT complexes only the mammalian names of class E components will be 
used.
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Complex Human protein Yeast protein Motifs Interacts with
Hrs/STAM Hrs
STAM1.STAM2
Vps27
Hse1
UIM, FYVE, VHS 
(JIM, VHS, SH3
Ubiquitin, PI(3)P, Tsg101 
Ubiquitin
ESCRT-I Tsg101
Vps28
Vps37A, B, C, D
Vps23
Vps28
Vps37
UEV
Coiled-coil
Ubiquitin, Hrs
ESCRT-II EAP30
EAP25
EAP45
Vps22
Vps25
Vps36
Coiled-coil 
GLUE, NZF
CHMP6
Ubiquitin
ESCRT-III CHMP2A, B 
CHMP6 
CHMP3 
CHMP4A, B, C
Vps2/Did4
Vps20
Vps24
Snf7/Vps32
Charged, coiled-coil 
Charged, coiled-coil 
Charged, coiled-coil 
Charged, coiled-coil
EAP25
Vps4 Vps4A, B Vps4 AAA ATPase, coiled- 
coil
ESCRT-III
Other class 
E Vps 
proteins
ALIX/AIP1 
CHMP5 
CHMP1A, B 
LIP5 
SLC9A6
Bro1/Vps31
Vps60/Mos10
Fti1/Did2
Vta1
Vps44/Nhx1
Charged, coiled-coil 
Charged, coiled-coil 
Charged, coiled-coil
Sodium/proton
exchanger
LBPA, Doa4, ESCRT-III 
ESCRT-III, LIP5 
ESCRT-III 
Vps4, CHMP5
Table 1.4. Class E Vps proteins and complexes (adapted from Hurley and Emr 2006).
Most components of the ESCRT machinery contain certain conserved 
domains, which are crucial for their function in protein sorting and will be 
discussed here briefly. For a detailed description of all class E Vps proteins 
see Hurley and Emr 2006 (Hurley and Emr 2006).
ESCRT-0
ESCRT-0 consists of the proteins Vps27 in yeast and Hrs (hepatocyte growth- 
factor-regulated tyrosine kinase substrate) in mammals and Hse1/STAM1 
(signal transducing adaptor molecule). Both components of the Hrs/STAM 
complex contain UlMs (ubiquitin-interacting motifs), which enable them to bind 
ubiquitinated cargo at the early endosome (for example see Bilodeau et al. 
2002; for example see Raiborg et al. 2002; Shih et al. 2002). Binding happens 
with a low affinity, but binding of multiple UlMs, with multiple ubiquitin moieties, 
leads to a high avidity interaction. Binding of non-ubiquitinated cargo might be
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possible via a VHS (Vps27/Hrs/STAM) domain present in both Hrs and STAM 
and recognising acidic cluster-dileucine motifs (Hislop et al. 2004; Hanyaloglu 
et al. 2005). In addition, Hrs but not STAM contains a so called FYVE domain 
(Fab1, YOTB, Vac1, EEA1), which enables it to bind the endosomal lipid 
Ptdlns3P [PI(3)P]. It is believed that PI(3)P can recruit Hrs to the endosome by 
a low affinity interaction (Burd and Emr 1998; Misra and Hurley 1999; Raiborg 
et al. 2001) and ensure its proper localisation. Depletion of PI(3)P leads to a 
lack of Hrs recruitment and the inhibition of MVB formation. Hrs is found in 
planar clathrin lattices on early endosomes (Sachse et al. 2004), and it is able 
to bind clathrin directly via a consensus sequence (LIEL) found at its extreme 
C terminus (ter Haar et al. 2000).
STAM is able to recruit the deubiquitinating enzymes UBPY (ubiquitin 
isopeptidase Y) (Kato et al. 2000) and AMSH (Me Cullough et al. 2004) via its 
SH3 (sre homology-3) domain. Apart from its deubiquitinating function AMSH 
is able to bind to the ESCRT-III component CHMP3 and therefore provide a 
link between ESCRTs-0 and -3 (Me Cullough et al. 2006). STAM expression is 
highly dependent on Hrs and in hrs (-/-) cells only trace amounts of both 
STAM1 and STAM2 can be detected (Kobayashi et al. 2005). ESCRT-0 is 
linked to ESCRT-I through a PTVP (consensus P(T/S)xP) motif in the C 
terminal portion of Hrs, which is recognised by the ubiquitin E2 variant (UEV) 
domain on Tsg101.
ESCRT-I
The ESCRT-I complex consists of three components, Tsg101, Vps28 and a 
member of the Vps37 family. As discussed above Tsg101 provides the link to 
ESCRT-0 by binding to Hrs. Apart from binding the PTVP sequence on Hrs, 
Tsg101 can interact through its UEV domain in the same way with other 
proteins of the Vps machinery. It binds ALIX/AIP1 (von Schwedler et al. 2003) 
and the E3 ubiquitin ligase Tal (Amit et al. 2004) via their respective P(T/S)xP 
sequences. The UEV domain, which is in fact a catalytically inactive variant of 
an Ub-conjugating enzyme (Katzmann et al. 2001) can also directly bind 
monoubiquitinated protein cargo. Furthermore, the UEV domain provides one
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of two possible ways of interaction between Tsg101 and the second ESCRT-I 
component Vps37B, which contains a PTAP motif on its own (Stuchell et al.
2004). The rest of Tsg101 is composed by a conserved helical C-terminal S- 
box domain making contact with Vps28, a proline rich domain and a coiled-coil 
region providing a second way of binding Vps37 via its own coiled-coil domain 
(Stuchell et al. 2004). It has been shown that Tsg101 is a crucial component of 
the MVB forming machinery and its depletion leads to the formation of a class 
E compartment and sorting defects (Doyotte et al. 2005).
The second component of ESCRT-I, Vps37, is found as a family of four 
proteins (Vps37A-D) in mammalian cells (compared to only one protein 
Vps37p in yeast) (Stuchell et al. 2004). The common feature of Vps37 proteins 
is their Mod-r domain (Begley et al. 1995), each of which contains at least one 
region that is predicted to form a coiled-coil. Apart from the mod-r and coiled- 
coil domains, the members of the Vps37 family are very different, they differ in 
size and while Vps37A contains a UEV domain similar to the one in Tsg101, 
Vps37B has a proline rich domain. Vps37B was found to interact with Vps28 
and itself, forming homo-oligomers independently of Tsg101 (Stuchell et al.
2004). Vps37A (Bache et al. 2004), Vps37B (Stuchell et al. 2004) and Vps37C 
(Eastman et al. 2005) can be functional components of ESCRT-I and are 
involved in MVB sorting. However, little is known about Vps37D, and it remains 
unclear whether the different family members are expressed in specific cell 
types.
The last member of ESCRT-I, Vps28, binds to both Tsg101 and Vps37B and it 
was found as part of a soluble ESCRT-I complex together with Tsg101 (Babst 
et al. 2000; Bishop and Woodman 2001). Recently it was found that Vps28 can 
bind to Yxx0 motifs and provide a link between proteins containing these 
motifs and the ESCRT machinery (Hui et al. 2006).
ESCRT-II
In yeast, ESCRT-II forms a link between ubiquitinated cargo, the endosomal 
membrane and the ESCRT-I and ESCRT-III complexes (Babst et al. 2002).
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The complex contains two EAP25 subunits, one EAP30 and one EAP45 
subunit. EAP30, EAP25 and the C-terminal domain of EAP45 form a tightly 
organised core, which contains two binding sites for the ESCRT-III subunit 
CHMP6 (Teo et al. 2004). The N-terminal part of EAP45 contains two different 
domains, which appear to be crucial for its function in MVB sorting. The yeast 
homologue of EAP45, Vps36 contains an NZF (Np14 zinc finger) domain, 
which is found in duplicate and can bind ubiquitin (Alam et al. 2004). The 
ubiquitin binding properties of the second of these NZF domains is important 
for the sorting function of EAP45, while no function so far could be 
demonstrated for the first NZF domain. It appears to be crucial for the 
mechanisms of MVB sorting that NZF domains are binding the same part of 
ubiquitin as UEV and UIM domains and a simultaneous binding is therefore 
impossible. In human EAP45 no NZF domain is found, it appears however that 
the ubiquitin binding function is fulfilled by a GLUE domain (Gram-like 
ubiquitin), which at the same time binds the lipid phosphatidylinositol (3,4,5)- 
triphosphate (Slagsvold et al. 2005).
ESCRT-III
The ESCRT-III complex can be subdivided into a membrane associated 
(CHMP6 and CHMP4) and a peripheral subcomplex (CHMP2 and CHMP3). 
Association of the membrane subcomplex with endosomes does not require 
the peripheral subcomplex. Membrane association of ESCRT-III appears to be 
dependent in part on myristoylation of CHMP6 (reviewed in Katzmann et al. 
2002). All ESCRT-III components are highly charged and contain coiled-coil 
regions (Babst et al. 2002). The major link between ESCRT-III and the 
upstream complexes occurs via ESCRT-II, as described above, but in addition 
in mammals CHMP4 and Tsg101 are bridged by ALIX/AIP1. ESCRT-III 
components are able to bind to the AAA type ATPase Vps4, which regulates 
their association with the membrane. CHMP3 has been proposed to bind the 
lipid phophatidylinositol (3,5) bisphosphate (Whitley et al. 2003). Further, 
ESCRT-III recruits the deubiquitinating enzyme Doa4, which removes the 
ubiquitin tag from cargo proteins prior to sorting into the MVB vesicles (Amerik 
et al. 2000).
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Other Vps proteins
ALIX/AIP1 is a monomeric protein interacting with ESCRT-I via a PTAP- 
Tsg101 interaction and with ESCRT-III via CHMP4 in mammals, as described 
above. In the yeast homologue, Bro1, no interaction with ESCRT-I has been 
shown so far. However, both proteins, ALIX/AIP1 and Bro1, contain a 
conserved N-terminal Bro1 domain, which appears to be sufficient for ESCRT- 
III binding and recruitment to the late endosome (Kim et al. 2005). The 
boomerang-like shape of ALIX led to speculations that its convex face could 
enable it to sense negative curvature in invaginating lumenal vesicles (Matsuo 
et al. 2004). ALIX/AIP1/Bro1 appears to have several functions; it is able to 
recruit the deubiquitinating enzyme Doa4 in yeast (Luhtala and Odorizzi 2004), 
and has been shown to bind Yxx0 motifs on viral and cellular proteins (see 
chapter 1.5.2) and play a direct role in their sorting. It has also been suggested 
to regulate the spatial distribution of endosomes (Cabezas et al. 2005).
The AAA ATPase Vps4 is responsible for the ATP-dependent disassembly and 
recycling of the ESCRT complexes (Babst et al. 1997; Babst et al. 1998). In 
humans Vps4 is a hetero-oligomer between Vps4A and Vps4B, each of which 
consist of an N-terminal MIT domain (microtubule interacting and trafficking) 
and a central ATPase domain. The MIT domain enables binding to ESCRT-III 
subunits. It has been suggested that Vps4 cycles between soluble inactive low 
molecular weight complexes and active, membrane-associated double-ring 
structures that bind ATP and co-assemble with the adaptor protein LIP5. This 
active form of Vps4 then disassembles the ESCRT-III complex by feeding 
individual membrane-bound components through its central pore into solution 
(Scott et al. 2005).
The role of other Vps proteins like CHMP1 and CHMP5, which share 
homology with the ESCRT-III components remains unclear, but a function in 
the regulation of Vps4 disassembly activity has been proposed since an 
interaction between the two has been shown (Babst 2005). CHMP5 
additionally interacts with LIP5, an adaptor protein required for MVB sorting 
and EGFR degradation (Ward et al. 2005)
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1.5.1.3. Sorting into multivesicular bodies
Sorting of proteins targeted for degradation in the lysosomes into the internal 
vesicles of MVBs requires the coordinated interplay of ubiquitination and 
ESCRT machinery. The attachment of single ubiquitin moieties to one or 
several lysine residues in the cytoplasmic domain of the cargo protein plays a 
central role in this sorting process and is sufficient to target proteins to the 
ESCRT machinery on endosomes. The major E3 ubiquitin ligase responsible 
for ubiquitination in this pathway in yeast is the HECT [homologous to E6-AP 
(E6-associated protein) C-terminus]-ligase, Rsp5. In mammalian cells, the 
RING (really interesting new gene)-ligase Cbl (reviewed in Urbe 2005) and the 
Nedd4 family of HECT domain E3 ubiquitin ligases have been implicated in the 
down-regulation of several receptor tyrosine kinases (reviewed in Rotin et al.
2000). Whilst in yeast Rsp5 is the only HECT ubiquitin ligase, humans encode 
at least nine, the best studied of which is Nedd4. Nedd4 and Nedd4-like 
proteins form a large family of ubiquitin ligases that regulate a variety of 
cellular functions (reviewed in Harvey and Kumar 1999). These proteins have 
three domains in common: an N-terminal lipid-binding (C2) domain that directs 
them to the membrane, WW modules, rich in tryptophan and present in 
multiple copies, and a C-terminal HECT domain that contains the ubiquitin 
ligase activity (Dunn and Hicke 2001; Hicke 2001).
Ubiquitinated cargo is recognised by Hrs in subdomains of the early 
endosomal membrane, and it has been proposed that Hrs might act as an 
adaptor molecule concentrating cargo in the flat clathrin lattices on the 
endosome and preventing recycling back to the plasma membrane (reviewed 
in Babst 2005). An alternative way for sorting of ubiquitinated cargo might be 
provided by GGA (Golgi-associated, y-adaptin homologs, Arf-binding) proteins. 
They have been shown to target ubiquitinated proteins from the Golgi for 
degradation in the lysosome (Scott et al. 2004) and GGA3 is important for the 
endocytic trafficking and degradation of ubiquitinated cell-surface receptors 
(Puertollano and Bonifacino 2004). Although ubiquitination has long been 
believed to be the signal for sorting into MVBs, there is evidence of alternative 
targeting mechanisms and it has been shown that protein targeting to MVBs is
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possible in the absence of ubiquitin (Reggiori and Pelham 2001). Theos and 
colleagues have recently revealed a mechanism, which relies entirely on 
lumenal determinants, is independent of ubiquitin and is resistant to the 
inhibition of ESCRT pathway function (Theos et al. 2006). In addition a 
regulatory step may already be in place at this early stage of protein sorting, 
through deubiquitinating proteins associated with STAM that act as an off 
switch and direct cargo out of the MVB pathway. For example the ubiquitin 
isopeptidase AMSH can limit the downregulation of EGF receptor (Me 
Cullough et al. 2004).
Analysis of the different ubiquitin-binding domains found in ESCRT 
components (e.g. UlMs and UEVs) has shown that all of these interactions 
occupy a similar surface on the ubiquitin molecule (see above). This 
observation implies recognition by only one ubiquitin-binding protein at the 
time and sequential interactions between ubiquitinated cargo and the different 
ESCRT proteins. It is therefore assumed that, at least in yeast, cargo must be 
handed over from ESCRT-0 to ESCRT-I and then ESCRT-II. It further appears 
that the ubiquitin binding properties of ESCRT-I and ESCRT-II not only serve 
for the sorting of cargo but also for the assembly of the ESCRT machinery 
itself, since some of the ESCRT components are ubiquitinated and ubiquitin 
binding mutations affect the formation of MVBs (reviewed in Babst 2005). 
However, it has recently been demonstrated that ESCRT-II is not essential in 
EGFR degradation in mammals (Bowers et al. 2006).
It is not understood how the internal vesicles of MVBs containing cargo are 
formed and pinched off from the limiting membrane. An insight into a possible 
mechanism comes from structural analysis of the ESCRT-III complex. All 
ESCRT-III proteins are small coiled-coils, this feature is reminiscent of another 
group of proteins, the SNARE (soluble N-ethylmaleimide-sensitive factor 
attachment protein receptor) proteins, which mediate membrane docking and 
fusion through the formation of energetically favourable coiled-coil bundles 
(Jahn and Grubmuller 2002). Lin and colleagues (Lin et al. 2005) proposed a 
model, where monomeric ESCRT-III subunits form intramolecular coiled-coil
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bundles via electrostatic interactions. In this closed conformation an interaction 
with membranes or other proteins is not possible. Competition from other 
proteins would then loosen the intramolecular interactions to form an open 
conformation, enable binding of the ESCRT-III components to the membrane 
and formation of oligomers of the different subunits. ESCRT-II or ALIX could 
be initiators of such a process. Binding of Vps4 to the C-terminal region of 
ESCRT-III subunits (Lin et al. 2005; Scott et al. 2005), and ATP-dependent 
disassembly of the complex then leads to the recycling of the components 
back into their closed conformation separated from the membrane.
1.5.2. ESCRTing virus release
The topology of intralumenal vesicle formation in MVBs is identical to virus 
budding, and it has emerged that the ESCRT machinery is also essential for 
the release of HIV and a number of other retroviruses, as well as 
rhabdoviruses, arenaviruses, filoviruses (e.g. Ebola) and maybe influenza 
viruses (reviewed in Pornillos et al. 2002; see Marsh and Thali 2003; Bieniasz 
2006). The molecular mechanism through which the ESCRT machinery 
facilitates assembly is best understood for retroviruses, including HIV. The 
virus has evolved strategies to mimic ESCRT components and use the 
machinery for its own purposes.
1.5.2.1. Viral late domains
Successful release of HIV particles from a membrane is dependent on the p6 
domain at the C-terminus of Gag. Mutations or deletions in p6 lead to a 
reduction in particle release after the onset of assembly but prior to scission of 
the particle, resulting in virions remaining tethered to the cell membrane and to 
each other as observed by EM (Gottlinger et al. 1991; Huang et al. 1995; 
Demirov et al. 2002). With HIV p6 mutants, budding profiles can be seen 
aligned along the plasma membrane like a set of lollipops (Pornillos et al.
2002). Mutational analysis of the p6 domain revealed a motif PTAP in the N- 
terminal part that appeared to be critical for virus production and responsible 
for eliciting the mutant phenotype (Huang et al. 1995). This motif was termed 
the late (L) domain, due to its function in late stages of virus release (Parent et 
al. 1995).
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Figure 1.6. Viral late domains. PT/SAP motives are shown in red, PPxY motives in blue and 
YxxL motives are shown in green. LRSL in HIV-1 Gag representing the AIP1/ALIX binding site 
is shown in yellow. A recently described late domain FPIV in SV5 M is shown in pink. * 
Orthomyxovirus with potential late domain, ** Paramyxovirus. Adapted from Pornillos et al. 
(2002) and Bieniasz (2006).
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These late domains are autonomous signals that can be moved around within 
a Gag or matrix protein (Parent et al. 1995). They have been identified in a 
number of enveloped virus particles and three different motifs are well 
established so far: P(T/S)AP (Gottlinger et al. 1991; Huang et al. 1995), PPxY 
(Xiang et al. 1996; Yasuda and Hunter 1998) and YxxL (Puffer et al. 1997) (x 
stands for any amino acid). A fourth L-domain motif, FPIV in paramyxoviruses, 
has recently been discovered (Schmitt et al. 2005). For a list of L-domains and 
their respective localisation in viral proteins see Figure 1.6. Mutations in all of 
the L-domains lead to an arrest in particle release and incomplete budding 
through the respective cellular membrane, resulting in the tethered particle 
phenotype (reviewed in Freed 2002; reviewed in Pornillos et al. 2002; Bieniasz 
2006). Viral proteins can contain one or several L-domain motifs and so far 
they have been discovered in the Gag proteins of all retroviruses, in the matrix 
protein VP40 of the filoviruses Ebola and Marburg, in the M proteins of the 
rhabdoviruses vesicular stomatitis virus (VSV) and rabies virus (RV), in the Z 
proteins of the arena viruses lymphocytic choriomeningitis virus (LCMV) and 
Lassa fever virus (LFV), in the M1 protein of the orthomyxovirus influenza and 
in the M protein of the paramyxovirus SV5 (reviewed in Bieniasz 2006). It 
appears that viruses from the same family do not necessarily contain the same 
type of late domain and their localisation within the viral proteincan also vary. 
Late domains are functionally interchangeable between different virus types 
and even different virus families. They can promote virus release when 
transplanted into a different context and when placed into other positions 
within a retroviral Gag protein, and it was shown that the HIV-1 PTAP motif 
can restore virus release when transplanted into a Rous sarcoma virus (RSV) 
with a mutant L domain (Parent et al. 1995). The L domain in RSV can also be 
replaced by the N-terminal part of the VSV M protein, which contains an L 
domain of its own (Craven et al. 1999). However, the ability of L domains to 
function in heterologous contexts is not universal (Strack et al. 2002; Martin- 
Serrano et al. 2004), but it has proven conceptually useful and facilitated the 
identification of new late domains. In addition, late domain function can be 
provided to mutant viral proteins in trans, another strong experimental tool for
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the study of viral release (Martin-Serrano et al. 2001; Martin-Serrano and 
Bieniasz 2003).
The autonomous way in which L domains function suggests that they work by 
recruiting other viral or cellular factor rather than directly affecting virus particle 
formation (Parent et al. 1995). This has proven to be correct and it was shown 
that late domains indeed act as docking sites for a set of cellular proteins, 
namely the components of the ESCRT machinery. The PTAP motifs found in 
viral L domains mimic the PTVP motif in Hrs (see above) and show the same 
propensity for binding Tsg101 (Garrus et al. 2001; Martin-Serrano et al. 2001; 
VerPlank et al. 2001; Demirov et al. 2002). It has become evident that not only 
the PTAP motif works in this way but viruses have evolved various 
mechanisms of hijacking the MVB sorting machinery for their own purposes.
1.5.2.2. Mechanisms for virus release involving the ESCRT machinery
An overview of L domain interactions with components of the ESCRT 
machinery is found in Figure 1.7. HIV-1 was the first virus for which a direct 
interaction with the ESCRT machinery was discovered, and it is to date also 
the most intensively studied example. With its two late domain motifs PTAP 
and LRSL (Strack et al. 2003) it holds two entry keys to the ESCRT machinery. 
The PTAP motif in HIV Gag binds the ESCRT-I component Tsg101 via its UEV 
domain. Tsg101 appears to be a vital factor for HIV-1 release. Reduced 
binding to Tsg101, by PTAP mutant Gag p6 domains, impairs particle 
production (Garrus et al. 2001; Martin-Serrano et al. 2001; VerPlank et al.
2001). Depletion of Tsg101 by siRNA results in the same tethered particle 
phenotype as L domain mutations (Garrus et al. 2001), and expression of 
PTAP binding fragments of Tsg101 induces a late budding effect (Demirov et 
al. 2002). Virus budding of p6 depleted or PTAP mutant HIV-1 can be rescued 
by fusion of either Hrs (Pornillos et al. 2003) or the ESCRT-I components 
Tsg101 (Martin-Serrano et al. 2001; Martin-Serrano et al. 2003), Vps37B 
(Stuchell et al. 2004) or Vps37C (Eastman et al. 2005) to Gag. It was 
suggested that Tsg101 and other components of ESCRT-I can be recruited by 
Gag to the site of virus budding at the plasma membrane in HEK293T cells
HECT 
Ubiquitin 
E3 ligase
Figure 1.7. ESCRT-machinery mediating retrovirus assembly. The protein components of 
the ESCRT-0, I, II and III complexes are shown in light blue, yellow, blue and green, 
respectively. Viral Gag protein is shown in red. Ubiquitin moieties and ubiquitination or de- 
ubiquitination are depicted in purple. Interactions between cellular proteins are shown with 
direct contacts or black arrows (according to Hurley, 2006 as stated in Table 1.6.). Interactions 
between viral late domain motifs and cellular proteins are indicated with orange arrows. 
Ubiquitinated cellular cargo for sorting into MVBs is depicted in grey.
(Martin-Serrano et al. 2003). However, ESCRT-I is not sufficient for HIV 
budding and it was demonstrated that Tsg101 binding by Gag leads to the 
recruitment and involvement of the whole ESCRT machinery (Martin-Serrano 
et al. 2003; von Schwedler et al. 2003).
The second way for HIV Gag to recruit the ESCRT machinery is mediated by 
the C-terminal LRSL motif in p6. This sequence can recruit AIP1/ALIX (Strack 
et al. 2003; von Schwedler et al. 2003). As discussed above AIP1/ALIX can 
bind ESCRT-I and ESCRT-III and therefore provides a PTAP-independent way 
for Gag to recruit the ESCRT machinery. It was suggested that p6 binding to 
AIP1/ALIX is important for particle release in the context of a minimal Gag
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construct (Strack et al. 2002; Strack et al. 2003), and it is assumed that p6, 
Tsg101 and AIP1/ALIX form a ternary complex, which is then recruiting 
ESCRT-III. The Tsg101 and AIP1/ALIX pathways seem to be independent 
despite the interaction, since siRNA against AIP1/ALIX only mildly affects HIV 
particle release, while siRNA against Tsg101 abolishes it (Martin-Serrano et al.
2003). Thus HIV appears to have adopted a belt and braces ability to recruit 
ESCRT-III either through Tsg101 or through AIP1/ALIX. However, dominant 
negative mutants of the AAA ATPase Vps4 affect both pathways indicating 
that ESCRT-III assembly and disassembly is required for particle budding 
(Garrus et al. 2001; Martin-Serrano et al. 2003). In addition, the adaptor 
protein LIP5 also appeared to be required for virus release in either the 
PTAP/Tsg101 or the LRSL/ALIX pathway and siRNA knock-down of the 
protein led to a decrease in HIV budding (Ward et al. 2005).
The recruitment of AIP1/ALIX is not unique to HIV-1. It has been shown that 
EIAV, a non-primate lentivirus, uses a similar mechanism. EIAV Gag contains 
a motif YPDL in its p9 domain, which appears to be part of the same class of L 
domains as the LRSL motif in HIV Gag (Strack et al. 2003). AIP1/ALIX binding 
is therefore mediating virus budding through recruitment of ESCRT-III, 
dependent on a Y/LxxL consensus motif. This motif is also found in at least 
two other lentiviruses, VISNA and bovine immunodeficiency virus. The affinity 
of the EIAV p9 domain for AIP1/AL1X appears to be higher then the affinity of 
the HIV p6 domain, which is thought to compensate for the lack of another L 
domain motif (Strack et al. 2003). In addition, it was also shown that EIAV 
budding is independent of Tsg101 binding (Garrus et al. 2001; Martin-Serrano 
et al. 2003; Shehu-Xhilaga et al. 2004). However, AIP1/ALIX is not the only 
protein binding to the EIAV YPDL motif, this motif also binds to the p2 subunit 
of the clathrin adaptor AP-2 (Puffer et al. 1998). It was further demonstrated 
that siRNA against both AP-2 and AIP1/ALIX led to additive suppression of 
EIAV budding and it is therefore believed that early and late endocytic factors 
are involved in viral assembly (Chen et al. 2005).
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A YxxL motif may also be responsible for budding of influenza virus. The 
influenza matrix protein M1 contains a motif YRKL, which is required for the 
formation of particles and behaves like an L domain in the sense that it can 
restore virus budding in a position-independent manner and its mutation 
causes a decrease in virus production. However, no interaction between YRKL 
and AIP1/ALIX could be demonstrated. Instead it was suggested that the motif 
may bind Vps28 and that siRNA depletion of this ESCRT-I component leads to 
a reduction in influenza virus release (Hui et al. 2006).
Viruses containing PPxY L domain sequences are clearly dependent on the 
ESCRT machinery for efficient budding because they appear to be sensitive to 
inhibition by Vps4 and CHMP protein-based dominant inhibitors (Garrus et al. 
2001; Martin-Serrano et al. 2003; Martin-Serrano et al. 2003). However, they 
do not directly bind to class E proteins and must therefore access the pathway 
in a different way. PPxY is a consensus sequence for interaction with WW  
domains, a protein module present in HECT ubiquitin ligases (see above), and 
it was found that the L domain in Rous sarcoma virus p2b can bind to the WW  
domain region of a Nedd4 homolog (Kikonyogo et al. 2001). The functional 
relevance of this binding was then supported by the finding that over­
expression of the W W  domain region from Nedd4-like proteins inhibited RSV 
particle production. It has been demonstrated that not only RSV Gag, but also 
the structural proteins of various other viruses bind HECT ubiquitin ligases. 
PPxY motifs in vesicular stomatitis virus M protein (Harty et al. 1999), Ebola 
virus VP40 (Harty et al. 2000; Yasuda et al. 2003), human T cell leukaemia 
virus Gag (Bouamr et al. 2003; Blot et al. 2004; Heidecker et al. 2004; Sakurai 
et al. 2004) and Mason Pfizer monkey virus Gag (Yasuda et al. 2002) bind to 
various HECT ubiquitin ligases including Nedd4, LDI-1,2, BUL1, WWP1, 
WW P2 and Itch. Whilst over-expression of certain HECT ubiquitin ligases can 
modestly increase virus production in some cases (Yasuda et al. 2002; 
Yasuda et al. 2003; Sakurai et al. 2004), over-expression of WWP1, WWP2 or 
Itch can rescue a release defect that has been caused by the expression of 
W W  domain protein fragments or by mutations in the PPxY motif (Martin- 
Serrano et al. 2005). Even though HECT ubiquitin ligases are ubiquitously
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expressed (Wood et al. 1998), they don’t play redundant roles in virus budding 
and bind to a limited subset of PPxY motifs, possibly dependent on the 
sequence context or the subcellular localisation. The widest involvement was 
found for W W P1, WWP2 and Itch, which can also be recruited to sites of viral 
budding by MLV Gag or Ebola VP40 proteins. Recruitment of the ligases 
promotes PPxY dependent virus release provided the ubiquitin ligase domain 
is catalytically active. In addition, it has been shown that W W P1, WWP2 and 
Itch are recruited to class E compartments induced by dominant negative 
forms of Vps4, which provides an indication for the HECT ubiquitin ligase 
mediated linkage of PPxY motifs to the Vps pathway (Martin-Serrano et al. 
2005).
In several viruses PPxY motifs are found in combination with other late domain 
motifs (see Figure 1.6.). While in HIV Gag the PTAP and LRSL motives 
provide alternative entry routes to the ESCRT machinery, this does not appear 
to be the case for HTLV-1, where a PTAP motif is present in combination with 
a PPxY motif. The PPxY motif recruits the HECT ubiquitin ligase Nedd4.1 
leading to ubiquitination of the protein and subsequent internalisation from the 
plasma membrane. In a second step the PTAP motif then interacts with 
Tsg101 in late endosomes/MVBs. Both steps are required for virus budding, 
mutations in the PPxY motif lead to accumulation of Gag at the plasma 
membrane, and PTAP mutations to accumulation in intracellular vesicles (Blot 
et al. 2004). Binding to multiple ESCRT components has also been proposed 
for MLV Gag, where an interaction with Nedd4 ubiquitin ligases appears to be 
essential for budding, while interactions with both Tsg101 and Alix can 
enhance virus release (Segura-Morales et al. 2005). In Ebola VP40, two late 
domain motives are found overlapping and they both appear essential for 
efficient virus release (Martin-Serrano et al. 2004).
It is not fully understood how ubiquitin ligases mediate virus budding. The fact 
that functional HECT domains are required for efficient virus release led to the 
assumption that ubiquitination of some substrate, most likely the PPxY motif 
containing virus protein itself may be required. Indeed several studies indicate
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that PPxY motifs induce ubiquitination of retroviral Gag proteins (Strack et al. 
2000; Blot et al. 2004; Martin-Serrano et al. 2004). It is also possible that 
ubiquitination of viral proteins or bystander proteins may stabilise interactions 
with components of the ESCRT machinery at the site of virus budding, since 
several of them are known to bind ubiquitin (see chapter 1.5.1.2.). Apart from 
ubiquitination HECT ubiquitin ligases may have additional functions. Martin- 
Serrano and colleagues have shown that VWVP1 fragments lacking a HECT 
domain are more potent dominant negatives than constructs carrying a non- 
catalytically active HECT domain. This may indicate that some function is 
retained in the catalytically inactive constructs. Also the isolated HECT domain 
of WWP1 is a sufficient signal for recruitment to class E compartments induced 
by mutant Vps4, even though it is not binding to membranes itself, though 
some interaction between HECT domains and Vps factors may exist (Martin- 
Serrano et al. 2005).
For viruses encoding PTAP or YxxL motif and no PPxY motives ubiquitination 
seems to inhibit rather than increase particle formation. It was shown that 
when the PPxY motif from Ebola Vp40 is transferred onto HIV Gag this motif 
remains inactive and cannot promote virus budding (Martin-Serrano et al.
2005). Also, the ability of PTAP and YxxL containing domains to induce virus 
release seems to correlate with their ability to reduce rather than increase the 
small amount of ubiquitin carried by HIV Gag (Martin-Serrano et al. 2004; 
Gottwein and Krausslich 2005).
A fourth L domain motif FPIV has recently been identified in the paramyxovirus 
SV5. This motif is able to restore viral budding when transferred to L domain 
mutant proteins and is therefore a functional L domain it self. The budding of 
the virus appears to be dependent on the ESCRT machinery, since it is 
sensitive to dominant negative Vps4 variants, and on the pools of free 
ubiquitin, shown by a budding block upon proteasome inhibitor treatment. 
Mutation analysis revealed that the sequence corresponds to a more general 
motif 0P xV  (where 0  is a large hydrophobic amino acid) and that the proline is
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essential for functionality. Interacting proteins are not known so far (Schmitt et 
al. 2005).
Currently, L domains interacting with components of the ESCRT machinery 
are being discovered in more and more viruses. Recent reports have shown 
late domain motifs interacting with Tsg101 in the orbivirus Bluetongue virus 
(Wirblich et al. 2006) and in the prototypic foamy virus (PFV) (Patton et al.
2005). It appears that all these viruses have one thing in common, ESCRT-III 
and Vps4 are required by all known types of late domains and virus budding is 
inhibited when their function is abrogated (Garrus et al. 2001; Martin-Serrano 
et al. 2003; Martin-Serrano et al. 2003; Schmitt et al. 2005). To date it is not 
known whether any other viral proteins apart from Gag or matrix can interact 
with the ESCRT machinery and studies are often based on virus like particle 
release since Gag proteins are sufficient to form particle on their own. 
However, the possibility that ESCRT components may have a role in the 
formation of infectious virus through potential interactions with envelope 
proteins is intriguing and will be investigated in this thesis.
1.6. Aims of this thesis
Transport of envelope proteins to the site of virus assembly is crucial for the 
formation of infectious virions and may therefore be highly regulated. It is not 
yet understood how envelope, which is rapidly endocytosed can be 
incorporated into virus budding from the plasma membrane or from 
intracellular compartments.
My aim in the work described herein was to study the signals and molecular 
mechanisms involved in intracellular trafficking of lentiviral envelope proteins 
and in particular HIV Env, with a view to gaining a deeper understanding of the 
determinants and machinery required for targeting these proteins to the site of 
viral assembly and their integration into infectious particles. For most analyses, 
the envelope protein of the HIV-1 strain HxB2, or chimeric proteins consisting 
of the cytoplasmic domain of this envelope protein fused to the ecto- and 
transmembrane domains of CD4 were used. Chapters 5 and 6 also include
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studies with SIVmaC239 envelope proteins. Chapter 2 outlines the methods used 
in this thesis.
Chapter 3 presents a detailed analysis of the potential trafficking motifs in the 
cytoplasmic domain of HIV Env by morphological and biochemical methods. I 
found that apart from an established membrane proximal GYxx0 motif, a 
second C-terminal dileucine motif can mediate efficient endocytosis. Both 
motifs act independently of each other and with no additive effects. Using 
RNAi methods, I could show a dependence of internalisation on the clathrin 
adaptor AP-2 and clathrin itself.
Chapter 4 addresses the intracellular trafficking pathways of HIV Env by 
immunofluorescence and time course studies. I was able to demonstrate that 
the protein is routed from the plasma membrane via early endosomes to a 
compartment different from a classical late endosome, but positive for the 
tetraspanin CD81. CD81 is a marker for the virus containing vacuole in HIV 
infected macrophages. The distribution of tetraspanins in HeLa cells was then 
further characterised in chapter 5.
The work described in chapter 6 and 7 investigates envelope protein 
incorporation into budding virus. It is known that retroviral assembly requires 
interaction of the viral Gag protein with the ESCRT machinery. I have used a 
yeast-2-hybrid analysis to identify interactions between this machinery and HIV 
and SIV Env and found binding to Vps37B a component of ESCRT-I by both 
Envs, as well as binding of SIV Env to WWP2, an E3-ligase. Subsequently I 
used pull-down experiments and virus release assays to further characterise 
the functional role of these proteins.
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2. Materials and Methods
All chemicals were purchased from Sigma-Aldrich company (Poole, Dorset 
UK) unless otherwise stated.
2.1 Molecular Biology
2.1.1. Solutions for Molecular Biology 
Liquid broth (LB)
10g/I bacto-tryptone, 5g/l bacto-yeast extract, 10g/I sodium chloride 
(autoclaved)
LBA
15g/l agar in LB (autoclaved). This was cooled to 55°C before the addition of 
antibiotics, and then poured into 10cm bacterial Petri dishes.
soc
2% Tryptone, 0.5% yeast exreact, 10 mM NaCI, 2.5 mM KCI, 10 mM MgCb, 10 
mM MgS0 4 , 20 mM glucose. This was purchased ready made in 10 ml 
aliquots from Invitrogen Life-Technologies (Paisley, UK)
TAE
40mM Tris-acetate, 1mM EDTA pH8.0 
10X DNA loading buffer
25% glycerol, 0.5% bromphenol blue, 10x TAE
2.1.2. Bacteria
One Shot Top10 (Invitrogen Life-Technologies, Paisley, UK) were used for 
DNA preparation
XL1-Blue supercompetent cells (Stratagene, Amsterdam, The Netherlands) 
were used for Quickchange mutagenesis
2.1.3. Bacteria Transformation
Bacteria for small scale and medium scale DNA preparations (Top 10) and for 
Quickchange mutagenesis (XL1-Blue) were transformed using the heat shock 
method. Cells were mixed with 1-5pl of DNA and incubated for 30min on ice. 
The bacteria were heat shocked for 30sec or 45 sec respectively at 42°C and
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then cooled on ice for 2min. 250|jl (Top 10) or 500pl (XL1-Blue) SOC medium 
was then added and the bacteria incubated on a shaker at 37°C for 1 hr before 
plating onto LBA plates containing antibiotics as required.
2.1.4. Small scale DNA preparation (miniprep)
Top 10 competent bacteria were transformed with the DNA to be amplified and 
grown in appropriate selective plates O/N. Single colonies were picked and 
grown in 2 ml LB culture for 24 hr. The bacteria were harvested by 
centrifugation at 13200 rpm/1 min/4°C. The supernatant was removed by 
aspiration. The pellet was resuspended in 100 pi P1 resuspension buffer 
(Qiagen, Crawley, West Sussex) and the cells lysed in 200 pi buffer P2 from 
the same company. Cells were stored on ice and neutralised in 150 pi ice cold 
buffer N3 (Qiagen) and incubated on ice for 5 min. Cellular debris were 
removed by 5 min centrifugation at 13200 rpm/4°C. The supernatant was 
transferred to a fresh tube and the DNA precipitated by addition of 2 volumes 
of ethanol at RT and 2 min incubation. The precipitate was collected by 5 min 
max speed centrifugation at 4°C. The pellet was washed in 1 ml 70% ethanol, 
air dried and dissolved in 50 pi H2O.
2.1.5. Medium scale DNA preparation (midiprep)
DNA midi-preparation was done according to the protocol from Qiagen using 
purification columns. Briefly, Top 10 competent bacteria were transformed with 
DNA to be amplified and grown on appropriate selective plates O/N. Single 
colonies were picked and grown in 2 ml liquid LB cultures during the day. The 
liquid cultures were diluted into 50 ml and grown O/N again. Bacteria were 
harvested by centrifugation for 1 hr/3500 rpm/4°C and the supernatant 
discarded. Plasmid DNA was purified using the DNA midipreparation kit from 
Qiagen according to the manufacturers instructions. The crude preparation 
was precipitated with 3.5 ml isopropanol by centrifugation for 1 hr/3500 rpm/4°C 
and subsequently washed in 2 ml 70% ethanol.
2.1.6. Agarose gel electrophoresis
0.5,1,or 2% agarose (Bioplastics, Landgraaf, The Netherlands) in TAE was 
heated in a microwave oven to dissolve, allowed to cool for a few minutes until
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just molten and 0.5 pg/ml ethidium bromide (Invitrogen Life-Technologies) 
added. The gel mix was then poured into a DNA minigel apparatus and 
allowed to set. Samples were prepared in 1X DNA loading buffer and loaded 
into the wells. Gels were run at 100V in TAE running buffer.
2.1.7. PCR
PCR amplification of Env cytoplasmic tails for cloning of CD4-chimeras or Y2H 
constructs was done with the Qiagen Hot Star Taq PCR kit. Primers were 
designed to introduce restriction sites as required (see primer list). A PCR mix 
was set up using 10 pi Hot Star reaction buffer, 10 pi dNTP mix (containing 
1.25 mM of each nucleotide), 1pl of each primer (from 100 pmol/pl stock), 0.1 
pg DNA template, 72 pi H2O and 1 pi Hot Star Taq polymerase. The DNA was 
amplified in a thermocycler with 15 min at 95°C, 32 cycles of 1 min 95°C, 1 min 
62#C and 2 min 72°C, the last cycle was finished with 10 min at 72°C. PCR 
products were immediately purified and frozen or used for restriction digests.
2.1.8. Purification of PCR products
PCR products and DNA from digests were purified using PCR purification 
affinity columns from Roche (Lewes, East Sussex).
2.1.9. Restriction digests
All restriction enzymes and buffers were from Promega (Southampton, UK). 
For digestion of PCR products, 80pl of the product were mixed with 50 units of 
each restriction enzyme and 10 pi of the respective 10x digestion buffer. The 
reaction was filled up to 100 pi with sterile H2O. Digestions were run for 4 hr at 
37°C. Vectors for cloning were digested by mixing 5 pg of DNA with 50 units of 
each required enzyme and 5 pi of 10x reaction buffer. The mix was filled up to 
50 pi with H2O and digested in the same way as PCR products.
2.1.10. Dephosphorylation
Restriction digested vectors were purified as described for PCR reactions and 
then directly used for dephosphorylation with calf intestinal alkaline 
phosphatase (Promega). The amount of phosphatase needed was calculated 
with the formula 0.01 units of phosphatase per pmol of vector end. I.e. the
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digestion of 5 pg of 7500 bp DNA has 2 pmol of ends and therefore needed 
0.02 units. 60 pi of a digest containing 5 pg DNA was mixed with 7 pi of 
phosphatase buffer and 2 pi of 0.01 unit phosphatase dilution. The mix was 
incubated for 30 min at 37°C and another 2 pi phosphatase added for a further 
30 min. The phosphatase was deactivated for 10 min at 56°C. The prepared 
DNA vectors were run on a 1 % agarose gel, the bands excised with a razor 
blade and purified using the PCR purification columns from Roche (as 
described above) according to the manufacturers instructions.
2.1.11. Ligation
PCR products and digested dephosphorylated vectors were quantified on a 
1% agarose gel. The ligation was set up to use a vector to insert molar ratio of 
1:10. 3pl of 10x ligation buffer and 1 pi of T4 ligase (Promega) were used to 
make up a reaction of 30 pi. Ligation reactions were run at 16°C O/N and 5 pi 
of the reaction was then directly used to transform competent bacteria. Correct 
insertion of PCR fragments was tested by restriction digests and agarose gels.
2.1.12. Site directed mutagenesis
Mutagenesis of single and multiple bases was done using the Quickchange 
mutagenesis method® (Stratagene, Amsterdam, The Netherlands). Briefly, 
primers, including the mutation as a mismatch, were designed according to the 
guidelines by the manufacturer. Sample reactions were prepared by mixing 5 
pi of 10x reaction buffer with 5-10 ng of dsDNA template, 125 ng of forward 
and reverse primer each and 1 pi of dNTP mix. The mix was brought to a 
volume of 50 pi with autoclaved H2O and supplied with 1 pi of PfuTurbo DNA 
polymerase (2.5U/pl). The DNA was amplified in a thermocycler starting with 
30 sec at 95°C and then running 18 cycles of 30 sec 95°C, 1 min 55°C and 8 
min 68°C. The product was cooled on ice and 1pl of the enzyme Dpnl directly 
added into the PCR tube to digest for 1h at 37°C. 1-2pl of DNA was then used 
to transform 50pl of XL1-Blue bacteria as described above and colonies picked 
after 1 day and prepared for sequencing.
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2.1.13. DNA sequencing
DNA for sequencing was prepared from single bacterial colonies after cloning 
or mutagenesis reactions by small-scale preparation (miniprep) as described 
above. The concentration was measured by spectrophotometry and 1 pg DNA 
was air-dried. Sequencing was done by MWG-Biotech AG (Martinsried, 
Germany). Primers for sequencing of pSVIII HxB2 Env are described in Table
2.1. All other sequencing primers were standard and commercially available.
2.1.14. Primers
All primers designed specifically for this study, were purchased from MWG- 
Biotech AG, and are listed in Table 2.1.
2.1.15. Plasmids
Plasmid pSVIII encoding HxB2 gp160 was a gift from Dr. Robin Weiss (Wohl 
Virion Center, Windeyer Institute, UCL, London) and has been described 
(Helseth et al. 1990). Mutations of potential trafficking motifs (see Figure 3.3) 
were introduced using Quickchange mutagenesis and the constructs were 
verified by sequencing.
Chimeric proteins containing the CD4 ecto- and membrane spanning domains 
linked to the cytoplasmic domain of the HxB2 Env gene (see Figure 3.3) were 
made using a unique Hind III restriction site engineered into the pT4b 
molecular clone of CD4 (provided by D. Littman, New York University, New 
York) at nt 1351 such that four residues from the CD4 cytoplasmic domain (- 
RCRH) were included in the constructs, essentially as previously described 
(Sauter et al. 1996; Bowers et al. 2000). These residues act as a spacer to 
place the HIV Env membrane proximal endocytosis motif at a requisite 
distance from the membrane for functional activity (Jing et al. 1990). Cloning of 
the CD4 fragment into pSP65 has been described (Sauter et al. 1996). 
Restriction sites for Hindlll and EcoRI were introduced into the HIV HxB2 Env 
cytoplasmic domain by PCR with forward primer 5’- 
ATAGTGAATAAGCTTAGGCAGGGATATTCACCATTA-3’ and reverse primer 
5’- GCCGAATTCTTATAGCAAAAT CCTTTCCAAGCCCTGTCTTATTC-3’. The 
fragment was digested with Hindlll and EcoRI and cloned into pSP64
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Sequencing primers
HxB2Envfwd1
HxB2Envfwd2
HxB2Envfwd3
HxB2Envfwd4
Mutagenesis of HxB2 
Env
Y712lfwd
Y712lrev
LL814AAfwd
LL814AArev
LL855AAfwd
LL855AArev
E852Afwd
E852Arev
Cloning of Y2H 
plasmids
HIVEcoYfwd
HIVEcolfwd
SIVEcoYfwd
SIVEcolfwd
SIVEcodGYfwd
HIVXhorev
HIVPstrev
SIVBamrev
Mutagenesis of Y2H 
plasmids
HIVGY/AAfwd
HIVGY/AArev
HIVx0/AAfwd
HIVx0/AArev
SIVSPP/AAfwd
SIVSPP/AArev
SIVPPP/AAfwd
SIVPPP/AArev
SIVSxY/AAfwd
SIVSxY/AArev
SIVPxY/AAfwd
SIVPxY/AArev
Cloning of Gag-Env 
fusion proteins
Env-Bglll (primer 1) 
Env-Bglll (primer 2) 
Env-Notl
Gag-BamHI (primer 1) 
Gag-BamHI (primer 2) 
Gag-BamHI (primer 3) 
Gag-Nhel 
Gag-Bglll 
Gag-Kpnl
T CTT GATT GTAACGAGGATT GTGGAAC 
T CGCCACAT ACCTAG AAGAATAAG ACAG 
CGCAAAACC AGC AAG AAAAGAAT G AAC AAG 
CATAATGATAGTAGGAGGCTTGGTAGGTTT
AGAGTTAGGCAGGGAATTTCACCATTATCGTTTCAGACC 
GGTCTGAAACGATAATGGTGAAATTCCCTGCCTAACTCTG 
AAGAAT AGT GCT GTTAGCGCGGCCAAT GCCACAGCCAT AGC 
GCTATGGCTGTGGCATTGGCCGCGCTAACAGCACTATTC 
CAGGGCTTGGAAAGGATTGCGGCATAAGATGGGTGGCTAGTG 
CACTAGCC ACCC AT CTTAT GCCGC AAATCCTTT CCAAGCCCT G 
ATAAGACAGGGCTTGGCAAGGATTTTGCTATAAGATGG 
CATCTTATAGCAAAATCCTTGCCAAGCCCTGTCTTATTC
GCCGAATT CAG AGTT AGGC AGGG AT ATT C ACC ATT A 
GCCGAATTCAGAGTTAGGCAGGGAATTTCACCATTA 
GCCGAATT CAAGTT AAGGC AGGGGTAT AGGCCAGT G 
GCCGAATT CAAGTT AAGGC AGGGG ATT AGGCCAGT G 
GCCGAATTCAAGTTAAGGCAGAGGCCAGTGTTCTCT 
CCGCTCGAGCGGGTTATAGCAAAATCCTTTCCAAGCCCT 
CCAATGCATTGGTTCTGCAGTTTATAGCAAAATCCTTTCCAAGCCCT 
CGGG AT CCGCGT C AC AAG AG AGT GAGCT C AAGCCCTT G
GAATT CAG AGTT AGGC AG GCAGCTT C ACC ATTAT C GTTT CAG 
CT GAAACG AT AATGGT GAAGCT GCCTGCCT AACT CT GAATT C 
AGGCAGGGATATT CAGCAGC AT CGTTT CAGACCCAC 
GTGGGTCT GAAACG AT GCTGCT G AAT AT CCCT GCC 
CCAGT GTTCT CTT CCGC AGCCT CTTATTT CC AGCAG 
CT GCT GGAAAT AAG AGGCT GCGG AAG AGAACACT GG 
CCAGTGTTCTCTCCCGCAGCCTCTTATTTCCAGCAG 
CT GCT GGAAAT AAG AGGCT GCGG GAG AGAACACT GG 
TT CT CTTCCCC ACCCGCT GCTTT CC AGC AGACCC 
GGTCT GCTGGAAAGCAGCGGGT GGGG AAGAGAAC 
TT CT CT CCCCC ACCCGCT GCTTTCC AGCAG ACCC 
GGTCTGCTGGAAAGCAGCGGGTGGGGGAGAGAAC
GAAGAT CT GAG AGTT AGGCAGGGAT ATT CA 
GAAG AT CT AG AGTT AGGC AGGG ATATT C ACC A 
AT AAGAAT GCG GCCGCTT AT AGCAAAAT CCTTT CC AAG 
CGGG AT CCAAAATT CCCTGGCCTTC CCTT G 
CGGG AT CCGT GCTTT AGCTT GT ACTTCTTCTTT CCC 
CGGG AT CCCTT CAG AGC AG AC GACCAGAGC 
CTAGCT AGCATGGGT GCGAGAGCGTCAGT A 
GAAGATCTTTGTGACGAGGGGTCGTTGCCAAAGAG 
GGGGT ACCAT GGGT GCGAGAGCGT CAGT ATTAA
Table 2.1. Primers. All primers designed for sequencing, cloning and site directed 
mutagenesis in this study are listed in 5’ to 3' direction. All other primers used were either 
standard sequencing primers (T7) or have been described previously.
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(Promega Biotec, Southampton, UK). The CD4-containing sp65 and HIV Env 
cytoplasmic domain-containing sp64 plasmids were then digested with Pvul 
and Hindlll and ligated to create an EcoRI fragment encoding CD4/HIV Env 
chimeric proteins. Quickchange point mutagenesis (Stratagene, Amsterdam, 
The Netherlands) was used to convert the Hindlll site to the original Env 
sequence using forward primer 5’AGGTGCCGGCACCGAAGAGTTAGGCA 
GGGATATTCACC-3’ and reverse primer 5’- GGTGAATATCCCTGCCTAAC  
TCTTCGGTGCCGGCACCT-3’ according to the manufacturers instructions. 
The constructs were verified by sequencing and cloned into vector pCR3.1 
(Invitrogen) using a Kpnl restriction site introduce by PCR upstream of the 
CD4 gene and the EcoRI site 3’ of the HIV Env sequence. Mutations of 
potential trafficking motifs (see Figure 3.3) were introduced using Quickchange 
point mutagenesis. Short tail constructs were generated by mutation of the 
codon for Gly at the position equivalent to 726 in the HxB2 sequence to a stop 
codon using the same method. Constructs were verified by sequencing and 
the proteins of appropriate molecular mass identified by western blotting for 
the CD4 domain.
Plasmids pCR3.1 containing the ecto- and membrane spanning domains of 
CD4 fused to the cytoplasmic domain of SIVmaC239 gp41 were constructed in 
the same way as described for the CD4-HIV Env chimera described above, in 
the laboratory of Dr. James A. Hoxie, University of Pennsylvania, Philadelphia 
and have been described previously (Bowers et al. 2000). Mutations of 
potential trafficking or protein-protein interaction motives were introduced using 
Quickchange mutagenesis in the laboratory of Dr. James A. Hoxie.
Y2H plasmids were obtained from Clontech (Palo Alto, CA, USA). Plasmid 
pGBKT-7 contains the DNA- binding domain of GAL-4, and pGADT-7 the 
activation domain of GAL-4 (see Figure 6.1). For plasmids containing HIV or 
SIV Env, the Env cytoplasmic domain sequence from the CD4-Env constructs 
described above was amplified by PCR. Upon amplification restriction sites for 
pasting into the multiple cloning site (MCS) of the Y2H vectors were introduced 
using primers as listed (Table 2.1). The sites were EcoRI and BamHI for SIV
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Env domains in both vectors and EcoRI and Xhol or Pstl for HIV Env domains 
in pGADT-7 and pGBKT-7, respectively. The vectors were digested with the 
required enzymes, dephosphorylated and ligated with the PCR fragments. 
Correct insertions were checked by sequencing. Mutations in the potential 
binding motifs were introduced with Quickchange Mutagenesis.
Y2H plasmids encoding components of the ESCRT machinery and the HECT 
E3-ubiquitin ligases WWP1, WWP2 and Itch were provided by Dr. Wesley 
Sundquist, University of Utah, Salt Lake City, USA. Some of these plasmids 
have been described previously (Stuchell et al. 2004). Y2H plasmids encoding 
all other E3-ubiquitin ligases used were obtained from Dr. Juan Martin- 
Serrano, Kings College, London, UK.
Vectors pCR3.1/YFP containing either full-length WWP2 from human origin or 
the amino acid residues 292-485 of the WW domain, were gifts from Dr. Juan 
Martin-Serrano, Kings College, London, UK and have been described (Martin- 
Serrano et al. 2005).
Expression plasmids pCAGGS/GST-p12 containing Vps37B, C or the WW  
domain of W W P2 were provided by Juan Martin-Serrano, Kings College, 
London, UK.
Plasmids pEGFP-N1, containing wt HIVhxb2 Gag or a PTAP/LIRL Gag mutant 
fused to GFP, were provided by Dr Wesley Sundquist, University of Utah, Salt 
Lake City, USA and have been described earlier (Hermida-Matsumoto and 
Resh 2000). These plasmids were used for the generation of Gag-Env fusion 
constructs (see chapter 6, Figure 6.6). For fusion to the PTAP/LIRL Gag 
mutant, the Env cytoplasmic domain was amplified by PCR from the pGADT-7 
HIV Y construct described above, introducing restriction sites for Bglll and 
Notl. Vector pEGFP-N1 containing the Gag mutant was digested with BamHI 
and Notl, thereby excising GFP, and ligated with the PCR Env fragment after 
dephosphorylation. For the fusion protein containing Gag without the p6 
domain and the Env cytoplasmic tail, Env was amplified from pGADT-7 HIV Y
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by PCR as described before, incorporating Bglll (primer 2) and Notl restriction 
sites. The Gag MA, CA and NC domains were amplified by PCR introducing 
restriction sites for Nhel and BamHI (primer 1). The Gag fragment was cloned 
into vector pcDNA3.1 and ligated to the Env PCR fragment after digestion of 
the vector with BamHI and Notl. For the construct encoding a myristoylated 
Gag p6 domain, Gag p6 was amplified from pEGFP-1 Gag wt by PCR 
incorporating restriction sites for BamHI (primer 3) and Bglll. The 93 bp at the 
N-terminus of Gag encoding the myristoylation site were amplified introducing 
restriction sites for Kpnl and BamHI (primer 2). Both fragments were 
subsequently cloned into vector pEGFP-N1. All primers used are listed in 
Table 2.1. All three constructs were cloned by Dr. Claudia Gonzales-Lopez.
The construct expressing the C-terminus of AP180 (AP180-C) was obtained 
from Dr. Harvey McMahon, MRC LMB, Cambridge, UK.
2.2. Cell culture
2.2.1. Solutions for cell culture 
Freezing medium
50% FCS (Bio-West, Ringmer, UK), 10% DMSO, antibiotics and DMEM or 
RPMI (Gibco Life Technologies, Invitrogen, Paisley, UK) as used for culturing 
of the cell line to be frozen 
Trypsin/EDTA
0.25% Trypsin and 0.7 mM EDTA in PBS, sterilised.
PBS
137 mM sodium chloride, 3.56 mM potassium chloride, 10 mM disodium 
hydrogen orthophosphate, 1.76 mM potassium dihydrogen orthophosphate, 
sterilised.
2.2.2. Growth media and passaging
For individual growth media see Table 2.2.
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Cell line
Hela
Hela CD4-HIV Env 
Hela CD4-SIV Env
PA317 CD4-SIV Env 
COS SP6 
HEK293T 
U937
Primary T-cells 
Sup T1
Jurkat tat CCR5
Primary
Macrophages
Source or 
generated by
Paul Maddon/Paul 
Clapham,
UCL, London
This study
Jim Hoxie
(Bowers et al. 2000)
Jim Hoxie
(Bowers et al. 2000)
Clare Futter,
UCL, London
Chad Swanson, 
KCL, London
Guido Poli,
Milan
Magda Deneka, 
isolated
from Buffy Coats
Jim Hoxie, 
Philadelphia
Jim Hoxie, 
Philadelphia
Magda Deneka, 
isolated from Buffy 
Coats
Growth medium
DMEM, 10% FCS, 
P/S
DMEM, 10% FCS, 
P/S, 750pg/mlG418
DMEM, 10% FCS, 
P/S, 400pg/ml G418
DMEM, 10% FCS, 
P/S, 400pg/ml G418
DMEM, 10% FCS, 
P/S
DMEM, 10% FCS, 
P/S
RPMI with glutamine, 
10% FCS, P/S
RPMI with glutamine, 
10% FCS, P/S, 20 
ng/ml IL-2
RPMI with glutamine, 
10% FCS, P/S
RPMI with glutamine, 
10% FCS, P/S, 
2mg/ml G418, 
Hygromycin
RPMI with glutamine, 
10% HS, P/S
Plasmids used for 
transfection
pCR3.1 CD4-HIV 
Env
Infected from PA317 
CD4-SIV Env 
supernatant
pMV6 CD4-SIV Env
CCR5, Tat
Table 2.2. Cells used in this study.
Passaging of adherent cells
Cells were maintained in 10 cm tissue culture dishes (Falcon, Becton 
Dickinson, Oxford, UK) in an incubator with 5% CO2 at 37°C. Cells were 
passaged on average twice a week. The medium was aspirated and the cells 
washed with 10 ml pre-warmed PBS. Cells were detached by addition of 1 ml 
Trypsin/EDTA quickly at RT (e.g. HEK293T cells) or in the incubator (e.g. 
HeLa cells). 10 ml pre-warmed growth medium was added to the cells
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immediately after detaching and cells were split onto plates or coverslips as 
required.
Passaging of suspension cells
Suspension cells were typically grown in 25 cm2 flasks (Falcon) in an incubator 
as described above. They were passaged 1-2 times a week. The cells were 
transferred to a 15 ml Falcon tube and collected by centrifugation at 1200 rpm 
for 3 min at RT. The medium was aspirated and 10 ml PBS added and the 
centrifugation step repeated to wash. The cells were supplied with 10 ml fresh 
medium and split onto individual flasks.
2.2.3. Cell lines and primary cells
For cell lines and primary cells used in this study and their respective growth 
media see Table 2.2.
For preparation of primary macrophages, peripheral blood mononuclear cells 
(PBMCs) were isolated from buffy coats obtained from healthy donors 
(National Blood Service, Essex, UK) essentially as previously described 
(Pelchen-Matthews et al. 2003). Briefly, PBMCs were purified using density 
gradient centrifugation through Lymphoprep (Axis-Shield Diagnostics Ltd, 
Upton Huntingdon, UK). Monocytes were prepared from freshly isolated 
PBMCs by adherence to gelatine-coated plates. The following day, adherent 
monocytes were replated into tissue culture plastic, and differentiated in the 
presence of 10% human serum AB (PAA Laboratories GmbH, Pasching, 
Austria) and 10 ng/ml of M-CSF (R&D Systems, Oxon, UK), in 
RPM 11640/penicillin/streptomycin for 2 days. After 2 days, medium was 
replaced with RPMI 1640/penicillin/streptomycin containing 10 % human serum 
AB, but no M-CSF, and cultured until required.
Primary macrophages were infected by spinoculation for 2 hr at 2500 rpm at 
RT using 2 focus forming units (FFU) of HIV-1 BaL per cell, and grown for 10 
days prior to analysis. Macrophages were prepared and infected by Dr. 
Magdalena Deneka.
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2.2.4. Freezing cells
Adherent cells were washed in PBS, trypsinised as for passaging and taken up 
in 10 ml growth medium. The cells were centrifuged for 5 min at 1200 rpm at 
RT and the medium aspirated. Suspension cells were centrifuged for 5 min at 
1200 rpm at RT and washed once with 10 ml PBS by centrifugation. Cells from 
one 10 cm plate or one 25 cm2 flask were taken up in 3 ml freezing medium as 
described and frozen in 1.5 ml aliquots at -80°C for a minimum of two weeks. 
Later, cells were transferred to liquid nitrogen. To defrost, the cells were 
thawed in a 37°C water bath immediately after removing from the nitrogen 
tank. They were transferred to 10 ml pre-warmed growth medium in a Falcon 
tube and centrifuged at 750 rpm/RT for 5 min to wash. The medium was 
aspirated and the cells were resuspended in 10 ml fresh medium and seeded 
into flasks or plates.
2.2.5. Transfections 
FuGENE transfections
Transfections were performed according to the manufacturers instructions. 
Cells were plated onto coverslips one to two days prior to transfection and 
grown to a density of 30-50%. For a transfection reaction in a 24-well typically 
2 pi FuGENE (Roche, Lewes, UK) were mixed with 0.33-0.66 pg DNA in 33 pi 
serum free DMEM. The mix was incubated for 20 min at RT and added drop- 
wise directly onto the cells in growth medium.
Lipofectamine transfections
Lipofectamine and Plus-Reagent were purchased from Invitrogen Life- 
Technologies (Paisley, UK). For transfections in 24-well plates the appropriate 
amount of DNA (up to 1 pg depending on the plasmid, see individual 
experiments) was mixed with 25 pi serum free DMEM and 4 pi Plus reagent. 
The mix was incubated for 15 min at RT. 1 pi Lipofectamine was prepared in 
25 pi SFM and the two mixtures pooled and incubated for a further 15 min. The 
cells were washed twice in SFM and supplied with 150 pi SFM. The 
transfection mix was added dropwise to the cells and the cells incubated at 
37°C for 4-5 hr. The medium was then completed with FCS and antibiotics and
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filled up to 1 ml. For transfections in 6-well plates or 10 cm dishes, the volumes 
were increased according to the well size.
Nucleofection
HeLa cells were nucleofected using Nucleofector (Amaxa, Koeln, Germany) 
cell line solution R and program A-28. The cells were passaged one day prior 
to nucleofection and seeded at a density to reach 70% confluency the day of 
the nucleofection. The cells were washed in PBS and trypsinised as for 
passaging and taken up in 10 ml fresh culture medium. They were collected by 
centrifugation at 1200 rpm at RT for 3 min and resuspended in 10 ml PBS. The 
cells were counted to yield 1x106 cells per nucleofection reaction. The required 
amount of cells was centrifuged again and taken up in 100 pi nucleofection 
solution R per reaction. The suspension was mixed with typically 1-5 pg DNA 
or RNA, incubated at RT for 3 min, and transferred to a cuvette for immediate 
nucleofection. Pre-warmed growth medium (900 pi) was added to the cuvette 
immediately after nucleofection to take up the cells. This cell suspension was 
seeded onto plates or coverslips as required, prepared with the necessary 
amount of pre-warmed medium.
Nucleofection of primary macrophages was done by Dr. E. Ruiz-Mateos. The 
macrophages were detached from plates using Trypsin/EDTA for 20-30 min 
and nucleofected essentially the same way as described for HeLa cells but 
using the solution from the Macrophage nucleofection kit (Amaxa) and 
program Y-10.
2.2.6. Selection of stable cell lines
Cells were transfected using the FuGENE method as described above. Two 
days after transfection the cells were transferred to 6-well plates and supplied 
with DMEM containing antibiotics for selection. G418 (750 pg/ml) was used for 
selection of CD4-HIV Env chimera expressing cells. Single colonies were 
picked and resuspended in 24-wells with selective medium. Growing colonies 
were trypsinised and diluted to give about one cell per 96-well. Plates were 
screened for cell growth and growing colonies transferred to bigger plates for 
expansion and subsequent expression testing by immunofluorescence.
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2.3. Antibodies
The antibodies used in this study are listed in Table 2.3.
2.3.1 Preparation of F(ab’)2fragments
F(ab’ )2 antibody fragments of the human monoclonal antibody 2G12 against 
HIV gp120 were generated using the ImmunoPure® Preparation Kit from 
Pierce (Rockford, IL, USA). Digestion buffer was prepared by dissolving 2.72 g 
of sodium acetate in 1 L of ultra pure water and adjusting the pH to 4.5. 
Antibody (1 mg in 500 pi) was diluted to 5 ml in digestion buffer, concentrated 
to a volume of 200 pi in an iCON™ Concentrator (Pierce) by centrifugation, 
and diluted to a final volume of 1 ml. Immobilised pepsin was prepared in 
digestion buffer as described by the manufacturer and the antibody solution 
added. Digestion was done for 4 hr at 37°C in a shaker. The crude digest was 
separated from the resin and the resin washed in 11.5 ml digestion buffer to 
pool with the digest. The product was purified using a protein A column as 
described by the manufacturer and fractions collected. The protein content in 
the product was checked by SDS-PAGE and coomassie staining (see Figure 
2 .1).
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Figure 2.1. F(ab)’2 preparation. Coomassie staining of non-reducing gel showing the 
undigested antibody compared to the digestion product after Protein A column purification.
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Antigen Antibody name Species/Isotype Source Use
Primary Reagents
CD4 #19 Mouse ascites James Hoxie3 IP
CD4 Q4120
fluid
Mouse lgG1 Quentin Sattentaub IF, WB
CD9 MCA469GA Mouse lgG2b Serotec IF
CD63 1b5 Mouse lgG2b Mark Marsh0 IF
CD81 M38 Mouse lgG1 Fedor Berditchevsky IF
Clathrin HC 23 Mouse lgG1 BD Bioscience WB
Clathrin LC Clathrin LC Rabbit polyclonal Frances Brodsky IF
c-myc 9E10 Mouse lgG1 BD Bioscience IP, WB
EEA1 Anti-EEA1 polyclonal Rabbit polyclonal MJ Clague, S. Urbe IF
EEA1 EEA1 MAb Mouse lgG1 BD Bioscience IF
Gamma-adaptin 100/3 Mouse lgG2b Sigma IF
GFP Anti-GFP MAb Mouse lgG1 Roche WB
GST GST (Z-5) Rabbit polyclonal Santa Cruz WB
HA HA-tag polyclonal Rabbit polyclonal BD Bioscience IP, WB
HIV gp41 CH02F5 Human IgG H. Katinger6 IF
HIV gp120 IAM 2G12 Human IgG H. Katinger1* IF
HIV p24 38:96K and EF7 Mouse lgG1 B. Wahrenb WB
LAMP1 Ra-LAMP1 Rabbit polyclonal Sven Carlsson IF
p2 of AP-2 AP-50 Mouse lgG1 BD Bioscience WB
Transferrin receptor H68.4 Mouse lgG1 IS Trowbridge IF
TGN 38/48 44 Rabbit polyclonal George Banting IF
Tubulin DM 1A Mouse lgG1 Sigma WB
Ubiquitin P4G7 Mouse lgG1 Covance WB
Ubiquitin (poly FK1 Mouse IgG Biomol Int. UK WB
only)
Ubiquitin FK2 Mouse IgG Biomol Int. UK WB
Vps28 Vps28 (N-12) & (S-16) Goat polyclonal Santa Cruz WB
Vps37B UT425 Rabbit serum Uta von Schwedler WB
WWP2 AIP2 Goat Polyclonal Santa Cruz WB
Secondary
Reagents
Goat IgG Ant -goat HRP Rabbit polyclonal Pierce WB
Human IgG Ant -human FITC Goat polyclonal Pierce IF
Human IgG Ant -human Biotin Goat polyclonal Pierce IF
Mouse IgG Ant -mouse Alexa 488 Goat polyclonal Molecular Probes IF
Mouse IgG Ant -mouse Alexa 594 Goat polyclonal Molecular Probes IF
Mouse IgG Ant -mouse HRP Goat polyclonal Pierce WB
Mouse lgG1 Ant -lgG1 Alexa 594 Goat polyclonal Molecular Probes IF
Mouse lgG1 Ant -lgG1 Alexa 647 Goat polyclonal Molecular Probes IF
Mouse lgG1 Ant -lgG1 Biotin Goat polyclonal Molecular Probes IF
Mouse lgG2b Ant -lgG2b Alexa 488 Goat polyclonal Molecular Probes IF
Rabbit IgG Ant -rabbit Alexa 488 Goat polyclonal Molecular Probes IF
Rabbit IgG Ant -rabbit Alexa 594 Goat polyclonal Molecular Probes IF
Rabbit IgG Ant -rabbit HRP Donkey polyclonal Pierce WB
Table 2.2. Antibodies used in this study. aEndres et al. 1996, bobtained via MRC AIDS 
Reagents Program, cFraile-Ramos et al. 2001. Use of antibodies is indicated as follows; 
Immunofluorescence (IF), Western blot (WB), Immunoprecipitation (IP).
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2.4. RNAi experiments
2.4.1 siRNA (Oligonucleotides)
|j1 subunit of AP-1
AAGGCAUCAAGUAUCGGAAGA (Martin-Serrano et al. 2005)
|j2 subunit of AP-2:
GAUCAAGCGCAUGGCAGGCAU (Fraile-Ramos et al. 2003)
CHC-2 clathrin
UAAUCCAAUUCGAAGACCAAU (Motley et al. 2003)
2.4.2. Transfections for RNAi
For knock-down the cells were nucleofected with 300 pmol of siRNA as 
described above, and the entire reaction was plated onto one 10 cm dish and 
incubated for 3 days at 37°C. The cells were then nucleofected again with 150 
pmol siRNA, plated onto coverslips and incubated for a further 3 days prior to 
analysis by immunofluorescence as described above and previously (Lui- 
Roberts et al. 2005).
For p2 knock-down, cells were nucleofected once with 150 pmol siRNA, 
seeded onto coverslips and into 6-well plates and incubated for 56 h prior to 
analysis by western blotting, transferrin and antibody-uptake experiments and 
immunofluorescence as described above.
For clathrin knock-down, cells were nucleofected with 300 pmol siRNA and the 
entire reaction was plated onto a 10 cm dish. After 24h the nucleofection was 
repeated using 150 pmol siRNA. The cells were plated onto coverslips and 
incubated for 56 h prior to analysis by antibody feeding assays and 
immunofluorescence.
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2.5. Cell preparation for IP and protein gels
2.5.1. Protease Inhibitors
Complete Protease cocktail (Roche, Lewes, East Sussex)
Tablets were dissolved to make a 25x stock dilution, which was then directly 
added to the lysis buffer
2.5.2. Buffers for Lysis
50mM Tris pH 7.4, 150mM NaCI, 5mM EDTA, 5% Glycerol, 1% Triton X-100. 
Protease inhibitors were added to the lysis buffer directly prior to use. For 
analysis of ubiquitinated proteins the lysis buffer was supplemented with 0.1%  
SDS and 1.25 mg/ml NEM.
2.5.3. Preparation of lysates
Lysis buffer was added to cell in plates or centrifuged suspension cells 
typically using 50pl per well for a 6-well dish or 200pl for a 10cm dish or 1x107 
suspension cells. Adherent cells were scraped into the buffer and cells were 
lysed for 30min on ice. Cellular debris were removed by centrifugation for 
15min at 13000 rpm and 4°C. Alternatively, cells were lysed in equivalent 
amounts of 2X protein loading buffer (as described for SDS-gel 
electrophoresis).
2.6. Immunoprecipitation
2.6.1. Preparation of Protein A Sepharose Slurry
Protein A coupled to Sepharose beads (Sigma) was swelled in PBS over night 
on a shaker. The beads were centrifuged for 10 min/1500 rpm and washed 
twice in PBS. Finally the beads were resuspended in PBS to increase the 
volume 10x and kept at 4°C.
2.6.2. Immunoprecipitation
Protein A Sepharose beads (20 pi) were prepared by centrifuging 200 pi of the 
slurry for 2 min/8000 rpm and aspirating the supernatant. Cell lysates (200 pi - 
as described above) and an appropriate amount of antibody were added to the 
beads and the precipitation incubated for 1 hr on a rotation wheel at 4°C.
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Precipitates were centrifuged for 5 min/8000 rpm at 4°C and then washed 
twice for 10 min at 4°C in 500 pi of lysis buffer (as described above) containing 
only 0.1% Triton X-100. Immunoprecipitates were eluted from the beads in 50 
pi non-reducing sample buffer (62.5 mM Tris pH 6.8, 10% glycerol, 2% SDS 
and 0.002% bromophenol blue) by vortexing, 5 min boiling and vortexing 
again. The beads were removed by 5 min centrifugation at 13200 rpm. For 
immunoprecipitation of ubiquitinated proteins SDS and NEM supplemented 
wash buffer was used as described for the lysis above.
2.7. SDS-Gel electrophoresis
2.7.1. Preparation of minigels
This method is based on that of Laemmli (1970). Resolving gels were 
prepared using 8-12% Protogel acrylamide solution (Gene Flow, National 
Diagnostics, Fradley, UK), Protogel buffer from the same company, 0.1%  
TEMED and 0.1% APS (from a 10% stock). Stacking gels were prepared using 
4 % Protogel, Protogel stacking buffer, 0.1% TEMED and 0.1% APS. Protein 
samples and broad range molecular weight markers (prestained rainbow 
markers, Amersham International pic., Little Chalfont, UK) were prepared by 
dilution in sample buffer (62.5 mM Tris pH 6.8, 10% glycerol, 2% SDS and 
0.002% bromophenol blue) for non-reducing gels. Reducing sample buffer was 
purchased from Sigma or prepared by addition of 50 mM dithiothreitol. 
Samples were heated to 95°C for 5 min just prior to loading onto the gel. Gels 
were run at 100 V in gel running buffer (25 mM Tris, 192 mM glycine, 0.1%  
SDS).
2.7.2. Coomassie staining
Gels were stained for 20 min at RT in coomassie solution (40% methanol, 10% 
acetic acid, 0.05% Coomassie R250) and destained for at least 1 hr in destain 
solution (30% methanol, 7% acetic acid). Gels were dried on Whatman paper 
using a gel drier (Bio-Rad).
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2.8. Western blotting
2.8.1. Solutions for western blotting 
Transfer buffer
1L 10x buffer was prepared with 0.25 M Tris, 1.92 M glycine and 200 ml 
methanol and 0.1% SDS 
Blocking solution
10% milk powder (Marvel, Spalding, UK) in PBS 0.1% Tween 
Probing solutions
Blocking solution with antibodies in dilutions of 1:100 -1 :2500
Washing buffers
Buffer 1: PBS, 0.1% Tween
Buffer 2: PBS, 0.3% Tween
Detection reagents
Super Signal® West Pico Chemiluminescent Substrate and Super Signal® 
West Dura Extended Duration Substrate were purchased from Pierce.
2.8.2. Blotting procedure
Extra thick blotting paper (Bio-Rad) and nitrocellulose membrane (Schleicher 
and Schuell, Whatman, Dassel, Germany) were soaked in transfer buffer and 
placed on a semi-dry blotting apparatus (Bio-Rad). A SDS-PAGE minigel was 
placed on top of the membrane directly after running and covered with another 
layer of extra thick blotting paper. Proteins were typically transferred for 30 min 
at 10 V. The transfer was analysed by placing the blot in Ponceau solution for 
2 min and rinsing in water. Blots were blocked in 10% milk blocking buffer for 
30 min or over night and quickly rinsed in washing solution 1. Blots were 
incubated for a minimum of 1 hr with the 1 ° antibody on a rolling rotor and 
subsequently washed three times in washing buffer 1. Another 1 hr incubation 
with 2° HRP-coupled antibody was followed by 3x5 min washes in washing 
buffer 2 and 3x5 min in washing buffer 1. Blots were developed by 30 sec 
incubation in detection reagent and placed in a film cassette. 
Chemiluminescence films (Amersham Bioscience, Little Chalfont, UK) were 
developed in a X-ograph X-ray film developer (Xograph Imaging systems, 
Tetbury, UK).
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2.9. Antibody feeding assays
2.9.1. Basic procedure
For antibody feeding, stable cell lines or transfected cells as indicated were 
grown on coverslips for the time required, washed twice in BM pH 7.4 (RPMI 
containing 0.2% BSA and 10 mM HEPES) and incubated for 15min-2h as 
indicated in 250pl BM containing antibody in dilutions of 1/100 to 1/500 at 
37°C. The cells were cooled on ice for 5 min, washed twice in 4°C BM to 
remove unbound antibody, fixed in 2.5% formaldehyde and processed for 
immunofluorescence.
2.9.2. Acid stripping
After feeding and cooling on ice, cells were washed twice in cold BM and the 
surface bound antibody was acid stripped by rinsing twice in cold elution 
medium (RPMI 1640 containing 10 mM MES and 0.2% BSA, pH 3.00) and 
incubating 2 x 3  min in elution medium. Cells were re-neutralised by washing 
twice in cold BM followed by 5 min incubation in BM. Cells were then fixed and 
processed for immunofluorescence.
2.10. Tf feeding assays
For transferrin (Tf)-feeding experiments, p2 siRNA transfected or mock treated 
Hela cells were washed 2x with BM (as described above) and incubated for 30 
min at 37°C in 250pl BM to remove endogenous Tf. The cells were then 
incubated in 250 pi fresh BM containing 200 nM human transferrin coupled to 
Alexa Fluor 594 (Tf-594) purchased from Molecular Probes Invitrogen (Paisley, 
UK) at 37°C. After 10 min the coverslips were placed on ice and washed with 
cold PBS. The cells were then fixed and processed for immunofluorescence as 
required. Alternatively, 594Tf was added for the last 10 min of an antibody 
feeding incubation.
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2.11. Immunofluorescence
2.11.1 Solutions for Immunofluorescence 
Fixation solution
Serum free DMEM containing 2.5% formaldehyde and supplemented with 
20mM HEPES (pH7.0)
Washing solution
Serum free DMEM supplemented with 20mM HEPES (pH 7.0) 
Permeabilisation solution
PBS++ containing 20% fetal calf serum, 15mM Glycine, 20 mM HEPES and 
0.05% Saponin
2.11.2. Basic immunofluorescence procedure
Cells cultured on glass coverslips were fixed in fixation solution for 20 min at 
room temperature. The cells were then washed twice in washing solution 
followed by incubation in phosphate-buffered saline containing 1 mM Mg++ and 
0.5 mM Ca++ (PBS++) at 4°C for 10 min. Subsequently, the cells were 
permeabilised and blocked in permeabilisation solution for 15 min at RT. For 
surface staining, the same buffer without Saponin was used. All subsequent 
incubations and washing steps were carried out in the 
permeabilisation/blocking buffer. The cells were incubated for 45 min at room 
temperature with antibodies against CD4, gp120, p24 or cellular proteins. After 
extensive washing, the cells were incubated at room temperature in the dark 
for 30 min with Alexa Fluor-labelled secondary antibodies. The cells were 
washed five times in permeabilisation buffer, twice in PBS++, and quickly in 
water before mounting on glass slides with Mowiol.
2.11.3. Microscopy and picture processing
Coverslips were examined at ambient temperature through a 60x oil immersion 
lens (NA 1.4) on a Nikon Optiphot 2 microscope fitted with a MRC 1024 
confocal laser scanner (Bio-Rad Laboratories). Images were acquired using 
the Bio-Rad Lasersharp software, taking either single confocal sections or Z- 
series stacks, which were assembled to projections using the same software. 
Disassembly of stacks into single layers and montages were done with the
102
software I mage J (NIH). Raw images were then imported into Adobe 
Photoshop CS2 and Illustrator CS2 to generate figures.
2.11.4. Colocalisation analysis
Colocalisation analysis was done using the softwares Volocity (Improvision, 
Coventry, UK) or MetaMorph (Universal Imaging Corp. Downingtown, PA, 
USA) as indicated for specific experiments. Raw images from confocal single 
sections in red and green channels were used for the analysis with both 
software packages. For Volocity, the images were imported into files and the 
channels pseudo-coloured in green and red, respectively. An image sequence 
was then created containing the two channels. The image sequence was 
processes using the colocalisation tool. A region of interest (e.g. transfected 
cell) was selected in the image view by rendering and cropping. Minimum 
thresholds for analysis were obtained by measuring the fluorescence intensity 
of a control image and non-specific background staining. No maximum 
threshold was set. Colocalisation was measured in the whole region of interest 
as determined above and values obtained were imported into Microsoft Excel. 
Percentage values of green channel colocalising with the red channel were 
used for further analysis and comparison of different data sets. Analysis in 
MetaMorph was essentially the same using green and red channel raw images 
as panels A and B to calculate colocalisation using the specific feature of the 
program. No image sequence creation was needed here and measurements 
generated were directly exported to Excel.
2.12. Endocytosis assays
2.12.1. Solutions for assays 
Binding medium (BM)
RPMI containing 0.2% BSA and 10 mM HEPES, pH 7.4 
Elution medium (EM)
RPMI with 10mM MES and 0.2% BSA, pH 2.3
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2.12.2. Antibody iodination
Antibodies were iodinated using the method of Bolton and Hunter (Bolton and 
Hunter 1973). Antibody (300|jg) was dialysed against 0.1 M disodium 
tetraborate buffer (pH 8.5) using a collodion microdialysis capsule with 4 
changes of buffer for 30 min each at 4°C. 0.5mCi of 125l Bolton and Hunter 
reagent (Amersham, GE Healthcare,) were transferred into a screw capped 
1.5 ml tube with a charcoal trap connected to collect vaporised iodine. 
Benzene was removed from the reagent using a steady, gentle stream of 
nitrogen gas, until no liquid was visible in the tube. The charcoal trap was 
discarded. Q4120 (50pg) in 0.1 M disodium tetraborate was added to the 125l 
reagent, mixed by vortexing, and incubated for 20 min at RT, mixing every 2-3 
min. The reaction was stopped by the addition of 0.2M glycine in 0.1 M 
disodium tetraborate to adjust the final volume to 300pl. The mix was then 
vortexed and incubated at RT for 5 min. Two 5pl aliquots were removed into 
separate tubes containing 495pl elution buffer (PBS with 0.25% gelatin, 0.02%  
sodium azide) for TCA precipitation (TCA aliquots, see below). The remaining 
mixture was fractionated on a 10DG column (Econo-pac, Bio-Rad 
Laboratories), which had been pre-washed with 20ml PBS and 20ml elution 
buffer. 25 fractions of 0.5ml were collected and 3pl of each counted on a y- 
counter to allow the elution profile to be plotted. The 125l-bound peak was 
pooled, split into 100pl aliquots and stored at -20°C. Three 10pl samples from 
each TCA aliquot (from the total reaction mix before fractionation), and two 5pl 
aliquots from the pooled iodinated antibody sample (from the protein peak 
following fractionation) were counted on a gamma-counter. 20pl of each TCA  
aliquot were added to 180pl elution buffer (in triplicate), and 5pl of the pooled 
antibody to 195pl elution buffer (in duplicate), 13% trichloroacetic acid (TCA) 
was added to each sample at 4°C. Samples were incubated on ice for one 
hour, centrifuged for 10min at 4°C at 13’000 rpm, and the supernatants 
collected. A further spin was performed in order to remove all remaining 
supernatant. Supernatants and pellets were counted in a y-counter. The TCA 
precipitations allowed accurate determination of the specific activity of the 
antibody preparation. Specific activity was approximately 500 Ci/mmol.
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2.12.3. Endocytosis assays
Quantitative endocytosis assays were performed essentially as described 
(Pelchen-Matthews et al. 1991). Cells were seeded in 24-well plates at a 
density of 1.2-1.8 x 105 cells per well and grown to confluency over 2 days. 
Four wells of each cell line per time point were set up. The cells were then 
cooled on ice, washed 2x with BM and incubated with 250 pi BM containing 
0.5 nM 125I-Q4120 for 2hr on ice. Subsequently, the free antibody was washed 
away by two rinses with BM, and the cells were warmed to 37°C by immersion 
into a beaker containing 1 I of 37°C BM and incubated at 37°C for indicated 
time points. The samples for the zero time point were kept on ice. At the 
indicated times the cells were immersed in 4°C BM to stop endocytosis. For 
half of the wells, the cells were washed in 4°C PBS and then harvested directly 
in 400pl NaOH and transferred to tubes for y-counting to determine the total 
cell-associated radioactivity. To determine the intracellular activity, the 
remaining cells were rinsed twice with 0.5 ml 4°C EM adjusted to pH 2.3 and 
then incubated 2 x 3  min with the same medium to remove cell surface-bound 
antibody. These cells were then harvested in NaOH as above. The proportion 
of the internalised activity for each time point was determined by dividing the 
acid-resistant activity by the total cell-associated activity and the endocytosis 
rates were calculated by analysis of data from the first 5 min of warm-up as 
described (Bowers et al. 2000).
2.13. Yeast-2-hybrid assays
All yeast-2-hybrid analysis was done using the Matchmaker 3 system from 
Clontech (Basingstoke, United Kingdom) and yeast strain AH 109 (James et al. 
1996), which is characterised by the following genotype: MATa, trp1-901, Ieu2- 
3, 112, ura3-52, his3-200, gal4A, gal80A, LYS2 :: GAL 1 uas-GAL 1 tata- HIS3, 
G A L2uas-G A L2tata-A D E2, UR A3 :: MEL1 uas~MEL1 tata- lacZ
2.13.1. Growth media 
YPDA
For 1L medium 10 g yeast extract, 20 g peptone (both Becton Dickinson) and 
950 ml water were autoclaved. 50 ml of 40% filter-sterilised glucose and 15 ml 
of 0.2% sterile adenine sulphate were added.
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YPDA -Agar
Preparation as for YPDA, but 20 g agar (Becton Dickinson) was added before 
autoclaving and the medium was used to pour plates.
SC-A
10 g agar in 400 ml water autoclaved 
SC-B
0.73 g yeast nitrogen base without amino acids and ammonium sulfate, 2.5 g 
ammonium sulfate and 10 g dextrose in 100 ml water filter sterilised 
Amino acid drop-out plates for selection
SC-B was supplied with amino acid drop-out mixes (Becton Dickinson) e.g. -  
Leu/-Trp, -His/-Leu/-Trp or-Ade/-His/-Leu/-Trp before sterilisation. 100 ml SC- 
B were mixed with 400 ml SC-A to pour plates. For X-a-Gal selection 500 pi of 
20 mg/ml X-a-Gal (Becton Dickinson) were added to the -Ade/-His/-Leu/-Trp 
medium and plates were subsequently kept in the dark.
2.13.2. Solutions 
LiAc
0.1 M LiAc, 10 mM Tris pH 7.5 and 1 mM EDTA made fresh for each use from 
sterile 10x LiAc and 10xTE (EDTA/Tris)
PEG 40%
8 ml of sterile 50% w/v PEG 3350 were mixed with 1 ml each of 10 x LiAc and
10x TE from above
Z-buffer
16.1 g/l Na2H P 0 4 x 7H20 , 5.5.g/l NaH2P 0 4 x H20 , 0.75 g /I KCI, 0.246 g/l 
M gS04 x 7H20 , pH 7.0 in water autoclaved 
p-Gal solution
100 ml Z-buffer, 0.27 ml p-mercaptoethanol (BDH), 1.67 ml (3-X-Gal (20 mg/ml 
in DMF) (Stratagene)
2.13.3. Vectors and constructs
For the vectors used see section 2.1.15. on plasmids. The individual 
constructs used are listed in chapters 5 and 6 respectively. Constructs 
containing SIV or HIV Env cytoplasmic domains were created as described in 
chapter 2.1.15. Constructs containing ESCRT components and the E3 ligases
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W W P1, W W P2 and Itch were a gift from Dr. Wesley Sundquist, University of 
Utah, Salt Lake City, USA and constructs containing all other E3 ligases were 
obtained from Dr. Juan Martin-Serrano, Kings College, London, UK.
2.13.4. Yeast transformation
For starter cultures 5-10 yeast AH 109 colonies were picked from an YPDA 
agar plate after 3-5 days of growth at 30°C. The colonies were suspended in 
50-100 ml YPDA in duplicate and grown over-night at 30°C. The next morning 
the ODeoo of the starter culture was determined in a spectrometer and the 
culture diluted to reach an ODeoo of approximately 0.2-0.3 in 500-800 ml YPDA 
depending on the number of transformations. The culture was grown for a 
further 3-5 hours until the OD600 reached a value between 0.5 and 0.7, before it 
was harvested in a centrifuge at 1800 rpm/10 min at RT. Harvested yeast was 
washed in 200 ml (for the 500 ml culture) or 400 ml (for the 800 ml culture) 
sterile H2O and centrifuged as above. A LiAc solution was prepared to yield 
0.5 ml per 100 ODs (e.g. yeast culture of 500 ml with OD600 0.5 yields 250 
ODs = 2.5 x 100 ODs, 1.25 ml LiAc are needed). The yeast was resuspended 
in the LiAc solution and incubated at RT for 1.5 h to make the yeast 
competent. Competent yeast was mixed with 0.2 x the volume (total volume of 
yeast + LiAc) of ssDNA from herring sperm (Sigma), which had been boiled for 
8 min and cooled on ice, the mix was directly used for transformations. 60pl 
yeast was aliquoted into sterile tubes and mixed with 1-2 pg of each AD and 
DBD vector DNA construct, 228 pi 40% PEG solution were added and the 
transformation mixed by vortexing. Transformations were set at 30°C O/N prior 
to 15 min heat shock at 42°C and plating onto -Trp/-Leu selective SC plates. 
The colonies on the selective plates were grown for 5 days before picking for 
analysis.
2.13.5. X-a-Gal selection assays
Colonies from double transfection selective plates (-Trp/-Leu) were randomly 
picked after 5 days, harvesting 5-10 colonies per transformation, and 
suspended in 10 pi YPDA. The suspension was added to fresh -Trp/-Leu 
plates as a drop to create master plates. These plates were incubated at 30°C 
for two days until growth was visible. Velvets and a replica press were then
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used to copy the master plates onto selective SC plates (all -Trp/-Leu), 
starting with X-a-Gal/-Ade/-His and then proceeding through to -Ade/-His and 
-H is  plates with the same copy. Last, the master plate was copied onto YPDA  
to check for successful transfer. The plates were set at 30°C and analysed 
daily for growth and the formation of blue colonies on the X-a-Gal plate.
2.13.6. Beta-Gal filter assays
Master plates were prepared as described above and grown for two days. For 
each master plate a Petri dish was fitted with a Whatman paper (Schleicher 
and Schuell, Dassel, Germany) and the paper soaked with 1.8 ml J3-Gal 
solution. A filter membrane (Amersham Bioscience) was slightly pressed onto 
the master plates and then carefully lifted off taking the colonies with it. The 
filter was dipped into liquid nitrogen for 10 seconds and thawed on a piece of 
Whatman paper. The filter was then placed onto the soaked paper in the Petri 
dish and set at 30°C until blue colonies appeared.
2.14. In vitro transcription-translation
In vitro transcription-translation of c-myc and HA-tagged proteins in the vectors 
pGADT-7 and pGBKT-7 was done using the “TNT coupled reticulate lysate 
system” from Promega. The mix for one reaction was set up with 25 pi rabbit 
reticulocyte lysate, 2 pi reaction buffer, 1 pi T7 RNA polymerase, 1 pi mix of 
amino acids (1mM, except methionine), 2pl 35S-methionine (Redivue, 
Amersham (10mCi/ml)), 1pl RNasin (40U/ml), appr. 1pg DNA template and 
nuclease free H2O to fill up to 50 pi. The mix was incubated for 90 min at 30°C 
and then analysed on SDS-PAGE.
2.15. Co-lmmunoprecipitation
Interactions between in vitro translated proteins were tested by co- 
immunoprecipitation. A protein A-Sepharose slurry was prepared as described 
above (section 2.6.1.). To absorb unspecific interactions to protein A, the 
translated proteins were incubated for 2 hr at RT rotating with 10% protein A- 
Sepharose. The beads were removed by centrifugation at 14’000 rpm/3min at 
4°C. Two proteins to be tested were pooled and incubated for 1-2 hr/RT. A 
specific immunoabsorbant was prepared by incubating 100 pi of 10% protein
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A-Sepharose with anti-HA or anti-myc antibodies for 2 hr at 4°C. The beads 
were centrifuged for 1 min/14000 rpm, the supernatant aspirated and the 
beads washed 5x in PBS containing protease inhibitors, vortexed, centrifuged 
again and resuspended in PBS 5% milk. The pre-incubated protein mix was 
added to the prepared beads and antibody and incubated with mixing O/N at 
4°C. The mix was centrifuged, the supernatant aspirated and the beads 
washed 3 x in buffer (150 mM NaCI, 50 mM Tris pH 7.4, 0.1% NP-40 and 
protease inhibitors) and 2x in PBS with protease inhibitors. After centrifugation 
the beads were resuspended in 2x non-reducing sample buffer and boiled to 
elute the bound protein. Samples were run on SDS-PAGE for analysis.
2.16. GST pull-down assays
HEK293T cells were plated at 0.7 x 106 cells/well in 6-well dishes and co­
transfected with the two constructs to be tested for interaction (one in 
pCAGGS/GST-p12) using Lipofectamine as described above. 48 hr post 
transfection the cells were lysed in 200 pi lysis buffer (see chapter 2.5.2) 
containing protease inhibitors. Samples were incubated 10 min at 4°C and 
centrifuged for 5 min/8000 rpm at 4°C to remove the cellular debris. The 
supernatant (20 pi) was stored for SDS-PAGE. The rest of the supernatant 
was incubated with 150 pi of 10% protein A-Sepharose for 1-2 hr at 4°C. 
Beads were removed by centrifugation at 500g for 5 min and supernatants 
incubated with 25 pi of a 50% glutathione-Sepharose slurry for 1-2 hr at 4°C. 
Beads were centrifuged at 500g/5 min/4°C and the unbound fraction removed. 
The pellet was washed 3x for 5 min at 4°C in lysis buffer (containing only 0.1 % 
Triton X-100) and the bound proteins eluted 3x in 12 pi non-reducing sample 
buffer each time at RT for 5 min. Eluates were pooled and analysed on SDS- 
PAGE.
2.17. VLP-release assays
Cells (HEK293T or HeLa) were grown in 6-well plates and transfected with 
plasmids encoding HIV Gag or Gag fusion proteins using the Lipofectamine or 
Nucleofection methods respectively. Cells were incubated from 20 to 48 hr 
before 2.5 ml of the supernatant medium were collected. Cellular debris were 
removed from the supernatant by centrifugation for 10 min at 4000rpm/10°C.
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The supernatant was then loaded onto a 20% sucrose cushion (20% sucrose 
in PBS sterile) and the VLPs were purified through the sucrose by 
centrifugation in a Beckmann Ultracentrifuge using rotor TLA55 for 90 min at 
47000 rpm/4°C. The supernatant was carefully aspirated and the VLP pellet 
resuspended in 30 pi of reducing SDS-PAGE sample buffer. The samples 
were boiled and processed for SDS-PAGE and western blotting
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3. Endocytosis of HIV envelope proteins
The assembly of enveloped animal viruses requires that the viral and cellular 
components that make up infectious particles are brought together at the same 
site within the infected cell at the same time. For the primate lentiviruses HIV- 
1, HIV-2 and SIV the key viral proteins required to generate infectious virus 
particles are Gag, Gag-Pol and Env (see chapter 1.2). While Gag alone can 
promote the formation of virus-like particles (VLPs), Env and Gag-Pol are both 
essential for the formation of infectious particles. Although a considerable 
amount is known about these proteins, little is understood of the mechanisms 
through which they are targeted to the sites of assembly in infected cells.
In many cell types, HIV assembles at the plasma membrane and, in the course 
of Gag oligomerisation, the viral membrane is derived from the plasma 
membrane of the infected cell. For these particles to be infectious, Env must 
be transported to the cell surface, but the levels of Env expression at the 
plasma membrane appear to be low (see chapter 1.4.2.1), and early studies of 
HIV infected T  cells showed that much of the newly synthesised Env is 
transported to lysosomes and degraded (Willey et al. 1988). It has recently 
become evident that in macrophages the assembly of Env-containing 
infectious HIV occurs on intracellular membranes, which have some 
characteristics in common with late endosomes, and not at the cell surface 
(Raposo et al. 2002; Pelchen-Matthews et al. 2003). The assembly of virus in 
distinct locations suggests that Env must contain the necessary trafficking 
information to ensure its correct delivery in different host cells. This 
information, and its appropriate interpretation in the infected cell, is likely to be 
essential for productive infection and pathogenesis. Indeed, deletion of a 
membrane proximal sorting/endocytosis motif in SIVmac239 Env enhances the 
viral cytopathic effect in vitro and abrogates pathogenesis in vivo (Sauter et al. 
1996; Fultz e ta l. 2001).
In comparison to other retroviruses HIV and SIV Env contain a relatively long 
cytoplasmic domain (150-200 amino acids, depending on the virus strain). This
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domain is essential for viral replication and pathogenesis in vivo although, for 
SIV at least, much of the cytoplasmic domain is unnecessary for growth in 
culture (Kodama et al. 1989). The cytoplasmic domain is believed to play key 
roles in virus assembly, and has been considered important for Env 
incorporation into virions and for Env interactions with the N-terminal matrix 
(MA) domain of HIV Gag (Cosson 1996; Vincent et al. 1999).
Previously, our lab has analysed the trafficking properties of SIVmac239 Env 
using chimeras containing the ecto -  and transmembrane domains of human 
CD4 fused to the cytoplasmic domain of Env, as well as native Env expressed 
from an alpha virus expression vector (LaBranche et al. 1995; Sauter et al. 
1996; Bowers et al. 2000). The CD4 chimeras offered the advantage that, 
while retaining similar trafficking properties to the native Env protein, they were 
more amenable to expression in stable cell lines and, as a consequence, to 
biochemical and morphological analysis (Sauter et al. 1996; Bowers et al.
2000). Using these approaches, it was demonstrated that a conserved GYxx0  
motif in the cytoplasmic domain of SIV Env functions as an endocytosis signal. 
The activity of this signal is dependent on a membrane proximal tyrosine (Y723 
in SIVmac239) that is highly conserved in all HIV-1, HIV-2 and SIV isolates 
(LaBranche et al. 1995). The corresponding tyrosine in HIV-1 Env (Y712 in HIV- 
1hxB2) also appears to function as an endocytosis signal (Rowell et al. 1995), 
and as a basolateral targeting motif in polarised cells (Lodge et al. 1997) (for a 
detailed discussion see section 1.4.2.1.). Previous studies also indicated that 
SIV Envs interact with clathrin adaptor complexes and that the membrane 
proximal G Yxx0 motif can bind both AP-1 and AP-2 adaptors (Bowers et al.
2000). In addition to the GYxx0 motif, SIV Env contains at least one additional 
endocytosis signal that remains to be mapped in detail (Bowers et al. 2000).
For HIV Env it was shown that the conserved GY7i2xx0 motif can also mediate 
endocytosis (Rowell et al. 1995; Wyss et al. 2001). However, mutation of Y7i 2 
did not abrogate internalisation indicating that additional motifs C terminal to 
Y7i 2 must be capable of mediating endocytosis (Wyss et al. 2001). Moreover, 
the GY7i2xx0  motif, as well as two dileucine motifs at position 814/815 and
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855/856 in the cytoplasmic domain can bind the p1 subunit of the clathrin 
adaptor AP-1 in vitro (Ohno et al. 1997; Boge et al. 1998; Berlioz-Torrent et al. 
1999; Wyss et al. 2001).
To study the endocytotic properties of HIV-1 Hxb2 Env in detail, I have used a 
set of Env mutants and a respective set of CD4-HxB2 Env cytoplasmic domain 
chimera. Using immunofluorescence and antibody feeding assays, as well as 
biochemical endocytosis assays with radiolabeled antibody, I demonstrated 
that the C-terminal dileucine motif is a functional endocytosis signal. The 
activity of this motif is functionally equivalent to that of the membrane proximal 
GYxx0 motif, the two signals operate independently and their activities are not 
additive. Immunofluorescence analysis showed that in the presence of either 
motif Env accumulates in intracellular organelles and only remains on the cell 
surface when both motifs are functionally defective. I employed RNA 
interference (RNAi) experiments to study the relevance of the clathrin adaptor 
molecules AP-1 and AP-2 for Env endocytosis in HeLa cells, and was able to 
show that both endocytosis motifs operate through interaction with AP-2 and 
the clathrin-mediated endocytic pathway.
3.1 Cellular distribution of HIV Env and Env cytoplasmic 
domain mutants
3.1.1. Cellular distribution of HIVHxb2 Env
To characterise the signals mediating Env trafficking and endocytosis I 
analysed the distribution of Env transiently expressed in HeLa cells. Cells were 
transfected with plasmid pSVIII containing HxB2 Env gp160 (referred to as 
construct Y wt) using FuGENE6 lipofection. Since expression of recombinant 
Env was low, the cells were treated with 5 mM sodium butyrate the night prior 
to analysis to increase expression levels. The distribution of the protein was 
analysed 48 h post transfection by immunofluorescence. Permeabilised cells 
were stained with a human monoclonal antibody that recognises a 
carbohydrate epitope on gp120 (2G12) and reacts specifically with post-ER 
forms of the protein (Buchacher et al. 1994). I found that the bulk of the protein 
was localised in the perinuclear area of the cell in a vesicular pattern and that
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little Env was expressed at the plasma membrane (Figure 3.1 A, top left panel). 
To further analyse Env distribution, I performed antibody-feeding assays. HeLa 
cells transiently expressing Env constructs were incubated with 2G12 for 2 h at 
37°C, then fixed and labelled intact or following permeabilisation, with a 
secondary FITC-coupled anti-human antibody. This allowed me to examine 
exclusively the Env population that had reached the plasma membrane and 
either remained at this site or undergone endocytosis. Little labelling was seen 
on intact cells (not shown), but on permeabilised cells a labelling pattern
Figure 3.1. Cellular localisation of HIV Env mutants. (A) HeLa cells transiently expressing 
HxB2 Env, or the indicated HxB2 mutants, were fixed, permeabilised and stained with a 
human anti-Env mAb (2G12) followed by a mouse anti-human antibody coupled to FITC. The 
steady state distribution of Env 48 h after transfection is shown. (B) The ability of the proteins 
to reach the cell surface was assessed by incubating live, Env expressing cells in media 
containing 20 pg/ml 2G12 for 2 h at 37°C prior to fixation, permeabilisation and staining with 
anti-human FITC. The staining in these cells indicates Env that had been exposed at the 
plasma membrane during the 2 h incubation. Env negative cells fail to show labelling with 
2G12 with either protocol (data not shown). All images show single 0.5 pm confocal sections. 
Scale bar 10-pm.
Y7121
YLL814/B15AA ILL814/815AA
Y712I
Y LL814/815AA I LL814/815AA
steady state staining antibody feeding
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similar to that observed above was seen (top left panel in Figure 3.1 B). These 
observations indicated that the steady state distribution of Env was achieved, 
at least in part, by transport of the protein to the plasma membrane and 
subsequent endocytosis.
3.1.2. Cellular distribution of HIV Env cytoplasmic domain mutants 
3.1.2.1. Generation of mutant Env constructs
To analyse the role of potential trafficking motifs on the surface expression and 
intracellular distribution of HIV Env, I decided to test a panel of mutant 
proteins, lacking either the membrane proximal GY7i2xx0 and/or more distal 
sequences. Apart from the highly conserved GY712XX0  motif the Env 
cytoplasmic domain contains several other short but highly conserved 
sequences, some of which overlap with potential tyrosine-based or dileucine- 
based sorting signals (Figure 3.2). A set of mutants base on HxB2 Env was 
generated by site directed mutagenesis (Figure 3.3). The GYxx0 motif was 
disrupted by changing Y 7i2 to I (Y7i2I). This single aa change was shown to 
completely inactivate G Yxx0 mediated sorting in SIV Env (Bowers et al. 2000). 
Further, the role of the dileucine motifs at positions 814/815 and 855/856 was 
investigated by generating dialanine mutants (Y LL8i4/8isAA and Y LLsss/sseAA). 
In addition, double mutants combining tyrosine and dileucine mutation were 
created. The mutants were transiently transfected into HeLa cells and their 
distribution analysed by immunofluorescence and confocal microscopy, as 
described in section 3.1.1.
3.1.2.2. Distribution of HIV Env mutants
Mutation of Y7i 2 to I did not markedly change the distribution of Env compared 
to the wt. The bulk of the protein was still seen in the perinuclear area of 
transfected cells, suggesting that this protein retained the ability to undergo 
endocytosis, though the distribution was perhaps a little more disperse (Figure 
3.1 A). When the dileucine motifs were changed to dialanine, Env localisation 
was almost identical to the wt Env, though again the distribution of the Y  
LLsss/sseAA construct was a little dispersed similar to the Y7i2I mutant.
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Figure 3.2. Sequence comparison for Env cytoplasmic domains. The amino acid sequences of representative isolates of different 
clades of the HIV-1 groups M, N, and O were aligned, and the sequence of SIVSMM is also shown for comparison. The amino acids are 
numbered as described by Korber et al. 1998. Amino acids conserved in all HIV-1 isolates and in SIVCPZ are shaded. Dileucines and 
YxxL motifs are in boldface. Strain HxB2 used in this study confers to subgroup B. Adapted from Wyss et al. 2001.
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Constructs containing a combination of LL8i4/8 isAA and Y712I mutations (I 
LL855/856AA) had a similar distribution to Y 7 1 2 I .  However, combination of 
LL855/856AA with Y 7 1 2 I  (I LL855/856AA) produced a protein that was redistributed 
to the plasma membrane with little evidence of intracellular protein (Figure 3.1
A). This result indicated that the C-terminal dileucine might play a role in Env 
internalisation, and was supported by antibody feeding experiments as 
described above (Figure 3.1 B). The distribution of the Env constructs after 2 
h Ab feeding was similar to that seen in the steady state labelling with all the
-1? ->P ^  <S>A>   V ' A A> A
HIV Env cytoplasmic domain RVRQGYSPLSFQTHLPTPRG PDRPEG IEEEGG ERDRDRSIRLVNGSLALIW DDLRSLCL
f  #  tf tf tf
FSYHRLRDLLLIVTRIVELLGRRGW EALKYW W NLLQYW SQELKNSAVSLLNATAIAVAEG
t f  t f  t f
TD R V IE W Q G A C R A IR H IP R R IR Q G LE R IU .
C D4-H IV  Env chimeras Hxb2 Env constructs
CD4 lumenal domain CD4TM gp41 cyt gp120 TM gP41
712 8 14 /15 855 /5 6
CD4-Y wt ....Y........ ............LL.. LL E n vY w t
CD4-Y712I .. 1.... .............LL. .LL Env Y712I
CD4-Y LL814/815AA ,...Y........ ............AA . LL Env Y LL814/815AA
CD4-Y LL855/856AA ....Y........ ............LL.. AA Env Y LL855/866AA
CD4-I LL814/815AA .. 1.... .............AA LL Env I LL814/815AA
CD4-I LL855/856AA .. 1.... .............LL.. AA Env I LL855/856AA
CD4-Y short .....Y.. (726 stop)
CD4-I short ..... I... (726 stop)
Figure 3.3. CD4-HIV Env chimeras and HxB2 Env cytoplasmic domain mutants. The
amino acid sequence of the HxB2 (HIV-1 Subtype B) gp41 cytoplasmic domain is shown with 
potential trafficking motifs shaded. Amino acids are numbered as described (Korber, 1998). 
CD4-Env chimeras were created by fusion of the gp41 cytoplasmic domain (gp41 cyt) to the 
ecto- and transmembrane domains of CD4 as described in Materials and Methods. Mutations 
were introduced as indicated. Short tail constructs were created by mutation of the codon for 
amino acid 726 to a stop codon. HxB2 Env constructs were generated by mutating the 
sequence of gp160 in vector pSVIII as described in Materials and Methods. Constructs 
combining Y7 1 2 I mutations with dileucine mutations are named I LL814/815AA and I LL855/856AA, 
respectively.
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constructs, except for the double I Ll_855/856AA mutant, antibody accumulated 
in the perinuclear region of the transfected cells, indicating that Env proteins 
had reached the cell surface and undergone endocytosis. By contrast, 
localisation of the I LLsss/sseAA mutant to the plasma membrane was even 
more pronounced than the steady state labelling. This led to the conclusion 
that the HxB2 Env contains at least two signals that mediate endocytosis and 
that, in addition to GY712XX0 , LLsss/sse but not LLsu/sis acts as a second 
endocytosis motif.
3.2 CD4-HIV Env chimeras
3.2.1. Generation of CD4-HIV Env chimeras
To compare the functional activities of the GYxx0 and LLsss/sss motifs as 
endocytosis signals I chose to determine the internalisation rates of proteins 
carrying either one or both of the putative signals. Since gp160 constructs are 
not expressed efficiently in the absence of other viral proteins, reproducible 
biochemical assays with native Env were not feasible. A chimeric system was 
therefore chosen, where the cytoplasmic domain of HxB2 gp41 was fused to 
the luminal and membrane spanning domains of CD4, as previously described 
for SIV Env (Sauter et al. 1996; Bowers et al. 2000). A detailed description of 
the cloning can be found in section 2.1. The set of constructs used is shown in 
Fig. 3.3. In addition to the constructs corresponding to the HxB2 Env mutants 
decribed above, two short tail variants where included, where a stop codon 
was introduced to replace the codon for G726. Thus the construct termed CD4- 
Y short, contained only the membrane proximal GYxx0, while construct CD4-I 
short was expected to contain no endocytosis information, equivalent to 
SIVcpmac Env (LaBranche et al. 1994). These constructs were used to generate 
stable HeLa cell lines.
3.2.2. Cellular distribution of CD4-HIV Env chimeras
To confirm that the CD4-Env chimeras were reliable models for native Env, 
their subcellular localisation was analysed by immunofluorescence (Fig. 3.4). 
Staining for a chimera containing the native HxB2 Env tail (CD4-Y wt) showed 
almost no cell surface staining and localised to the perinuclear area of the
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Figure 3.4. Localisation of CD4-HIV Env chimeras. HeLa cell lines stably expressing CD4- 
Env chimera were fixed, permeabilised and stained for CD4 with Q4120 and anti-mouse 
Aiexa-Fluor 488 to visualise steady state expression (A) or fed with Q4120 for 2 h at 37°C, 
then fixed, permeabilised and stained with anti-mouse Aiexa-Fluor 488 to show the CD4-HIV 
Env pool that has trafficked over the plasma membrane (B). All panels are single confocal 
sections. Scale bars -10  pm.
transfected cells. This was also the case for CD4 -Y712I, CD4-Y LL814/815AA and 
CD4-Y LI_855/56AA, (Fig. 3.4 A). CD4-Y short localised predominantly to internal 
vesicles, but these were more dispersed than for CD4-Y wt, suggesting that 
the cytoplasmic domain may contain information crucial for correct intracellular 
trafficking. Mutation of LL814/815AA in combination with Y712I (CD4-I LL814/815AA)
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still led to predominantly internal localisation, but again the distribution of this 
chimera appeared to be more dispersed and present at the plasma membrane 
to a greater extent than the corresponding Env variant. The CD4-I short and 
CD4-I LLsss/sseAA constructs, were localised predominantly at the plasma 
membrane as expected, since these mutants should lack both of the putative 
endocytosis motifs (Fig. 3.4 A) in agreement with the results for the 
corresponding Env constructs (see Fig. 3.1).
Plasma membrane targeting and internalisation of the CD4-Env chimeras was 
assessed in antibody feeding assays, essentially as described in section 3.1.1, 
using antibody Q4120 against CD4. As for Env constructs, the CD4-Env 
chimeras showed intracellular staining, consistent with the idea that the 
proteins reached the cell surface and were subsequently internalised (compare 
Fig. 3.1 B and 3.4 B). The low level of antibody labelling at the cell surface 
suggested this internalisation was very efficient. All constructs showed 
evidence of internalisation with the exception of the variants CD4-I short and 
CD4-I LLsss/sseAA, where labelling was seen primarily at the plasma 
membrane, suggesting that endocytosis of these constructs was reduced or 
abolished (Figure 3B). Together, these observations indicate that the CD4-Env 
chimeras provide a good model for HIV Env trafficking, and provide further 
evidence of a role for the C-terminal dileucine motif in Env endocytosis.
3.3. Biochemical analysis of CD4-HIV Env endocytosis
3.3.1. Endocytosis of CD4-HIV and CD4-SIV Env chimera
To determine the endocytotic activity of CD4-Env constructs 125I-Q4120 anti- 
CD4 was used in established biochemical assays as described by Pelchen- 
Matthews et al. (Pelchen-Matthews et al. 1991) and detailed in Materials and 
Methods. Previous experiments in our lab have shown that CD4-SIV Env 
chimeras are rapidly internalised from the cell surface and that 80% of the 
protein is found inside the cell after 60 min (Bowers et al. 2000). To test 
whether the cytoplasmic domain of HIV Env mediates similarly efficient 
endocytosis, internalisation of CD4-HIV Env chimera was compared to 
internalisation of CD4-SIV Env chimera, both expressed in stable PA317 cell
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lines. Both constructs were endocytosed rapidly from the plasma membrane 
(approx. 22%/min for CD4-HIV Env and 30%/min for CD4-SIV Env in the first 2 
min after warming up) and to a high extent (60-70% of the total after 60 min) 
(Figure 3.5). Endocytosis rates for HIV Env chimera are therefore comparable 
to the rates obtained with the SIV Env chimera.
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Figure 3.5. Endocytosis of HIV and SIV Env chimera. PA317 cells expressing the CD4-HIV 
Env or SIV Env chimera were incubated with 125I-Q4120 for 2 h at 4°C. Endocytosis was 
initiated by immersing the plates in BM at 37°C. At the end of the indicated time periods, the 
cells were transferred to ice cold BM, washed and the total and intracellular radioactivity 
determined as described in Materials and Methods. The graphs show the intracellular (acid- 
resistant) radioactivity as a percentage of the total cell-associated radioactivity at each time 
point. The error bars indicate the standard errors from the mean calculated for three assays for 
each cell line.
3.3.2. Endocytosis of CD4-HIV Env cytoplasmic domain mutant chimera
To measure the endocytosis activity of the different CD4-HIV Env constructs, 
with mutations in the potential trafficking motifs stable HeLa cells lines 
described in section 3.2.1. were used in 125I-Q4120 endocytosis assays. 
Representative endocytosis curves for all constructs are shown in Figure 3.6 
and the results of several experiments are summarised in Table 3.1. Chimeras 
containing the complete HIV Env cytoplasmic domain (CD4-Y wt) were 
internalised rapidly (approx. 6%/min in the first 5 min after warming to 37°C)
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and to a high extent (80% of the total after 60 min; Fig. 3.6 and Table 3.1). A 
similar endocytosis rate was also seen for CD4-Y short, confirming that the 
GYxx0 signal and can mediate efficient internalisation as previously shown 
(Wyss et al. 2001). However, mutation of Y712I did not diminish internalisation 
of constructs with a full-length cytoplasmic domain and the rates remained 
essentially the same, indicating that a second signal capable of mediating 
efficient internalisation is present. By contrast, the CD4-I short construct was 
internalised slowly (approx. 0.8%/min; Table 3.1 and Fig. 3.6) and to only a low 
extent (1 0 % of the total after 60 min) comparable to the bulk flow endocytosis 
of CD4 molecules lacking a cytoplasmic domain (Pelchen-Matthews et al. 
1992; Pitcher et al. 1999). These results were consistent with the high surface 
expression seen for this construct (Fig. 3.4). For LL814/815AA mutants, with 
either Y712 or Y712I, the rates and extents of internalisation were reduced only 
moderately compared to CD4-Y wt, indicating that the CD4-I LL814/815AA 
construct retained a functional endocytosis motif. By contrast, the CD4-I 
LLsss/sseAA construct showed a reduced internalisation rate similar to that 
found for CD4-I short, indicating that the functional endocytosis signals had 
been removed.
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Figure 3.6. Endocytosis of CD4-HIV Env chimeras. HeLa cells expressing the CD4-HIV Env 
chimera were incubated with 125I-Q4120 for 2 h at 4°C. Endocytosis was initiated by immersing 
the plates in BM at 37°C. At the end of the indicated time periods, the cells were transferred to 
ice cold BM, washed and the total and intracellular radioactivity determined as described in 
Materials and Methods. The graphs show the intracellular (acid-resistant) radioactivity as a 
percentage of the total cell-associated radioactivity at each time point for representative cell 
lines. The error bars indicate the standard errors from the mean calculated for several assays 
for each cell line. The data for all assays is summarised in Table 3.1.
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Together the morphological and biochemical data indicate that the cytoplasmic 
domain of HxB2 Env contains two functionally redundant endocytosis motifs, 
the membrane proximal GY712XX0  motif and the C-terminal dileucine motif 
(LI_855/856). Both motifs function with equivalent efficacy, and show no 
significant additive activity. Little if any endocytic trafficking activity is 
associated with the dileucine motif at 814/815.
Table 3.1. Endocytosis of CD4-spacer-HIV Env chimeras in stable HeLa lines.
Chimera type Endocytosis rate3 %/min ± SD
Intracellular (n)b 
%
Ywt 6.0 ± 1.2 81 (6)
Y712I 6.7 ± 1 .9 86 (4)
Y short 6.5 ± 3.6 92 (4)
I short 0.8 ± 0.5 10(3 )
Y LL814/815AA 5.1 ± 1.4 77 (2)
Y LL855/856AA 6.0 ± 1.6 78 (5)
I LL814/815AA 4.3 ±0.1 64 (2)
I LL855/856AA 0.3 ±0.1 15(3 )
aEndocytosis rates were calculated for the first 5 min after warming to 37°C as the mean and 
standard deviation from the mean (SD).
bProportion of initial cell surface counts that are intracellular after 60 min at 37°C for the 
indicated number of assays (n).
3.4. Analysis of additional regulatory sequences
The data presented above implies that the C-terminal dileucine LL855/856 is a 
functional endocytosis motif. Dileucine motifs have been frequently found to 
regulate endocytosis in cellular proteins (see section 1.4.1). In some cases, 
dileucine-based sorting signals require an acidic amino acid at position -4 
and/or -5 relative to the first leucine (Letourneur and Klausner 1992; Pond et 
al. 1995) or a phosphorylated serine (Pitcher et al. 1999) to be active. The C- 
terminal dileucine of HIV-1 has a glutamic acid at position -3 (aa 852 in HxB2). 
To test whether this residue has any regulatory effect on LL855/856 mediated 
endocytosis, a mutation E852A was introduced into HxB2 Env in the context of 
a Y712I mutation, where endocytosis should be entirely governed by LL855/856,
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Figure 3.7. Influence of E852 on Env endocytosis. C-terminal sequence the Hxb2 Env 
cytoplasmic domain with E852 highlighted in blue and mutant constructs used in this
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experiment listed (A). Hela cells were transfected with the mutant constructs and after 48 
hours either fixed, permeabilised and stained with 2G12 anti-gp120 and secondary anti-human 
FITC reagent (panel B), or fed for 15 min with 2G12, subsequently fixed, permeabilised and 
stained with anti-human FITC (C). Single confocal sections are shown. Scale bars = 10 pm
or in context of the double mutant I LLsu/sisAA (see Figure 3.7 A). The cellular 
distribution of these new constructs was compared to Y 712I, I LL814/815AA (both 
containing an intact LL855/856 motif), and I LLass/sseAA (where both endocytosis 
motifs are disrupted) mutants by steady state immunofluorescence (Figure 3.7
B) and antibody-feeding experiments (Figure 3.7 C). Localisation of the Env 
constructs was predominately intracellular in a vesicular pattern in a 
perinuclear region of the cell, except for I LUss/sseAA, where redistribution to 
the plasma membrane was observed in agreement with the data presented 
above (Figure 3.7 B). Thus LL855/856 can mediate intracellular localisation of 
Env in the combined absence of E852, the membrane proximal Y7i2xx0 motif 
and LL814/815- Antibody-feeding experiments reinforced these findings. Only the 
I LLsss/sseAA double mutant accumulated at the plasma membrane after 15 min 
2G12 feeding at 37°C, all other mutants were endocytosed (Figure 3.7 C). It 
can therefore be concluded that Ess2 exerts no regulatory effect on the activity 
of the C-terminal dileucine endocytosis motif.
3.5. Effects of clathrin adaptors on Env endocytosis
It was previously shown that HIV and SIV Env cytoplasmic domains can bind 
the clathrin AP-1 and AP-2 adaptor protein complexes through the conserved 
GYxx0 motif (Ohno et al. 1997; Boge et al. 1998; Berlioz-Torrent et al. 1999; 
Bowers et al. 2000; Wyss et al. 2001). Pull-down assays have also suggested 
that LL8i4/815 and LLsss/sse bind AP-1 (Wyss et al. 2001), but no previous 
evidence suggested that either of these motifs bind AP-2 or that the C terminal 
LL motif can mediate endocytosis of HIV Env.
3.5.1. Clathrin adaptor AP-2
To examine the functional activities of these signals in more detail, I used 
small interfering RNAs (siRNA) against the p2 subunit of AP-2, which have 
been demonstrated to inhibit p2/AP-2 mediated endocytosis (Fraile-Ramos et 
al. 2003; Motley et al. 2003). HeLa cells expressing CD4-Env constructs were
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Figure 3.8. AP-2 is required for normal CD4-Env distribution. HeLa cells expressing CD4- 
HIV Env constructs were transfected with a siRNA against the p2 subunit, or with buffer only
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(mock). After 56 h the cells were analysed for p2 expression by western blot (A) using clathrin 
heavy chain as a loading control. At the same time cells were fed with Alexa-Fluor 594 
conjugated Tf for 10 min at 37*C prior to fixation. Cells were then permeabilised and stained 
with Q4120 to show steady state distribution of CD4-Env by single confocal sections (B). Intact 
cells were stained with Q4120 and analysed for cell surface expression of CD4-Env (C), 
projections of Z-series stacks of confocal sections are shown. In both (B) and (C) a 
redistribution of CD4-Env constructs to the cell surface was observed. Scale bars - 10pm.
treated with the siRNA and the levels of p2 expression were analysed 56 h 
after nucleofection by western blot. To check protein loading, blots were also 
probed with an anti - clathrin heavy chain antibody. Typically siRNA reduced 
the expression of p2 by 80% (quantification of westernblot in Fig. 3.8 A). To 
test whether loss of p2 affected endocytosis, siRNA and mock treated cells 
were incubated with Alexa 594-coupled human diferric transferrin (594Tf) for 10 
mins at 37°C and the distribution of 594Tf assessed by fluorescence 
microscopy. In mock treated cells Tf was seen within endocytic vesicles with 
little labelling at the cell surface (Fig. 3.8 B). By contrast the majority of p2 
siRNA treated cells showed Tf accumulation at the plasma membrane, 
suggesting that endocytosis was inhibited. A minor fraction of siRNA treated 
cells did internalise Tf, suggesting that these cells had not taken up the siRNA 
or that the knock-down was incomplete.
To examine how p2 siRNA affected trafficking of the CD4-Env constructs, 
siRNA transfected and 594Tf-fed CD4-Env expressing HeLa cells were stained 
with anti-CD4 antibody. We found that the steady state distribution of CD4-Y 
wt was predominantly intracellular in mock and siRNA treated cells, but plasma 
membrane expression of the protein was increased in the p2 knock-down 
cells, indicating that CD4-Y wt internalisation from the plasma membrane was 
reduced or even stopped (Figure 3.8 B). It was assumed that the intracellular 
pool of CD4-Y wt represented protein that had not been cycling via the plasma 
membrane. The same change in distribution was observed for the CD4-Y 
LL855/856AA mutant, where endocytosis is mediated entirely by the GYxx0 
motif. To assess whether p2 knock down also affects endocytosis mediated by 
the C-terminal dileucine motif, we analysed the distribution of CD4 -Y712I 
constructs and found that plasma membrane expression was increased in the
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Figure 3.9. AP-2 is required for CD4-Env internalisation. HeLa cells expressing CD4-Env 
constructs were transfected with an siRNA to reduce expression of the p2 subunit of the AP-2 
complex or buffer only (mock). After 56 h the cells were fed with Q4120 anti-CD4 for 15 min at 
37°C (A) or for different time points as indicated (B). Alexa-Fluor 594 conjugated Tf was added 
for the last 10 min of feeding. Cells were then fixed, permeabilised and stained with a Alexa- 
Fluor 488 coupled secondary anti-mouse antibody. Projections of confocal Z-series are shown 
in A and B. The small panels in (A) represent the bottom (b) and middle (m) sections of the Z- 
series stack for CD4 staining shown on the left. Scale bars - 10pm.
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siRNA transfected cells (Figure 3.8 B). To further assess the observed 
redistribution to the plasma membrane and visualise the surface fraction of the 
protein, I stained intact siRNA and 594Tf treated cells with anti-CD4 antibody. It 
was apparent that mock treated cells for all three CD4-Env constructs show 
very low plasma membrane expression of CD4-Env (Figure 3.8 C). However, 
RNAi treatment led to an increase in plasma membrane expression levels, 
confirming the redistribution of CD4-Env in AP-2 knock-down cells.
Analysis of the steady state distribution could not determine whether the 
increased plasma membrane expression was indeed due to a reduction in 
endocytosis, or whether it resulted from an increase in transport to the plasma 
membrane. Antibody-feeding experiments were therefore performed, 
incubating mock and p2 siRNA transfected CD4-Env expressing HeLa cells 
with anti-CD4 for 15 min, adding 594Tf for the last 10 min. In mock treated cells 
the majority of the CD4-Env was internalised to a perinuclear area within 15 
min (Figure 3.9 A), with a similar distribution to that seen for the steady state 
staining (Figure 3.8 B). Efficient internalisation was observed for the construct 
with the wt cytoplasmic domain as well as for the two mutants lacking one of 
the two internalisation motifs. p2 siRNA treatment led to accumulation of CD4- 
Env at the plasma membrane, indicating that AP-2 is required for efficient 
endocytosis (Figure 3.9 A). This effect was observed for all three constructs, 
providing evidence of a role for AP-2 in Env internalisation mediated by either 
the G Yxx0 or the C-terminal dileucine motif. However, when antibody feeding 
was extended to 30 min or longer, internal pools of CD4-Env were also seen in 
the siRNA treated cells (Figure 3.9 B). This indicates that either residual AP-2 
was present or that CD4-Env may be internalised, albeit less efficiently, 
through AP-2 independent clathrin-mediated endocytosis (Motley et al. 2003) 
or clathrin-independent mechanisms.
3.5.2. Clathrin adaptor AP-1
To analyse whether the previously described interaction between HIV Env and 
the AP-1 clathrin adaptor and the observed recruitment of AP-1 by HIV Env to 
the TGN (Wyss et al. 2001) are directly relevant to HIV Env distribution and to 
examine a role for AP-1 in Env endocytosis we used siRNA against the p1
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Figure 3.10. Depletion of the p1 subunit of the AP-1 complex by RNAi. HeLa cells 
expressing CD4-Y wt were transfected with a siRNA against the p1 subunit. After 3 days the 
cells were transfected again with the same siRNA. Q4120 staining of fixed cells (A) or Q4120 
uptake assays (B) were performed 3 d after the second transfection. All cells were labelled for 
y-adaptin. p1 knock-down is indicated by a diffuse y-adaptin distribution. CD4-HIV Env 
distribution did not appear to be affected in either case by the knock-down. Scale bars - 10pm.
subunit of AP-1 (Hirst et al. 2003). As the incomplete AP-1 complex in p1 
deficient cells cannot be recruited onto membranes, the y-subunit of AP-1
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became cytosolic in |j1 RNAi treated cells (Fig. 3.10 A and 3.10 B), compared 
to its normal Golgi associated perinuclear distribution in mock treated cells. 
The impact of p1 depletion on CD4 Env distribution was again assessed by 
steady state staining (Fig. 3.10 A) and antibody feeding (Figure 3.10 B). We 
found that in both cases CD4 Y wt distribution was similar in mock and in RNAi 
treated cells. The protein is found predominantly in perinuclear vesicles, and 
can traffic over the plasma membrane, from where it is reinternalised. This 
suggests that AP-1 is not required for CD4-Env endocytosis and is not 
essential for its transport to the plasma membrane.
3.6. Clathrin and HIV Env endocytosis
The previous two sections demonstrated that efficient endocytosis of the CD4- 
HIV Env chimera is dependent on the clathrin adaptor AP-2 but not AP-1. 
However, it needs to be shown that internalisation is mediated by a clathrin 
dependent pathway. In addition, an AP-2 independent, slower internalisation 
pathway may exist and it remained unclear whether this activity was 
dependent on clathrin.
3.6.1. Effects of Clathrin knock-down
To investigate the role of clathrin in Env internalisation I chose to knock-down 
clathrin function by two independent methods, RNAi and dominant negative 
constructs.
3.6.1.1. Clathrin knock-down by RNAi
RNAi knock-down of the clathrin heavy chain has been described previously 
(Motley et al. 2003). To investigate the effect of clathrin knock-down on the 
distribution of CD4-HIV Env, HeLa cells expressing CD4-Y wt were 
nucleofected with siRNA targeted at the clathrin heavy chain in two 
subsequent rounds as described in Materials and Methods. To assess clathrin 
knock-down, siRNA or mock treated cells were fixed, permeabilised and 
stained with a rabbit antibody against clathrin light chain, which is 
concomitantly down-regulated. In mock cells, a strong perinuclear, punctate 
staining pattern was observed that almost completely disappears in RNAi 
treated cells (Figure 3.11). CD4-Env distribution in the knock-down cells was
steady state
131
antibody feeding
B
surface staining
Figure 3.11. Clathrin knock-down in CD4-HIV Env expressing HeLa cells. HeLa cells 
stably expressing CD4-Y wt constructs were nucleofected with two rounds of siRNA directed at 
the clathrin heavy chain or in buffer only (mock). Three days after the second nucleofection the 
cells were assayed for clathrin expression and CD4-Env distribution. For steady state staining 
(A) the cells were fixed, permeabilised and labelled with Q4120 anti-CD4 and anti-clathrin 
rabbit serum. Antibodies were detected with Alexa-Fluor labeled secondary reagents. (B) Cells 
were incubated for 15 min or 1 hr in BM containing Q4120, fixed and permeabilised and stained 
with anti-clathrin and secondary reagents to both antibodies. Surface expression of CD4-Env 
(C) was analysed by staining fixed, intact cells with anti-CD4 Q4120 and Alexa-Fluor coupled 
anti-mouse secondary reagent. Scale bars = 10 pm.
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analysed by steady state staining of fixed and permeabilised cells with anti- 
CD4 Q4120. Compared to the previously described perinuclear pattern 
observed in mock treated cells, a redistribution of CD4-Env to the plasma 
membrane was found in the clathrin knock-down cell (Figure 3.11 A) indicating 
a role for clathrin in the regulation of Env surface expression. Surface staining 
on intact cells provided further support for this observation (Figure 3.11 C). 
While in mock treated cells hardly any CD4-Env is observed at the cell surface, 
surface expression is markedly increased in the RNAi treated cells.
The effects of clathrin knock-down on CD4-Env internalisation were studied by 
antibody-feeding assays. RNAi or mock treated cells were fed with Q4120 anti- 
CD4 at 37°C for either 15 min or 1 hr as described above in section 3.5.1. In 
mock cells, the bulk of the antibody was detected in internal vesicles after 15 
min and accumulated there over longer feeding periods (Figure 3.11 B, left 
panels). In RNAi treated cells CD4-Env staining was seen at the cell surface 
after 15 min feeding, indicative of an inhibition of endocytosis. However, after 1 
hr antibody-feeding antibody was internalised in the clathrin knock-down cells 
and found in a perinuclear region (Figure 3.11 B, right hand panels). This 
result agrees with the findings in AP-2 knock-down cells. Thus, I conclude that 
clathrin is required for efficient endocytosis of CD4-Env, but slow endocytosis 
is found in knock-down cells either due to residual protein or to other 
pathways, which are clathrin and AP-2 independent.
3.6.1.2. Inhibition of endocytosis by AP180-C expression
To investigate the role of clathrin in CD4-HIV Env endocytosis further I chose 
to reduce the functional pool of clathrin in the CD4-Y wt expressing HeLa cells 
by transfecting an inhibitory AP180 construct (AP180-C; Ford et al. 2001). 
AP180-C contains a clathrin-binding domain and has a dominant-negative 
effect on clathrin function. If clathrin is needed for efficient but not slow CD4- 
Env internalisation, the AP180-C construct is expected to have the same effect 
as the clathrin knock-down by RNAi. HeLa cells stably expressing CD4-Y wt 
were nucleofected with AP180-C and assayed for CD4-Env distribution by 
steady state staining and antibody feeding (Figure 3.12). The effects of AP180- 
C expression corresponded well to the results from clathrin knock-down
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experiments described above. While control cells show a predominant 
perinuclear steady state distribution of CD4-Y wt, the majority of the protein is 
redistributed to the plasma membrane in AP180-C expressing cells. Efficient 
internalisation was inhibited, shown by cell surface accumulation of antibody 
after 15 min antibody feeding, while a slower clathrin-independent endocytosis 
pathway allowed internalisation to a perinuclear area after 1 hr.
control steady state 15 min fed 1hfed
Figure 3.12. Inhibiting clathrin function by AP180-C expression. HeLa cells stably 
expressing CD4-Y wt were nucleofected with myc-tagged AP180-C or mock treated (control). 
Two days post-nucleofection, the cells were either fixed and permeabilised for steady state 
staining with anti-CD4 Q4120 and anti-myc. Alternatively, cells were fed for 15 min or 1 hr as 
indicated with Q4120 in BM. Fed cells were fixed and permeabilised and subsequently stained 
with anti-myc and secondary reagents. Single confocal sections are shown. Scale bars = 10 
pm.
3.6.2. Effects of Env expression on endocytosis of cellular proteins
Since HIV Env is often expressed highly in transfected cells and appears to 
utilise AP-2 and the clathrin machinery for endocytosis, the question arose 
whether the hijacking of this machinery had any effect on the distribution of 
cellular proteins using AP-2/clathrin pathways. I chose to use transferrin (Tf) 
internalisation as a model system. HeLa cells were transfected with HxB2 Env 
and analysed 48 hr after transfection for Tf internalisation by Tf594 feeding
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Figure 3.13. Influence of Env expression on transferrin internalisation. Hela cells were 
transfected with HxB2 Env constructs and assayed after 48 hours. For panels (A) and (B), 
cells were starved for 30 min in BM and then fed with labelled transferrin (Tf-A!exa594, red) for 
15 min. Fed cells were fixed, permeabilised and stained with 2G12 anti-gp120 and anti-human
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FITC secondary antibody. (A) depicts a projection of confocal sections and (B) single confocal 
sections. Panel (C) shows single confocal sections of cells colabeled for Env (2G12 and anti- 
human-FITC, green) and transferrin receptor (H68.4 and anti-mouse Alexa-Fluor 594, red). 
Scale bars = 10 pm.
(as described in section 3.4.1) and staining for the transferrin receptor (TfR). 
Env expression was visualised by steady state staining with 2G12 anti-gp120. 
Env expressing cells showed a reduced uptake of Tf594 in comparison to 
untransfected cells (Figures 3.13 A and B) and punctate intracellular staining 
appeared lower or disappeared. However, there was no apparent difference in 
TfR distribution between transfected and control cells. In both cases TfR 
staining was punctate and intracellular. It could therefore be concluded that 
Env expression affects Tf internalisation. However, the mechanism behind this 
effect was unclear. As there was no apparent increase in surface expression of 
TfR, Env expression may have inhibited recycling of TfR to the cell surface as 
well.
3.7. Discussion
3.7.1. Identification of endocytosis motifs
The envelope glycoproteins encoded by primate immunodeficiency viruses are 
crucial components of the viral particle and essential for viral infectivity by 
binding the viral receptor and co-receptor on the host cells. In addition, as an 
external component of HIV and SIV particles they are a primary target for host 
immune responses and prominent candidates for vaccine development. It has 
become evident that surface expression of the lentiviral Envs in infected cells 
is tightly regulated (Marsh 1997; Marsh and Pelchen-Matthews 2000), and 
several motifs in the cytoplasmic domains of both HIV and SIV Envs are 
implicated in trafficking and endocytosis. In HIV it has been shown that Y712, 
which is part of a GYxx0 motif, as well as two dileucine motifs can bind to 
clathrin adaptors and may therefore function in clathrin-mediated sorting and 
endocytosis (Ohno et al. 1997; Boge et al. 1998; Berlioz-Torrent et al. 1999; 
Wyss et al. 2001). I have conducted a detailed morphological and biochemical 
analysis of potential endocytosis motifs in the Env protein of HIV-1 HxB2. I 
confirm that Y 712 is part of a functional signal that regulates Env cell surface
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expression and mediates efficient internalisation independently of other signals 
in the protein. I also show that the Y712I mutation, which inactivates the 
membrane proximal GYxx0 signal, does not change the plasma membrane 
expression of either native HxB2 Env constructs or a CD4-Env chimera, and 
that internalisation rates for these mutants are similar to those of constructs 
with an intact GYxx0 motif (Figures 3.1, 3.4 and 3.6 and Table 3.1). This 
supports the notion that additional endocytosis signals are present in the 
cytoplasmic tail (Berlioz-Torrent et al. 1999; Bowers et al. 2000).
It had previously been suggested that the C-terminal dileucine (LLsss/sse) is 
involved in restricting Env surface expression (Wyss et al. 2001). However, the 
mechanisms for this activity has remained unclear and a role in sorting Env 
from the TGN to the plasma membrane has been suggested (Wyss et al.
2001). My morphological analysis (Figures 3.1 and 3.4) now shows that 
mutation of LL855/856 alone does not change Env distribution and feeding 
experiments demonstrated that transport to the plasma membrane is still 
efficient. Also, the endocytic properties of this mutant remain unchanged 
compared to constructs with an intact cytoplasmic tail (Figure 3.6). I assume 
that in this case endocytosis is entirely mediated by the GYxx0 motif. A 
combination of Y712I and LLass/sseAA mutations leads to redistribution of the 
majority of Env to the plasma membrane in both full length Env constructs and 
CD4 Env chimeras, supporting the idea that LL855/856 affects surface 
expression (Figures 3.1 and 3.4). But, in contrast to earlier studies, I now show 
that the increase in plasma membrane expression is due to the loss of a 
functional endocytosis motif. Efficient endocytosis is abolished in the double 
mutant and the rates of uptake are similar to constructs lacking functional 
endocytosis motifs (CD4 HIV I short, Figure 3.6 and Table 3.1; tail less CD4 
(Pelchen-Matthews et al. 1991; Pitcher et al. 1999)), thus identifying the C- 
terminal dileucine as a second endocytosis motif. Significantly, the endocytotic 
properties of this motif appear to be independent of the GY712XX0  motif.
I could not find any evidence for regulation of the LL855/856 motif. Some leucine- 
based endocytosis motifs are regulated by an acidic amino acid residue at
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position -4 and/or -5 relative to the first leucine (Letourneur and Klausner 1992; 
Pond et al. 1995) or phosphorylation of a serine (Pitcher et al. 1999). The C- 
terminal dileucine of HIV-1 has a glutamic acid at position -3 (aa 852 in HxB2), 
however, mutation of this residue does not markedly change the distribution or 
endocytosis of Y 712I Env, where internalisation is entirely governed by the 
dileucine motif (Figure 3.7). I also investigated the roles for other potential 
trafficking motifs, e.g. dileucine 814/815, but did not find any evidence of an 
involvement in regulating endocytosis. Moreover the double mutant Y712I 
LL.855/856AA shows only basal rates of endocytosis, so the existence of other 
signals can be excluded.
HIV Env is therefore different from SIV Env, where a conserved C-terminal 
dileucine is present but does not appear to show any endocytotic activity 
(Bowers et al. 2000), even though some influence of the C-terminal dileucine 
on cell surface Env expression has been reported. Neither did I observe an 
additive effect of the two internalisation signals on endocytosis rates in HIV 
Env as previously suggested for SIV Env (Bowers et al. 2000). This shows that 
there are differences between trafficking of SIV and HIV Envs, even though the 
proteins are similar. These differences may have a significance for the 
assembly and biology of the two viruses.
3.7.2. Mechanisms of Env endocytosis
It has been demonstrated previously that GY712XX0  as well as LL.814/815 and 
LL855/856 bind the clathrin adaptors AP-1 and AP-2 (Ohno et al. 1997; Boge et 
al. 1998; Berlioz-Torrent et al. 1999; Bowers et al. 2000; Wyss et al. 2001). I 
provide evidence that in the absence of AP-2, in RNAi treated cells, HIV Env 
constructs are accumulated at the plasma membrane independently of which 
endocytosis motif is used (Figures 3.8 and 3.9). However, CD4-Env 
endocytosis is not abrogated but slowed down by the knock-down, in contrast 
to what appears to be a complete block of Tf internalisation, indicating that 
even though AP-2 is required for efficient internalisation of Env, an AP-2 
independent internalisation pathway may exist.
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There is evidence of interaction between the C-terminal dileucine motif in Env 
and AP-1, and it was suggested that Env recruits AP-1 to the TGN, where it is 
required for the correct routing of Env to the plasma membrane (Wyss et al.
2001). I used an RNAi approach to knock down AP-1 and analysed the 
distribution and endocytosis of CD4-Env chimera. I found no obvious change 
in Env distribution in these cells and showed that the protein is still trafficking 
to the plasma membrane, indicating that AP-1 is not essential for exit of Env 
from the TGN. However, these experiments did neither address the kinetics of 
Env transport to the plasma membrane nor was the intracellular trafficking of 
Env analysed. AP-1 may therefore be involved in efficient export of Env from 
the TGN or Env targeting to endosomal compartments.
Using an RNAi approach and a dominant negative inhibitor of clathrin coated 
vesicle formation, I could further demonstrate that Env endocytosis is indeed 
dependent on clathrin (Figures 3.11 and 3.12). My observations were 
analogous to the findings with AP-2 knockdowns. Both, clathrin and the AP-2 
adaptor protein are required for efficient Env internalisation, while a slower 
pathway may exist that is independent of both. It is unclear, whether this 
second, clathrin independent pathway is present in cells which have not been 
treated with RNAi. It may be possible that knock-down of the AP-2/clathrin 
machinery leads to up-regulation of alternative pathways, and that Env is 
internalised in these cells through pathways, which are not normally 
operational.
In addition, I have tested the effects of Env expression on transferrin 
internalisation and found that Env inhibits transferrin uptake but does not 
increase plasma membrane expression of the transferrin receptor. I therefore 
concluded that Env is able to hijack the AP-2 clathrin machinery for its own 
purposes and not only affects internalisation of cellular proteins but may also 
inflict their recycling to the plasma membrane. Whether similar effects exist in 
HIV infected cells or whether these are solely side effects of severe Env over­
expression remains to be established.
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In summary, I produced morphological and biochemical evidence that the C- 
terminal dileucine (LL855/856) is a second endocytosis motif in the HIV Env 
cytoplasmic tail and works independently of Y 712XX0 . Further, I could 
demonstrate that the C-terminal dileucine is involved in regulating Env surface 
expression and mediates internalisation in an AP-2 dependent manner. This 
shows that even though both the GY712 xx0  motif and LL855/856 are highly 
conserved in HIV and SIV, at least for endocytosis in HIV they are functionally 
redundant, suggesting other roles for these motifs. Potential functions in the 
pathogenesis of the virus are intriguing and will be discussed further in chapter 
6.
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4. Intracellular trafficking of HIV envelope proteins
In chapter 3, I demonstrated that in HeLa cells HIV-1 Env is transported to the 
plasma membrane from where it is internalised to a perinuclear compartment. 
However, the nature of this compartment and the route taken to reach it 
remained elusive. Endocytosis can be mediated by two independent 
conserved trafficking motifs in the cytoplasmic domain of Env. This 
redundancy of signals may indicate that one or both of them have other 
functions and may be involved in intracellular targeting.
Previous studies indicated that determinants in the cytoplasmic domain of 
gp41 direct the protein to the frans-Golgi network (TGN) (Wyss et al. 2001; 
Blot et al. 2003). It was also suggested that a diaromatic motif (Y8o2W 8o3) was 
required for retrograde transport to the TGN mediated by TIP47 (Blot et al. 
2003), a protein required for transport of mannose-6-phosphate receptor from 
endosomes to the TGN (Diaz and Pfeffer 1998). Mutation of the diaromatic 
motif led to a defect in Env incorporation into virions and a redistribution of Env 
to a vesicular endosome like compartment.
It is further known that in macrophages the assembly of infectious HIV-1 
occurs on intracellular membranes that have some characteristics in common 
with late endosomes and resemble multivesicular bodies (Raposo et al. 2002; 
Pelchen-Matthews et al. 2003). Env is observed on virions accumulating in this 
compartment and the released virus is infectious (Pelchen-Matthews et al. 
2003; Kramer et al. 2005). Analysis of macrophage-derived virus, and 
morphological studies by EM and immunofluorescence have revealed that the 
membranes of this compartment contain several tetraspanins, which can be 
incorporated into the membranes of budding virus. Among these are the late 
endosomal marker CD63, as well as CD9, CD81 and CD53 (Pelchen- 
Matthews et al. 2003; Mark Marsh personal communication).
In order to understand how Env is brought to the intracellular site of virus 
assembly, I decided to study its subcellular localisation in detail and dissect its
141
trafficking pathways after internalisation from the plasma membrane. CD4-Env 
chimeras and HxB2 Env were studied in parallel using immunofluorescence 
colocalisation analysis and pulse-chase antibody feeding experiments in HeLa 
cells. A set of mutants of potential trafficking motifs (as described in chapter 3) 
was used in both systems (chimera and HxB2 Env), to try and identify 
determinants for intracellular targeting in the gp41 cytoplasmic tail.
CD4-Env chimeras localised predominately to the TGN, which was reached via 
early, but not late endosomes, and independently of any of the potential 
trafficking motifs studied. HxB2 Env constructs were similarly found partly 
colocalising with the TGN. However, the bulk of the protein appeared in a 
compartment positive for the tetraspanin CD81, but not classical late 
endosomal markers. This compartment was accessible from the plasma 
membrane and could be reached via early endosomes. Env targeting 
appeared to be independent of any other viral proteins and the studied motifs 
in the gp41 cytoplasmic domain. This compartment may be analogous to the 
compartment, where virus is assembled in infected macrophages, and Env 
could be found colocalising with CD81 and viral Gag proteins. The data 
presented here indicates that intrinsic information for targeting to viral 
assembly sites is found not only in HIV Gag, but also in Env, and that the viral 
components are brought together by their own individual trafficking 
characteristics.
4.1. Trafficking of CD4-Env chimera
CD4-Env chimera have been described in chapter 3 and demonstrated to be a 
good model to study Env endocytosis, since they show similar properties to 
HxB2 gp160 and can be efficiently expressed in HeLa cells. I therefore 
decided to use the chimeras to further analyse the cellular distribution of HIV 
Env and study intracellular trafficking.
142
4.1.1. Colocalisation of CD4-HIV Env chimera with cellular markers
4.1.1.1. Localisation of G Yxx0 and dileucine mutants
In order to identify the intracellular compartment where CD4-Envs localised 
and to determine whether any of the putative trafficking motifs described in 
chapter 3 target the protein to these locations, immunofluorescence 
colocalisation experiments were conducted. Stable HeLa cell lines expressing 
CD4-Env cytoplasmic domain mutants (see Figure 3.3) were labelled for CD4 
together with markers for early and late endosomes and the Golgi apparatus.
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Figure 4.1. CD4-Env colocalisation with the TGN. Hela cells stably transfected with CD4- 
Env different constructs as indicated were fixed and permeabilised. The cells were stained with 
anti-CD4 Q4120 and anti-mouse Alexa-Fluor 594 (red) and anti-TGN38 44 and anti-rabbit 
Alexa-Fluor 488 (green). Constructs containing an intact Y712xx0 motif are shown in panel (A) 
(see previous page) and constructs with a Y712I mutation in panel (B). All panels show single 
confocal sections. Scale bars = 10 pm.
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Mutants containing an intact membrane proximal GY712XX0  motif in 
conjunction with mutation of dileucine motifs (Figure 4.1 A) were compared to 
a set of mutants with an inactivated Y712I motif (Figure 4.1 B). It was observed 
that staining for all constructs with an intracellular localisation, i.e. constructs 
containing either an intact GY712XX0  motif or an intact C-terminal dileucine, 
was colocalising with staining for TGN46 (an antibody raised against the 
mouse homolog TGN38 that cross reacts with the human TGN46 was used for 
all experiments), a transmembrane protein residing primarily in the TGN. This 
localisation appeared to be independent of any of the mutated trafficking 
motifs. A similar degree of colocalisation was observed for constructs with 
intact (Figure 4.1 A) and mutated (Figure 4.1 B) GYxx0 motifs and for single 
dileucine mutants. TGN localisation was only reduced in constructs combining 
Y7i2 l and L U 55/856AA mutations (I LL855/856AA) and Y712I mutants with a 
truncated cytoplasmic tail (I short), where redistribution to the plasma 
membrane was observed due to the lack of a functional endocytosis motif.
4.1.1.2. Localisation of Y802W803 mutants
It has previously been reported that mutation of a diaromatic motif Y8o2W 8o3 in 
the HIV-1 Env cytoplasmic tail inhibits retrograde transport to the TGN, leading 
to a dispersed distribution of the protein and impaired HIV-1 replication, 
possibly by abrogating an interaction with TIP47 (Blot et al. 2003). To test 
whether this YW  motif has a function in CD4-Env chimera targeting, a new 
mutant was generated where Y8o2 and W 8o3 were changed to alanine (Y 
YW8o2/803AA; Figure 4.2 A). The mutant was used to generate a stable HeLa 
cell line and analysed by antibody feeding experiments and steady state 
immunofluorescence. Steady state staining for CD4 and TGN46 showed an 
almost complete colocalisation of the two proteins (Figure 4.2 B). Feeding of 
anti-CD4 for 2 hr at 37°C led to a staining pattern very similar to the steady 
state distribution. Staining was detected in dense vesicles in a perinuclear area 
(Figure 4.2 C), indicating that the mutant was still able to reach the TGN and 
that the diaromatic motif is not needed for TGN targeting of the CD4-Env 
chimera.
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Figure 4.2. Localisation of a YW802/803AA mutant. The sequence of the HIV Env
cytoplasmic tail with the conserved YW motif shaded in blue and the respective mutant CD4- 
Env construct are shown in panel (A). Panel (B) shows single confocal sections of Hela ceils 
stably expressing the mutant, fixed permeabilised and stained for CD4 (red) and TGN46 
(green). Cells in panel (C) were fed for 2h with anti-CD4 Q4120 and then fixed, permeabilised 
and stained with anti-mouse Alexa
488. A single confocal section is shown. Scale bars = 10 pm.
4.1.2. Analysis of CD4-HIV Env chimera trafficking
4.1.2.1. Pulse-chase analysis of CD4-Y wt
The data presented above indicated that the CD4-Env chimeras are 
internalised from the plasma membrane and transported to the TGN, but the 
intracellular pathways taken remained unclear. To analyse the route in detail, I 
used time-course antibody feeding experiments. Since continuous antibody 
feeding would fail to show proteins moving in distinct steps, I used a pulse
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Figure 4.3. Pulse-chase analysis of CD4-Env trafficking in the endocytic pathway.
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CD4-Y wt expressing cells were fed with anti-CD4 Q4120 for 2 hr at 20‘C. Cells were shifted to 
37°C for indicated times, fixed, permeabilised and stained with secondary anti-mouse Alexa 
488 (green) and for subcellular markers as indicated (red). Insets represent 3x magnifications 
of the framed areas. Scale bars = 10 pm.
chase approach, where a single wave of transport could be studied. To 
synchronise trafficking, I used the fact that exit from early endosomes is 
inhibited at 20°C and antibody from the cell surface is accumulated in this 
compartment (Marsh et al. 1983).
HeLa cells stably expressing the CD4-Env chimera were incubated in binding 
medium containing anti-CD4 for 2 hr at 20°C. The cells were washed to 
remove the unbound antibody and supplied with fresh binding medium. Cells 
were then shifted to 37#C for different periods of time and subsequently cooled 
on ice and fixed. The localisation of CD4-Env at different time points was 
analysed by immunofluorescence and colocalisation with cellular marker 
proteins. Time course analysis of CD4-Y wt is shown in Figure 4.3. CD4-Y wt 
was accumulated in early endosomes during feeding at 20°C and colocalised 
with EEA1. This indicated that the chimera was transported to early 
endosomes after internalisation from the plasma membrane and not directly 
routed to the TGN. The early endosomal localisation was maintained for at 
least 5 min after warm-up. Rapidly thereafter the protein started to colocalise 
with TGN markers (10-20 min), where it accumulated and remained until 30 
min and longer after the temperature shift. Little colocalisation was seen with 
markers for late endosomes and lysosomes (CD63 and LAMP1) at 10 min 
after warming to 37°C and was not maintained.
4.1.2.2. Pulse-chase analysis of CD4-Env mutants
To test whether transport to the early endosome or subsequent trafficking to 
the TGN are dependent on either the membrane proximal GY712XX0  motif or 
on determinants in the rest of the cytoplasmic tail, the time course analysis 
described in section 4.1.2.1 was repeated with the mutant constructs CD4-Y  
short (Figure 4.4) and CD4-Y712I (Figure 4.5). For both mutants the results 
were essentially the same as for the wt constructs. An accumulation in early
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Figure 4.4. Pulse-chase analysis of CD4-Env Y short trafficking in the endocytic 
pathway. CD4-Y short expressing cells were fed with anti-CD4 Q4120 for 2 hr at 20“C. Cells 
were shifted to 37°C for indicated times, fixed, permeabilised and stained with secondary anti­
mouse Alexa-Fluor 488 (green) and for subcellular markers as indicated (red). Insets represent 
magnifications of the framed areas. Scale bars are 10 pm.
endosomes was observed until about 5 min after shifting to 37°C and then the 
protein moved to the TGN, where it was seen to accumulate after 20 min. Little 
or no colocalisation was found with late endosomal or lysosomal markers. 
These results indicate that neither the GYxx0 motif nor the dileucine motifs are 
required for transport from early endosomes to the TGN. They also suggest
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that CD4-Env constructs are not routed via late endosomes or that trafficking 
through this compartment is fast and only small amounts of the proteins are 
present in the compartment at any one time.
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Figure 4.5. Pulse-chase analysis of CD4-Env Y712I trafficking in the endocytic pathway.
CD4-Y712I expressing cells were fed with anti-CD4 Q4120 for 2 hr at 20”C. Cells were shifted 
to 37°C for indicated times, fixed, permeabilised and stained with secondary anti-mouse Alexa- 
Fluor 488 (green) and for subcellular markers as indicated (red). Insets represent 3x 
magnifications of the framed areas. Scale bars = 10 pm.
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Figure 4.6. Effects of PI3P(5) kinase inhibition. Hela cells grown on coverslips were 
supplied with 0.4 pM Piramed PI3P(5) kinase inhibitor at 2, 3 or 4 hours prior to fixation. Cells 
were permeabilised and then stained for the early endosomal marker EEA-1 and the late 
endosomal marker CD63. Antibodies were detected with an Alexa Fluor-coupled secondary 
anti-mouse reagent. Single confocal sections are shown, scale bars = 10 pm.
4.1.3. Block of trafficking through late endosomes
It has been shown that in macrophages infectious HIV assembles in a 
compartment positive for CD63, and that this molecule can be incorporated
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into the viral envelope (Pelchen-Matthews et al. 2003). However, I found no 
evidence for CD4-Env trafficking to a CD63 positive compartment. It is possible 
that Env trafficking through late endosomes is fast and may be modulated 
through interaction with other viral proteins. If this is the case, it should be 
possible to arrest Env in a late endosome by blocking exit from the 
compartment. To test this hypothesis I attempted to block trafficking through 
late endosomes by inhibition of phosphatidylinositol-3-phosphate 5-kinase 
(PIKfyve). PIKfyve and its product PI(3,5)P2 are required for endocytic 
membrane homeostasis, and competition by dominant negative constructs 
leads to multiple swollen vacuoles in the perinuclear area (Ikonomov et al. 
2001), most probably because membrane recycling from late endosomes is 
perturbed.
The effects of a chemical inhibitor of PIKfyve (from Piramed Ltd., Slough, UK) 
on the morphology of endosomes was tested in HeLa cells. Cells were treated 
with 0.4pM of the inhibitor for different amounts of time and fixed. Early and 
late endosomes were analysed by immunofluorescence staining for EEA1 or 
CD63, respectively. CD63 positive endosomes were enlarged in treated cells 
compared to control cells as early as 2 hr after addition of the inhibitor, 
suggesting an accumulation of membrane and most possibly also protein 
(Figure 4.6). The effect increased and persisted when the cells were left with 
the inhibitor for longer. However, the effect was reversible when the inhibitor 
was removed (data not shown). No pronounced effect on early endosomes 
was seen for up to 4 hr (Figure 4.6), indicating that membrane transport 
through this compartment remained unaffected.
The effects of PIKfyve inhibition on CD4-Env trafficking were studied by pulse- 
chase analysis as described in section 4.1.2. Stable HeLa cells expressing 
CD4-Y wt were treated with the inhibitor for 1 hr and subsequently fed with 
anti-CD4 for 2 hr at 20°C in the presence of the inhibitor. The cells were then 
shifted to fresh 37°C medium for chase times of 5 min to 20 min with the 
inhibitor present. It was found that delivery and accumulation in early 
endosomes was unaffected by the inhibitor (Figures 4.7 A and B). CD4-Env
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Figure 4.7. CD4-Env trafficking in PI3P(5) kinase inhibitor treated cells. Hela cells 
expressing CD4-Ywt were treated for 1 hr with Piramed PIKfyve kinase inhibitor and 
subsequently fed for 2 hr at 20°C with anti-CD4 Q4120 in the presence of the inhibitor. Cells 
were warmed to 37°C for indicated times, fixed and permeabilised. Cells in panels (A) and (B) 
were stained with anti-mouse Alexa-Fluor 594 and polyclonal anti-EEA-1 plus anti-rabbit 
Alexa-Fluor 488. Cells in panel (C) were labelled with anti-mouse lgG1 Alexa 594 and anti- 
CD63 1B5 plus anti lgG2b-biotin and streptavidin Cy5. Cells in panel (D) were stained with 
anti-mouse Alexa-Fluor 594 and anti-TGN38 plus anti-rabbit Alexa-Fluor 488. Panels (A), (B) 
and (D) are single confocal sections, panel (C) is an epifluorescence image. Colours shown in 
merged panels are pseudo colours applied in Adobe Photoshop. Scale bars are = 10 pm.
153
reached the TGN 20 min after the shift to 37°C (Figure 4.7 D) and the PIKfyve 
inhibition did not lead to accumulation of the protein in CD63 positive late 
endosomes, since no colocalisation with this compartment was detected 
(Figure 4.7 C). These results led to the conclusion that CD4-Env can be 
transported from the early endosome to the TGN by a pathway that does not 
involve late endosomes.
4.2. Trafficking of HIVHxb2 Env
With respect to HIV assembly in a CD63-positive late endosome compartment, 
it seems surprising that this compartment is apparently not reached by the 
CD4-Env chimera. However, it may be possible that the cytoplasmic domain of 
Env is not sufficient to ensure correct targeting and other determinants in the 
transmembrane or ectodomain of Env are needed, or that the ecto-and 
transmembrane domains of CD4 affect trafficking in a way that is not yet 
understood. I therefore expressed the full-length HxB2 Env in HeLa cells and 
studied its intracellular trafficking.
4.2.1. Colocalisation with cellular markers
As with the studies of CD4-Env chimera, the intracellular distribution of HxB2 
Env was analysed by immunofluorescence and colocalisation with marker 
proteins for different cellular compartments. HeLa cells were transfected with 
plasmid pSVIII encoding HxB2 gp160 (Env) and fixed 48 hr post-transfection. 
The distribution of the protein was then visualised by staining permeabilised 
cells with anti-gp120 and antibodies against early and late endosomal 
markers, TGN46, transferrin receptor and tetraspanins.
Env was found in a perinuclear vesicular distribution in all the pictures 
analysed (Figure 4.8). As with the CD4-Env chimera, extensive colocalisation 
of Env with TGN46 was observed (Figure 4.8 A). This agrees well with 
previous data showing transport of Env from the plasma membrane to the 
TGN (Blot et al. 2003). However, Env distribution was slightly more disperse 
than the distribution of the CD4-Env chimera and showed some partial overlap 
with EEA1 and transferrin receptor (TfR) (Figure 4.8 A). This suggests that Env 
is not exclusively found in the TGN at steady state, but smaller fractions reside
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Figure 4.8 A. Colocalisation of HxB2 Env with cellular markers.
in early endosomes and possibly also recycling endosomes. In addition to 
these conventional cellular markers, Env expressing cells were costained with 
an antibody against the tetraspanin CD81. This protein is found in the 
membrane of viruses budding from macrophages (Pelchen-Matthews et al. 
2003), and in the viral vacuole in these cells (M. Deneka MRC-LMCB, personal 
communication). A substantial colocalisation of Env and CD81 was found in 
the HeLa cells (Figure 4.8 A), which provides the first evidence of independent
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Figure 4.8. Colocalisation of HxB2 Env with cellular markers. Hela cells were transfected 
with pSVIII gp160 using FuGENE. Cells were treated with 5 mM sodium butyrate 30 hr post­
transfection and fixed and permeabilised 48hr post-transfection. Cells were labelled with 2G12 
anti gp120 plus anti-human FITC (green) and antibodies for various cellular markers as 
indicated (A) (see previous page) or late endosomal markers (B) plus secondary reagents 
coupled to Alexa-Fluor 594 (red). Small panels depict 3x magnifications of the framed areas. 
Scale bars = 10 pm.
Env trafficking to a compartment with the characteristics of the virus assembly 
site in macrophages.
By analogy to the CD4-Env data, no colocalisation was observed between Env 
and markers for the late endosome (CD63 and lisobisphosphatic acid (LBPA)) 
or the lysosome (LAMP1, see Figure 4.8 B). This indicated that the lack of late 
endosomal colocalisation observed with the chimera was not due to any
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Figure 4.9. Hxb2 Env colocalisation with CD81. Hela cells were transfected with 
pSVIIIgpl60, fixed, permeabilised and co-labelled with anti-gp120 2G12 (green) and anti- 
CD81 M38 (red). Antibodies were detected with anti-human FITC and anti-mouse Alexa-Fluor 
594. Two different transfected cells from the same experiment are shown. Panels (A) and (A') 
represent projections of confocal Z sections and panels (B) and (B’) are montages of the 
respective sections. Scale bars =10 pm.
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determinants in the CD4 part of the protein or the absence of the 
transmembrane and ectodomains of Env.
4.2.2. Colocalisation of HIV Env with CD81
To visualise the colocalisation of CD81 and Env in more detail, 
immunofluorescence analysis of the steady state distribution was performed as 
described above. Two examples of costained cells are shown in Figure 4.9. 
Stacks of single confocal sections were acquired and assembled into 
projections (Figures 4.9 A and A’). The tetraspanin CD81 was found at the 
plasma membrane and in a vesicular pattern in a perinuclear area. Many of 
these intracellular vesicles were stained for Env as well, which was found 
predominately intracellularly. Montages from stacks of confocal sections 
(Figures 4.9 B and B’) demonstrate that the majority of colocalisation between 
Env and CD81 was found around the middle of the cell.
To see whether the CD81 compartment is a part of the endocytic pathway, 
HeLa cells were incubated for 2 hr with anti-CD81 M38 at 37°C and 
subsequently fixed, permeabilised and stained with a secondary Alexa-Fluor 
conjugated anti-mouse reagent. Staining was observed at the plasma 
membrane and in intracellular vesicles, indicative of CD81 being a trafficking 
molecule, which recycles over the plasma membrane (Figure 4.10). The 
experiments were conducted in cells transfected with Env, and the cells were 
co-fed at the same time with anti-gp120 2G12, to test whether Env is 
transported to the CD81 compartment after internalisation from the plasma 
membrane. Colocalisation of Env and CD81 in vesicles close to the nucleus 
was observed after 2 hr feeding (Figure 4.10), demonstrating that Env reaches 
the CD81 compartment via the endocytic pathway. However, analysis of earlier 
time points indicated that internalisation rates of Env and CD81 are different, 
since Env was found in a perinuclear area after less than 30 min feeding, while 
CD81 staining was still predominately at the plasma membrane and 
colocalisation was only seen after longer incubation (data not shown).
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Figure 4.10. Anti-Env and Anti-CD81 co-feeding. Hela cells were transfected with pSVIII 
gp160 and expression boosted with sodium-butyrate. Two days post-transfection the cells 
were co-fed for 2 hr at 37°C with 2G12 anti-gp120 (green) and M38 anti-CD81 (red). Cells 
were fixed permeabilised and stained with secondary reagents anti-human FITC and anti­
mouse Alexa-Fluor 594. Single confocal sections are shown. Panels to the right represent 3x 
magnifications of the framed area. Scale bars =10 pm.
4.2.3. Pulse-chase analysis of intracellular trafficking
The previous experiments demonstrated a steady state distribution of Env in 
the endocytic pathway ranging from early endosomes to the TGN and a 
compartment positive for CD81, but excluding late endosomes. In order to 
understand when and how these different compartments are reached after Env 
internalisation from the plasma membrane, time course antibody feeding 
experiments were performed analogous to the experiments described in 
section 4.1.2. HeLa cells transfected with HxB2 Env were fed with anti-gp120 
for 2 hr at 20°C to accumulate bound antibody in early endosomal 
compartments. The cells were then either stained intact with secondary anti­
human FITC to detect surface bound antibody, or permeabilised to visualise 
cellular markers and internalised Env-antibody complexes. Alternatively, the 
cells were shifted to 37°C for 5, 10 or 20 min and then analysed by 
immunofluorescence.
Cells that were not shifted to 37°C show strong staining for Env at the plasma 
membrane (Figure 4.11 A, top panel), and colocalisation of internalised Env
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Figure 4.11 A and B. Pulse-chase analysis of Env trafficking in the endocytic pathway.
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Figure 4.11. Pulse-chase analysis of Env trafficking in the endocytic pathway. Hela cells 
were transfected with HxB2 gp160. After 48 hr the cells were fed with anti-gp120 2G12 for 2 hr 
at 20°C. Cells were fixed directly (A) or shifted to 37°C for 5 min (B) (Panels (A) and (B) are on 
previous page), 10 min (C) or 20 min (D), fixed, permeabilised (except for top panel in (A), 
where surface staining is shown) and stained with secondary anti-human FITC (green) and for 
subcellular markers as indicated (red). Scale bars = 10 pm.
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with EEA1 indicated an accumulation in early endosomes, as observed for the 
CD4-Env chimeras (Figure 4.3). Under these conditions limited colocalisation 
with CD81 was observed (Figure 4.11 A). After 5 min internalisation at 37°C, 
Env was still predominately localised to early endosomes. However, some 
colocalisation with CD81, but no overlap with late endosomal markers (CD63), 
was seen at this time point (Figure 4.11 B). Longer incubation at 37°C led to an 
increase of Env in the CD81 compartment (Figure 4.11 C) but not in the CD63 
compartment. After 20 min Env was still observed colocalising predominantly 
with CD81, overlap with TGN46 was minor and no overlap was observed with 
late endosomal markers (LBPA, Figure 4.11 D). These results indicate that 
Env is internalised to early endosomes, from where it can be transported to a 
compartment positive for CD81, where it accumulates. Env is not trafficking via 
late endosomes or lysosomes, but may reach the TGN after longer periods of 
internalisation. The large amount of Env observed in the TGN at steady state 
might be partly due to protein that is in transit through the exocytic pathway 
and has yet to reach the plasma membrane.
4.3. Localisation of HIVHxb2 Env mutants
The observation that HxB2 Env is found in a compartment positive for CD81 
that may be analogous to the HIV assembly compartment in macrophages, 
raised the question as to whether any of the conserved trafficking motifs in the 
Env cytoplasmic domain are involved in targeting to this compartment. It would 
be especially interesting to know, whether the membrane proximal GY712XX0  
motif plays a role in regulating sorting to the CD81 compartment, since this 
motif is highly conserved in HIV and SIV Envs and plays a role in SIV 
pathogenesis, but is not essential for endocytosis (see chapter 3).
4.3.1. Colocalisation of HIV Env mutants with cellular marker proteins
Mutants of trafficking motifs in the HIV Env cytoplasmic tail have been 
described in chapter 3 (Figure 3.3). In order to investigate whether any of the 
mutations affected the cellular distribution of Env, immunofluorescence 
colocalisation analysis was performed as described for the wt Env protein 
(section 4.1). HeLa cells were transfected with the mutant Env constructs, and 
fixed and permeabilised 48 hr post-transfection. The cells were stained with
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Figure 4.12 A and B. Colocalisation of HxB2 Env mutants with cellular proteins.
163
Env Y LL855/856AA
CD81
Figure 4.12. Colocalisation of HxB2 Env mutants with cellular proteins. Hela cells were 
transfected with pSVIII HxB2 Env gp160 single mutants as indicated for panels (A), (B) and (C) 
and processed for immunofluorescence 48 hr post-transfection. Permeabilised cells were 
stained with 2G12 anti-gp120 (green) and antibodies against subcellular markers (red) as 
indicated in individual panels. Antibodies were detected with anti-human FITC and anti-rabbit 
or anti-mouse secondary reagents coupled to Alexa-Fluor 594. Single confocal sections are 
shown and insets represent magnifications of the framed areas. Scale bars =10 pm.
2G12 anti-gp120 and antibodies against the cellular marker proteins EEA1, 
CD63, TGN46 and CD81. It was observed that the single mutants Y 7 1 2 I ,  Y 
LL814/815AA and Y LL855/856AA were all distributed between the early 
endosomes, the TGN and the CD81 compartment. None of the mutants 
colocalised with the late endosomal marker CD63 (Figure 4.12). This agrees 
with the data for the wt protein, and it can therefore be assumed that none of 
the mutations disturbed the previously identified trafficking pathways of Env. 
However colocalisation of mutant Y 7 1 2 I ,  where the membrane proximal GYxx0 
motif was inactivated, with CD81 appeared to be slightly reduced compared to 
the wt (Figure 4.12 A) but it was difficult to determine whether this reduction 
was significant.
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Figure 4.13. Colocalisation of HxB2 Env mutants with cellular proteins. Hela cells were 
transfected with pSVIII HxB2 Env gp160 double mutants as indicated for panels (A) and (B) 
and processed for immunofluorescence 48 hr post-transfection. Permeabilised cells were 
stained with 2G12 anti-gp120 (green) and antibodies against subcellular markers (red) as 
indicated in individual panels. Antibodies were detected with anti-human FITC and anti-rabbit 
or anti-mouse secondary reagents coupled to Alexa-Fluor 594. Single confocal sections are 
shown and insets represent 3x magnifications of the framed areas. Scale bars = 10 pm.
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The double mutant I LLsu/sisAA was colocalising to a large extent with EEA1 
and showed some overlap with TGN46 and CD81, colocalisation with CD63 
was minor (Figure 4.13 A). The changes in the overall distribution of the 
mutant compared to the wt protein were however minor. When both 
endocytosis motifs were inactivated, mutant I LL855/856AA, Env was 
redistributed to the plasma membrane and overlap with intracellular markers 
was reduced. Some colocalisation was observed with EEA1 and TGN46, 
which could result from protein that had not reached the plasma membrane. 
Targeting to the CD81 compartment was almost abolished and colocalisation 
of Env and CD81 was minor (Figure 4.13 B).
These experiments did not identify a signal clearly responsible for CD81 
targeting, since functional endocytosis seemed to be sufficient for Env 
trafficking to the compartment. The GYxx0 motif may be involved in targeting, 
but this data needs further support, and it has to be kept in mind that Env 
trafficking from the TGN to the CD81 compartment may be possible, which is 
independent on the endocytic pathway and functional endocytosis motifs.
4.3.2. Quantification of Env colocalisation with CD81
The data presented above suggested a potential reduction in targeting to the 
CD81 compartment when the membrane proximal GYxx0 motif was 
inactivated by a Y712I mutation. However, quantification was needed to 
establish whether a targeting defect was present. A series of 10 -  20 single 
confocal sections of cells double labelled for either wt Env, or the mutant, and 
CD81 were acquired. Representative images of each set are shown in Figures
4.14 A and B. Both series of pictures were subjected to analysis with the 
colocalisation modules of Volocity and Metaporph software, in parallel, as 
described in Materials and Methods. Both programs produced essentially the 
same results, which were expressed as the amount of Env staining 
colocalising with CD81 divided by the total amount of Env staining, leading to 
percentage values of colocalisation for both mutants. Average values from the 
analysis of ten frames each and their standard deviation are shown in Figure
4.14 C. The analysis showed that 81% of the total amount of wt Env 
colocalised with CD81. For the Y712I mutant, the colocalisation was reduced to
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Figure 4.14. Colocalisation of Env with CD81. HeLa cells were transfected with HxB2 Env 
constructs (wt (A) or Y712I (B)) and Env distribution in comparison to CD81 was analysed on
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fixed and permeabilised cells by immunofluorescence 48 hr post-transfection. Env was 
detected with 2G12 and anti-human FITC (green) and CD81 with M38 and anti-mouse Alexa- 
Fluor 594 (red). Single confocal sections and 3x magnifications of the framed areas are shown 
in (A) and (B). (C) shows quantification of colocalisation for both constructs with CD81 
analysed in Volocityand Metamorph as described in Materials and Methods. Average values 
from 10 independent pictures each are shown. Error bars depict the standard deviation for all 
samples.
74%. The difference of these values was smaller than expected from looking at 
the images and did not indicate a role for the GYxx0 motif in targeting to the 
CD81 compartment. However, it must be taken into consideration that analysis 
of the steady state distribution of these proteins is shown and that analysis of 
endocytosed Env might give a different result.
4.3.3. Colocalisation of endocytosed HIV Env mutants with CD81
Mutation of the GY712XX0  motif or the dileucine motifs LLsu/s-is and LL855/856 
had only a minor effect on Env distribution and its colocalisation with CD81 at 
steady state. However, these motifs may play a role in Env targeting after 
endocytosis. To test this antibody feeding experiments and subsequent 
analysis of colocalisation -with CD81 were performed. HeLa cells were 
transfected with the HIV Env wt or the mutants Y712I, Y LLsu/sisAA and Y  
LL855/856AA to analyse the contribution of the individual signals. The cells were 
fed with 2G12 anti-gp120 for 1 hr at 37°C prior to fixation. Internalised antibody 
was detected with an anti-human FITC-coupled secondary reagent and the 
cells were costained with anti-CD81 M38. All four constructs showed 
colocalisation with CD81 as observed for the steady state distribution, 
indicating that none of the mutations abrogated delivery to the compartment 
via the endocytotic pathway. The mutants Y712I and Y LL.855/856AA overlapped 
with CD81 to a lesser extent than the wt and Y LLsu/sisAA, in agreement with 
the observations for steady state colocalisation (Figure 4.15). These results 
also suggest that the bulk of Env in the CD81 compartment was derived from 
the plasma membrane, and they confirm that none of the investigated 
trafficking motifs was required for targeting to the CD81 compartment.
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Figure 4.15. Trafficking of Env constructs into the CD81 compartment. HeLa cells were 
transfected with pSVIII Env constructs as indicated in individual panels for 48hr. The cells were 
fed with anti-gp120 2G12 in binding medium for 1 hr at 37°C, fixed permeabilised and stained 
with anti-human FITC (green) and anti-CD81 M38 and anti-mouse Alexa-Fluor 594 (red). 
Single confocal sections are shown, insets represent 3x magnifications of the framed areas. 
Scale bars = 10 pm.
4.4. HIV Env in macrophages
Expression of HIV Env in HeLa cells may help to understand the signals and 
pathways involved in Env trafficking, but since these cells are not naturally 
infected by HIV, they are a limited model system. Macrophages are a natural 
target for HIV infection and they are particularly interesting, because HIV 
appears to assemble on intracellular membranes of a compartment 
characterised by the tetraspanins CD81, CD9 and CD63 (Magda Deneka, 
MRC-LMCB, personal communication; (Pelchen-Matthews et al. 2003). I have 
previously shown that Env is targeted to a compartment positive for CD81 in 
HeLa cells independently of other viral components, and EM studies of HIV 
assembly in macrophages showed incorporation of Env into budding virions. 
However, it is unclear whether Env is targeted to the site of viral assembly in 
macrophages independently of other viral components. I therefore chose to 
analyse Env in HIV-1 infected macrophages and in macrophages transiently 
expressing HxB2 Env.
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In the previous experiments antibody 2G12 was used to detect HIV Env in 
transfected cells. This antibody is a human IgG and would therefore be 
recognised by Fc receptors on the surface of macrophages. To avoid this, the 
antibody was digested with pepsin to generate F(ab ’)2 fragments that do not 
contain the Fc part, but are still recognised by secondary reagents (see 
Materials and Methods section 2.3.1 and Figure 2.1).
4.4.1. Env in infected macrophages
In order to test whether Env can be detected in the viral vacuole in infected 
macrophages immunofluorescence analysis was performed. Macrophages 
derived from monocytes isolated from buffy coats were infected with HIV-1 
strain BaL and fixed 10 days after infection. The cells were permeabilised to 
stain for intracellular viral proteins. Intracellular Env was detected with 2G12 
F(ab ’ )2 fragments and anti-human FITC-coupled secondary reagents, and the 
cells were co-stained for either viral capsid (p24) with mAbs or for CD81 with 
antibody M38 and anti-mouse Alexa-Fluor 495 coupled secondary antibody. 
Env was detected almost exclusively in the viral vacuole overlapping with p24 
staining (Figure 4.16 A). Some plasma membrane staining was observed, 
which was probably due to non-specific binding of the secondary FITC coupled 
antibody to Fc receptors since it was also found in uninfected cells negative for 
p24.
CD81 staining in macrophages was found at the plasma membrane and in 
intracellular vesicular structures. In infected cells these intracellular structures 
co-stained for Env (Figure 4.16 B). It could therefore be concluded that Env is 
transported to a CD81 positive compartment in infected macrophages. This 
compartment is equal to the compartment where HIV Gag is delivered and the 
virus may assemble. It is not clear from these experiments whether Env 
targeting is independent of other viral components, since the cells were 
infected with the full virus and all other viral components were expressed.
BFigure 4.16. Env in infected macrophages. Macrophages were infected with HIV-1 BaL for 
10 days, fixed, permeabilised and stained for capsid (p24) with a mouse mAb and F(ab’)2 
fragments of anti-gp120 2G12 (A). A projection of confocal sections (top panel in A) and single 
confocal sections through the middle of the virus compartment (bottom panels in A) are shown. 
Alternatively the cells were stained with mAb M38, anti-CD81 (B). Single confocal sections are 
shown. Antibodies were detected with anti-mouse Alexa-Fluor 594 (red) and anti-human FITC 
(green). Scale bars = 10 pm.
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Figure 4.17. Recombinant Env expression in macrophages. Monocyte-derived 
macrophages were nucleofected with pSVIII HxB2 Env plasmids and the distribution of Env 
was analysed 48 hr post-nucleofection and after treatment with sodium butyrate to boost 
expression. The cells were fixed and permeabilised. For panel (A) the cells were stained with 
anti-gp120 2G12 F(ab’)2 fragments and anti-CD81 M38. Antibodies were detected with anti­
human FITC (green) and anti-mouse Alexa-Fluor 594 (red) secondary reagents. A projection 
of confocal sections is shown to the left and two examples of single confocal sections are 
shown to the right. For panel (B) cells were stained with 2G12 F(ab’)2 fragments and anti­
human FITC (green) and anti-CD63 1b5 and anti-mouse Alexa-Fluor 594 (red). For panel (C)
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cells were stained with M38 and 1 b5 and the antibodies were detected with anti-lgG1 Alexa- 
Fluor 594 (red) and anti-lgG2b Alexa-Fluor 488 (green) secondary reagents. Single confocal 
sections are shown in (B) and (C). Scale bars = 10 (jm.
4.4.2. Transient expression of HIV Env in macrophages
In HeLa cells trafficking of Env to a compartment positive for CD81 appears to 
be independent of other viral components and in HIV-1 infected macrophages 
Env is found in a CD81 positive compartment together with Gag. To test 
whether Env can reach the macrophage CD81 compartment without the rest of 
the virus, I transiently expressed the HxB2 Env constructs (as described in 
chapter 3) in monocyte-derived macrophages. Macrophages were trypsinised 
at day 7 and nucleofected with pSVIII HxB2 Env as described in Materials and 
Methods. The cells were fixed 48 hr after nucleofection and after one night 
treatment with 5 mM sodium butyrate to boost Env expression. Env distribution 
was analysed by immunofluorescence of permeabilised cells. F(ab ’)2 
fragments of 2G12 were used to visualise Env expression, and the cells were 
co-stained for CD81 and CD63. Env localised to internal vesicles close to the 
nucleus. In some cells only one Env containing larger compartment was found, 
in other cells the Env pattern was more disperse. In both cases Env was partly 
colocalised with CD81 (Figure 4.17 A). As with HeLa cells, little or no 
colocalisation of Env with CD63 was observed (Figure 4.17 B). To show that 
the CD81 and CD63 compartments are truly distinct in macrophages, cells 
were double stained for both tetraspanins and colocalisation was analysed by 
immunofluorescence. Indeed the overlap between CD81 and CD63 was only 
minor (Figure 4.17 C). It can therefore be concluded that Env is transported to 
a compartment positive for CD81 in macrophages, independently of other viral 
components, and that this compartment is different from late endosomes.
4.5. Coexpression of HIV Env and HIV Gag
The data presented above argues that in macrophages HIV-1 Env possesses 
intrinsic information directing it to a CD81 positive compartment, where Gag is 
also found and where budding seems to occur. However, it may still be 
possible that Gag co-expression can change the distribution of Env, since 
these two proteins have been reported to interact (Vincent et al. 1999;
Hourioux et al. 2000). I therefore decided to co-express HxB2 Gag and Env 
recombinantly in different cellular backgrounds.
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Figure 4.18. Co-expression of HIV Env and Gag in HeLa cells. HeLa cells were transfected 
with HxB2 Env and 8 hr later with Gag-GFP using FuGENE. The cells were fixed, 
permeabilised and stained with anti-gp120 2G12, anti-human Biotin coupled secondary 
reagent and Streptavidin TxR (red). The distribution of Env Y wt is shown in (A), the mutant 
Env construct I LL855/856AA was used in (B). Single confocal sections are shown. In (B) two 
examples of cells from the same experiment are shown. Scale bars = 10 pm.
4.5.1. Env and Gag co-expression in HeLa cells
To investigate whether Gag and Env colocalise in HeLa cells and/or whether 
Gag changes the distribution of Env, the cells were sequentially transfected 
with HxB2 Env (Y wt) and an HxB2 Gag-GFP construct. Two days later and 
after boosting Env expression with sodium butyrate, the cells were fixed and 
stained for Env with 2G12. Env was observed in a predominantly perinuclear
174
vesicular pattern, reminiscent of the pattern seen in single transfected cells. 
Env staining was partly colocalising with the punctate pattern of Gag-GFP 
(Figure 4.18 A). Gag-GFP even appeared to be concentrated around the area, 
where Env was localised.
When cells were transfected with the Env double mutant I LL855/856AA and 
Gag-GFP, Env staining was predominately observed at the plasma membrane, 
due to the lack of an endocytosis motifs. The vesicular pattern for Gag was 
found spread over the cell or close to the plasma membrane (see two 
examples Figure 4.18 B) and little colocalisation between Gag and Env was 
observed. These results indicate that Gag does not appear to influence Env 
distribution, which is determined by the Env trafficking motifs.
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Figure 4.19. Co-expression of HIV Env and Gag in HEK293T cells. HEK293T cells were 
transfected with HxB2 Env and Gag-GFP (A) or Env only (B) using Lipofectamine. Cells were 
either fixed and stained for Env with anti-gp120 2G12 and anti-human biotin coupled 
secondary reagent and Streptavidin TxR (red) (A), or fed for 2 hr with 2G12 and stained with 
anti-human FITC (B). Single confocal sections are shown. Scale bars = 10 pm.
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4.5.2. Env and Gag co-expression in HEK293T cells
HEK293T cells were used as an alternative system to perform Gag/Env 
colocalisation studies. Again the cells were transfected with HxB2 Env and 
Gag-GFP and stained with 2G12 48 hr post-transfection. No expression boost 
with butyrate was required in this case, since HEK293T cells express high 
levels of Env. In contrast to HeLa cells, Env staining was observed 
predominately at the plasma membrane, where it showed an extensive overlap 
with Gag-GFP (Figure 4.19 A). The reason for this different distribution was not 
clear and potential relocalisation of Env by Gag had to be considered. 
However, when HEK293T cells were transfected with Env alone and fed for 2 
hr with anti-gp120 2G12 before fixation, the plasma membrane staining 
remained (Figure 4.19 B). This indicates that the different distribution of Env in 
HEK293T cells is not dependent on Gag, but again on information in Env alone 
and on differences in the endocytotic machinery of these cells. It can therefore 
be concluded that Gag is not influencing Env distribution and information for 
targeting is contained in Env itself.
4.6. Discussion
In order to study how new infectious viruses are formed in infected cells, it is 
necessary to understand how the different viral components are brought 
together in the same compartment of the cell at the same time. It is particularly 
interesting to explore the trafficking pathways of the viral envelope proteins, 
since they are essential for the infectivity of the newly formed virus, and 
inhibiting their incorporation would reduce the virus infectivity and spreading. In 
this chapter I used two strategies to study trafficking of HIV-1 envelope 
proteins: A CD4-Env chimera, which can be expressed easily in HeLa cells, 
and HxB2 envelope protein constructs containing the full sequence of HIV-1 
Env.
4.6.1 Intracellular trafficking of CD4-HIV Env chimera
Immunofluorescence analysis of CD4-Env steady state distribution in HeLa 
cells showed that the protein is localised to the TGN. The localisation only 
changed when both endocytosis motifs, the membrane proximal GY712XX0  and 
the C-terminal LL855/856 were mutated together. These results agree with earlier
176
data, where CD8-Env chimeras were found in the TGN (Blot et al. 2003). 
Mutation of Y 712, LLau/s-is or LL855/56 alone does not change the localisation of 
the chimeras, even though all three of these motifs have previously been 
shown to bind the clathrin adaptor AP-1, which acts at the TGN and mediates 
export of proteins (Wyss et al. 2001). In addition, the effects of a diaromatic 
motif Y8o2Wao3 on CD4-Env distribution were tested. This motif has previously 
been reported to be required for binding to TIP47, a protein that was 
suggested to mediate transport of Env from late endosomes to the TGN (Blot 
et al. 2003). I did not find any evidence for involvement of the diaromatic motif 
in CD4-Env targeting, steady state distribution remains unchanged in the TGN, 
and feeding experiments showed that the mutants are transported to the TGN 
after internalisation from the plasma membrane. However, these results only 
suggest that the diaromatic motif is not essential for targeting to the TGN, they 
do not exclude an involvement of TIP47 in Env trafficking or another role for 
the diaromatic motif. Since there is no evidence of HIV assembly on the TGN, 
it can be assumed that further trafficking of Env is necessary to ensure its 
incorporation into budding virus, and the observation that a deficiency in TIP47 
binding leads to replication incompetent virus may point at a role in transport 
out of the TGN (Blot et al. 2003).
A pulse-chase analysis of CD4-Env internalisation revealed a trafficking 
pathway leading via early endosomes to the TGN. This is consistent with 
clathrin-mediated internalisation as discussed in chapter 3. Surprisingly, CD4- 
Env is not detected residing or passing through late endosomes positive for 
CD63, not even when exit from this compartment is blocked. CD63 was 
previously detected on HIV derived from infected macrophages and observed 
in the compartment of virus assembly in these cells (Pelchen-Matthews et al. 
2003). However it has to be taken into consideration that my studies were 
done in HeLa cells, where the endocytotic pathway may be different from that 
in macrophages. Further more, as the CD4-Env chimeras only contain the 
cytoplasmic domain of HIV Env, additional information resident in the 
transmembrane- or the ectodomain of Env may be necessary for correct
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targeting to the virus assembly site. Alternatively, determinants in the CD4 part 
of the chimera may alter trafficking.
4.6.2. Intracellular trafficking of HIVHxb2 Env
In order to exclude a potential influence of CD4 on trafficking and to have the 
full-length sequence of HIV Env, I studied trafficking of HxB2 Env constructs. 
At steady state Env constructs are found partly colocalising with the TGN in 
agreement with the CD4-Env chimera data. However, their distribution appears 
more disperse and at the same time some colocalisation with the early 
endosomal antigen EEA1 and transferrin receptor can be observed. Most 
interestingly, I discovered colocalisation of HIV Env with the tetraspanin CD81. 
CD81 is found in the viral vacuole in macrophages and is also incorporated 
into the membrane of viral particles (Pelchen-Matthews et al. 2003). This 
provides the first evidence of Env trafficking to a compartment that bears 
similarities with the viral vacuole in macrophages independently of other viral 
components.
Detailed analysis of Env trafficking pathways demonstrates that the CD81 
compartment can be reached by endocytosis and transport through early 
endosomes. A smaller fraction of Env is also discovered in the TGN after 
longer endocytosis periods and after reaching the CD81 compartment, 
suggesting trafficking between these two compartments. Env is not observed 
at any time in CD63 positive endosomes indicating that the CD81 
compartment is different from late endosomes. This agrees with the data 
obtained from CD4-Env chimera trafficking. Antibody feeding experiments 
further showed that the CD81 compartment can be reached from the plasma 
membrane and that CD81 itself recycles via the cell surface. CD81 localisation 
to the plasma membrane was reported previously, and it was shown that in T 
cells HIV buds from cell surface domains, which are enriched in CD81 (Booth 
et al. 2006). This implies that Env targeting to membranes containing CD81 
may not only be important in macrophages but also in other cell types. Further 
support for this theory may be provided by the observation that Env is localised 
predominately to the plasma membrane in HEK293T cells (see Figure 4.19) 
independently of Gag co-expression. The bulk of CD81 in HEK293T cells is
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observed at the plasma membrane (data not shown). These results imply that 
Env itself contains determinants responsible for targeting to CD81 enriched 
membranes, independently of where in the cell these membranes are, or that 
Env may be able to interact with CD81 directly.
The fact that the membrane proximal GYxx0 motif is not essential for 
endocytosis, even though it is highly conserved (see chapter 3), and that it is 
important for pathogenesis in SIV (Fultz et al. 2001), led to the hypothesis that 
this motif may be involved in Env targeting to the CD81 compartment. I 
therefore analysed colocalisation of Env mutants with CD81 by steady state 
immunofluorescence and antibody feeding experiments. No significant 
differences to the distribution of wt Env were found when the colocalisation 
was quantified, indicating that the GYxx0 motif is not essential for targeting to 
the CD81 compartment. Neither do the mutations of dileucine motifs LLsu/sis 
or Ll_855/856 abrogate targeting. Thus, the mechanisms of Env trafficking to the 
CD81 compartment remain elusive and may indeed be due to a direct 
interaction of the two proteins.
Little is known about the distribution of tetraspanins and the nature of the 
CD81 compartment. It is unclear to what extent the CD81 compartments in 
HeLa cells and in macrophages are comparable, and whether their function is 
the same in both cell types. My data suggests that the distribution of CD81 
considerably differs between those two cell types. While in macrophages 
CD81 is predominately observed at the plasma membrane and in larger 
vesicles at the bottom of the cell, HeLa cells also show a perinuclear 
population of CD81. A more detailed understanding of the distribution of CD81 
itself and its relation to other membrane proteins is therefore required in order 
to understand the relevance of the Env/CD81 colocalisation in HeLa cells as a 
model for Env trafficking in infected macrophages. Recently, information about 
tetraspanin distribution in macrophages with respect to HIV infection has been 
gathered (Magda Deneka, MRC LMCB, personal communications) and 
chapter 5 of this study will shed light on tetraspanins in HeLa cells.
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In summary, I have shown that HIV Env is targeted to a compartment positive 
for the tetraspanin CD81 in HeLa cells and macrophages (see Figure 4.20 for 
a summary of Env trafficking). This compartment appears to be different from 
CD63 positive late endosomes but resembles the viral vacuole in infected 
macrophages. HIV Env contains the information for delivery to this 
compartment and is not dependent on any other viral proteins, in particular HIV 
Gag. It can thus be concluded that Gag and Env may contain their own 
intrinsic information that is responsible for delivering them to the site of virus 
assembly.
C la th r in -c o a te d  p it
C la th r in -c o a te d
Late endosome  
C D 63 /L A M P 1 A
Lysosom e
N uc leus
Figure 4.20. Summary of intracellular HIV Env trafficking. HIV Env (shown in purple) is 
transported after synthesis and processing from the TGN to the plasma membrane and re­
internalised via clathrin-coated pits to early endosomes. It is subsequently targeted to a 
compartment positive for CD81, from where it can recycle back to the plasma membrane 
possibly via the TGN.
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5. Tetraspanin distribution in HeLa cells
In the previous chapter I demonstrated that HIV Env is targeted to an 
intracellular compartment positive for the tetraspanin CD81 in HeLa cells, as 
well as in transfected macrophages. CD81 is also found in the virus containing 
compartment in infected macrophages, and it is, together with the other 
tetraspanins CD9 and CD63, incorporated into the membrane of intracellularly 
budding virus (Pelchen-Matthews et al. 2003). Previous data further suggested 
that CD81 is enriched in plasma membrane domains, where HIV is budding 
from in infected T cells (Booth et al. 2006; Nydegger et al. 2006).
At least 32 different tetraspanin proteins are known in mammals. They are 
characterised by four transmembrane domains, hence the name, and several 
conserved amino acids. Among these are an absolutely conserved CCG motif 
and two other cysteine residues that contribute to two crucial disulfide bonds 
within the second extracellular loop (Kitadokoro et al. 2001; Seigneuret et al.
2001). Individual tetraspanins are expressed at several thousand copies per 
cell and several different tetraspanins are present in almost all cell types of all 
species that have been analysed to date (Hemler 2003). It has been reported 
that tetraspanins are organised in specific membrane microdomains (TEMs, 
tetraspanin-enriched microdomain), which arise through homo-multimerisation 
of the tetraspanins and cis interaction of the multimers with various other 
transmembrane proteins as well as with cholesterol and gangliosides. 
Palmitoylation of the tetraspanins appears to be crucial for organisation into 
TEMs, and it is believed that TEMs can form signalling platforms that are 
distinct from so-called lipid rafts (reviewed in Hemler 2005).
Tetraspanins have been associated with various functions in cells including 
sperm-egg fusion (CD9; Chen et al. 1999), strengthening of integrin mediated 
adhesion (CD151; Lammerding e ta l. 2003), or signalling, e.g. CD81 mediated 
activation of ERK1/2 pathways (Carloni et al. 2004). However, genetic analysis 
of mutant phenotypes also revealed that the various tetraspanins may 
compensate for each other’s function and are often redundant. Tetraspanins
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are also thought to be involved in cancer, and it was shown that CD82 acts as 
a suppressor of tumor cell metastasis by inhibiting cell motility (Dong et al. 
1995).
In addition to cellular functions, a fundamental role for tetraspanins in a 
number of viral infections has been indicated. The best characterised of these 
is the involvement of CD81 in Hepatitis C virus (HCV) infection, where it may 
act as a cellular receptor for the virus (Pileri et al. 1998). However, CD81 alone 
is not sufficient for HCV entry. CD81 may also play a role in viral egress. It has 
been speculated that the HCV E2 protein may be integrated into TEMs, which 
can then facilitate its transport out of the cell. In the absence of CD81 E2 was 
retained in the ER and not transported to exosomes (Masciopinto et al. 2004). 
Further, it was found that CD82 is involved in HTLV-1 mediated syncytium 
formation through an interaction with HTLV-1 Env (Fukudome et al. 1992). Co­
expression of the two proteins inhibited syncytium formation by binding of Env 
to glycosylated forms of CD82 in the ER.
A role for tetraspanins in HIV infection was first suggested when it was 
observed that CD63 surface expression is upregulated in infected cells 
(Meerloo et al. 1992), and it has been speculated that CD63 might be involved 
in viral trafficking and/or association with intracellular vesicles for fusion and 
release. Recently, it has also been shown that antibodies to CD63 can inhibit 
HIV infection of macrophages by CCR5 tropic viruses (von Lindern et al. 
2003). A detailed review about the roles of tetraspanins in viral infection can be 
found in Martin et al. 2005 (Martin et al. 2005).
The subcellular distribution of tetraspanins is poorly understood, and the aim of 
the work described in this chapter was to try and get an insight into how these 
proteins are related to HIV protein trafficking and assembly. Colocalisation of 
HIV proteins with CD81 was observed in both macrophages as well as the 
model system of a HeLa cell, but it is not known whether the tetraspanins 
themselves behave the same in both cell systems. I therefore chose to analyse 
CD81 distribution by morphological means and compare it to other
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tetraspanins as well as other cellular markers. This way, I was able to draw 
parallels between HeLa cells and macrophages, as well as show differences. 
These findings will help to understand protein trafficking better, and may also 
show the pros and cons of HeLa cells as a model system for HIV assembly.
5.1. CD81 distribution in HeLa cells
CD81 distribution in HeLa cells appears to be somewhat different to the 
distribution seen in macrophages (see Figures in chapter 4). I therefore 
analysed CD81 in the HeLa cell line, which was used for Env expression, by 
immunofluorescence in detail. Staining of permeabilised cells with anti-CD81 
M38 revealed three different dominant distribution patterns in single confocal 
sections (Figure 5.1 A). A subset of cells showed a punctate perinuclear 
staining for CD81 (panel a), while another subset contained only a few larger 
vesicles and plasma membrane staining (panel b). When the cells were 
growing very dense, CD81 was predominately observed at the plasma 
membrane at lateral cell-cell contacts (panel c). The first kind of distribution 
was reminiscent of the CD81 seen colocalised with HIV Env (see chapter 4).
To understand how CD81 was organised in three dimensions in cells, Z-series 
of confocal sections were acquired and assembled to projections. This method 
demonstrated that single cells may contain a punctate perinuclear CD81 
population, as well as bigger vesicles, and a plasma membrane pool (Figure
5.1 B). Disassembly of the projection and presentation of the single sections 
as a montage from the bottom (Figure 5.1 B1) to the top (Figure 5.1 B20) of 
the cell further demonstrated that while the bigger vacuole like structures were 
found predominantly at the bottom of the cell (panels 2-6), the perinuclear 
pattern was seen higher up around the nucleus (panels 7-16). This observation 
may explain why in single sections the two patterns were not observed in one 
single cell and why predominantly the perinuclear fraction appeared to 
colocalise with Env, which is found higher in the cell close to the nucleus.
Finally, cells were stained intact to assess the plasma membrane fraction of 
CD81. Membrane expression was relatively low on HeLa cells and not
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Figure 5.1 A and B. Cellular distribution of CD81.
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Figure 5.1. Cellular distribution of CD81. HeLa cells were grown on coverslips and fixed. 
They were then either permeabilised and stained (A and B) or stained intact with anti-CD81 
M38 and Alexa-Fluor 488 coupled anti-mouse antibody. Panels (A a-c) show single confocal 
sections of internal staining. Panel (B) shows a projection of the confocal sections adjacent to 
it, numbered 1-20 starting at the bottom of the cells. Panels in (C) are single confocal sections 
of intact stained cells. Scale bars = 10 pm.
continuous. Staining was observed in distinct spots reminiscent of specific 
plasma membrane domains or even microvili (Figure 5.1 C). Whether this 
observation is indicative of teraspanin-enriched microdomains (TEMs), what 
has recently been suggested (Nydegger et al. 2006), remains to be 
established.
5.2 . C D 81  a n d  o th e r  te tra s p a n in s
5.2.1. CD81 and CD9
In macrophages the majority of CD81 colocalises with the tetraspanin CD9 and 
both proteins are found in the virus containing compartment in HIV infected 
cells (Magda Deneka, MRC LMCB, personal communications). To test 
whether the two tetraspanins colocalise in HeLa cells, double label 
immunofluorescence experiments were performed and the distribution of the 
two proteins was compared in cell cultures of different density. In sparse and 
well-spread cells CD9 was found in large vesicles at the bottom of the cell, 
where it almost perfectly colocalised with CD81 (Figure 5.2 A top panels). 
Colocalisation was also observed at the plasma membrane, in particular at the 
interface of two cells. However, it was observed that plasma membrane 
expression of CD9 was higher than plasma membrane expression of CD81. 
The small perinuclear vesicles, which had been observed for CD81 before,
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A
B
Figure 5.2. CD81/CD9 colocalisation.
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HeLa cells were grown on coverslips, fixed, permeabilised and stained for CD81 with M38 and 
anti-lgG1 Alexa-Fluor 594 (red) and with a mAB against CD9 and anti-lgG2b Alexa-Fluor 488 
(green). Panels in (A) show two examples of confocal single sections and panel (B) shows a 
projection of the adjacent confocal sections numbered from the bottom to the top of the cell. 
Scale bars = 10 pm.
were distinct from the CD9 pattern. When dense populations of HeLa cells 
were analysed, it was noted that the intracellular pool of CD81, distinct from 
CD9, increased and less colocalisation of intracellular protein was observed. 
The two predominant populations of CD81 in these cells were either at the 
plasma membrane colocalising with CD9 or intracellular in a perinuclear area 
distinct from CD9. These changes may be due do a change in cell shape 
leading to higher cells with a smaller area of basal membrane (Figure 5.2 A 
lower panels).
To analyse the 3D distributions of CD81 and CD9 in detail, Z-series of confocal 
sections were acquired and arranged as a projection of the whole cell as well 
as a montage of sections through the cell to show colocalisation in each 
individual layer (Figure 5.2 B). This analysis revealed that the bulk of 
colocalisation between the two tetraspanins was associated with large 
vesicular structures at the very bottom of the cell (sections 2-4). Plasma 
membrane staining of CD9, but not CD81 was strong throughout the whole 
cell. A punctate perinuclear pattern for CD81 exclusively was observed higher 
up in the cell, starting from section 3, and was found all the way around the 
nucleus to the very top of the cells. These results indicate that in contrast to 
macrophages, HeLa cells contain different populations of CD81, of which only 
the bottom fraction was colocalised with CD9. Interestingly, HIV Env was found 
associated with the perinuclear fraction of CD81 in HeLa cells, which appears 
to be distinct from CD9.
5.2.2. CD81 and CD63
In macrophages the distribution of the intracellular fraction of CD81 appears 
very distinct from the distribution of CD63 (see Figure 4.17 C). However, CD63 
as well as CD81 are found on membranes of HIV budding from macrophages
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Figure 5.3. CD81/CD63 colocalisation. HeLa cells were grown on coverslips, fixed, 
permeabilised and stained for CD81 with M38 and for CD63 with 1b5. The antibodies were 
detected with anti-lgG1 Alexa-Fluor 647 and anti-lgG2b Alexa-Fluor 488. The colours shown 
are pseudo colours applied in Adobe Photoshop, CD81 is depicted in green and CD63 in red. 
(A) Shows single confocal sections. (B) Shows a projection of confocal sections and the 
individual sections numbered from the bottom to the top of the cell. Scale bars = 10 pm.
(Pelchen-Matthews et al. 2003), and both proteins are found in the virus 
containing compartment. In HeLa cells HIV Env was colocalised with CD81, 
but not CD63 (see chapter 4). The distribution of CD81 in these cells though
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was found to be slightly different from CD81 in macrophages, and its punctate 
pattern was somewhat more reminiscent of the distribution of CD63 and late 
endosomes. The distribution of the two proteins was therefore analysed and 
compared to the CD9 versus CD81 analysis described above. Single confocal 
sections showed that CD81 positive vesicles at the bottom of HeLa cells were 
distinct from vesicles labelling for CD63, neither was CD63 observed at the 
plasma membrane of these permeabilised cells (Figure 5.3 A). When confocal 
sections were acquired as Z-series through the cell and overlaid to create a 
projection, a population of yellow vesicles was observed indicating 
colocalisation. However, when the projection was presented as a montage of 
single sections it became clear that there was no overlap of CD81 and CD63 
at any level of the cell and the apparent overlay was due to vesicles being 
placed on top of each other in the projection. I can therefore conclude that 
CD81 and CD63 reside in distinct compartments in HeLa cells.
5.2.3. Surface expression of tetraspanins
It was previously reported that tetraspanins can interact with other membrane 
proteins as well as with membrane cholesterol and gangliosides at the plasma 
membrane, which leads to their organisation into TEMs (reviewed in Hemler 
2005). TEMs are believed to have a function in viral infection and may provide 
a platform for viral release (reviewed in Martin et al. 2005; Booth et al. 2006; 
Nydegger et al. 2006). In macrophages the tetraspanins CD9 and CD81 are 
expressed at the plasma membrane to a high extent (see Figures 4.16 and 
4.17, as well as Magda Deneka personal communications). In HeLa cells little 
is known about tetraspanin distribution at the cell surface, and my studies so 
far had concentrated on internal pools of CD81, since HIV Env appeared to be 
associated with these. However, when CD4+ HeLa cells are used as a model 
system for HIV infection, the viral Gag protein was observed to localise to 
specific domains at the plasma membrane (Rudner et al. 2005). Expression of 
the tetraspanins CD81, CD9 and CD63 at the plasma membrane was 
therefore addressed by immunofluorescence staining of intact HeLa cells. 
Figure 5.4 demonstrated that when single confocal sections were acquired 
under equivalent conditions for all three tetraspanins, CD9 surface expression 
appeared markedly higher than expression of CD81 or CD63. CD63
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expression was lowest and highly variable between cells. However, even 
though the microscopy conditions were the same for all samples, it has to be 
considered that the intensity of staining observed was also dependent on the 
affinity of the antibodies used and might therefore differ. All three proteins 
showed a punctate distribution that was similar, but not the same, for the 
different tetraspanins. CD81 was partly colocalising with both CD9 and CD63 
(see magnifications of merged panels) but the colocalisation appeared random 
and no evidence for specific microdomains was found.
CD81
Figure 5.4. Surface expression of tetraspanins. HeLa cells were grown on coverslips and 
fixed. The cells were stained intact for CD81 with M38 and for CD9 (upper panels) or CD63 
with 1b5 (lower panels). Antibodies were detected with anti-lgG1 Alexa-Fluor 647 and anti- 
lgG2b Alexa Fluor 488 secondary reagents. Pictures were pseudo-coloured in Adobe 
Photoshop and CD81 is shown in green. Small panels represent magnifications of the framed 
areas. Scale bars = 10 pm.
5.3. CD81 and other markers of the endocytic pathway
I have previously shown that CD81 is located in the endocytic pathway and 
that the proteins traffic over the plasma membrane, as antibodies can be fed 
into internal CD81 positive compartments (see Figure 4.10). Pulse-chase 
antibody feeding analysis also demonstrated that the compartment may be 
located downstream of early endosomes, since HIV Env reached it after
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accumulation in early endosomes. To further position the internal CD81 
positive compartment in the endocytic pathway I conducted 
immunofluorescence co-staining analysis with markers for various endocytic 
organelles. I did not observe any colocalisation between CD81 and EEA1, 
transferrin receptor or fed fluorescent transferrin (data not shown), suggesting 
the CD81 co-staining structures were not early or recycling endosomes. 
However, when cells were stained for CD81 and TGN46, partial colocalisation 
between the perinuclear populations of CD81 and TGN46 was observed 
(Figure 5.5). It remains to be established, whether this colocalisation is truly 
happening in the TGN or in the endocytic pathway, since TGN46 itself can 
recycle over the plasma membrane.
TGN38
Figure 5.5. CD81/TGN colocalisation. HeLa cells were grown on coverslips, fixed, 
permeabilised and stained for CD81 with M38 and anti-TGN38 44. The antibodies were 
detected with anti-mouse Alexa-Fluor 594 (CD81, red) and anti-rabbit Alexa-Fluor 488 
(TGN38, green). The small panel shows a magnification of the framed area. Scale bars = 10 
pm.
5.4. Discussion
CD81 is found associated with the virus-containing compartment in infected 
macrophages, in the membrane of HIV particles budding from macrophages 
and together with HIV Env in HeLa cells. It is therefore possible that this 
tetraspanin plays a role in virus assembly or budding. Since HeLa cells have 
been used as a model system to study HIV Env trafficking, it is important to 
learn how these cells compare to the real HIV host cells, the macrophages and 
T cells, and to understand how organelles, where HIV Env is found, are 
distributed. I therefore analysed the distribution of CD81 in HeLa cells in detail.
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I observed that CD81 is present in three different pools in HeLa cells; a plasma 
membrane fraction, large vesicles at the bottom of the cell and smaller vesicles 
in a perinuclear area higher up in the cell. Part of the membrane fraction as 
well as the complete population in large vesicles colocalises with CD9. CD9 is 
another tetraspanin, which is found associated with the viral containing 
compartment in macrophages, where the overlap of CD9 and CD81 is almost 
complete. Interestingly, the perinuclear fraction of CD81 that was previously 
shown to be associated with HIV Env, is distinct from CD9. This indicates a 
potential difference between HeLa cells and macrophages, but it may also 
mean that CD81 can be recruited by HIV or may be required for virus 
assembly, while CD9 just happens to be in the same compartment in certain 
cell types. However, these differences have to be taken into consideration in 
future studies.
In agreement with recent data in macrophages, the distribution of CD81 
appears to be distinct from CD63. Even though the CD63 compartment 
appears strikingly different in HeLa cells compared to macrophages (compare 
Figures 4.17 and 5.3), in both cell types no overlap with CD81 was found. In 
infected cells however, CD63 was discovered in the CD81 positive viral 
vacuole (Pelchen-Matthews et al. 2003), suggesting that the virus may modify 
a cellular compartment for its own purposes. A similar mechanism might also 
exist in cells were HIV is budding from the plasma membrane. CD63 appears 
to be enriched in membrane domains, from where HIV was budding in HeLa 
cells transfected with a plasmid carrying the HIV-1 proviral genome (Nydegger 
et al. 2006), while I demonstrated here (Figure 5.4) that CD63 surface levels in 
HeLa cells are generally low. Also, colocalisation between CD63 and CD81 is 
only partial at the plasma membrane, which disagrees with the pre-existence 
of TEMs containing both tetraspanins, and may suggest that the virus can 
trigger the formation of TEMs.
I have further shown that CD81 is able to undergo endocytosis and is recycling 
via the plasma membrane at steady state. However, it is found in a 
compartment that is distinct from early- or recycling endosomes, but is partially
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colocalised with markers for the TGN. Whether CD81 is truly residing in the 
TGN or whether the colocalisation is due to recycling of TGN46 itself awaits 
further analysis.
In summary, I have demonstrated that CD81 in HeLa cells shares common 
features with its counterpart in macrophages, but the distribution of the two is 
not equal with respect to colocalisation with CD9. These differences have to be 
considered when HeLa cells are used as a model system for HIV assembly 
and it may be required that findings in this system are verified for example in 
macrophages.
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6. Interactions between Env and the ESCRT machinery
In the previous chapters the intracellular trafficking pathways of HIV Env were 
characterised, and it was demonstrated that Env contains determinants that 
target it to the site of viral assembly independently of other viral proteins. 
However, the mechanism by which Env is incorporated into budding viruses 
remains elusive.
HIV budding requires components of the ESCRT machinery, a set of protein 
complexes involved in multivesicular body sorting (reviewed in Katzmann et al.
2002). Gag can recruit Tsg101, a component of the ESCRT-I complex, via a 
PTAP motif in its p6 domain, the so-called late domain (Garrus et al. 2001). 
When the PTAP motif is mutated, particles fail to undergo scission and remain 
tethered to the membrane like lollipops (Pornillos et al. 2002). Recently, a 
second late domain motif (LRSL) at the C-terminus of HIV Gag was identified. 
This motif binds to AIP1/Alix, a protein that interacts with both the ESCRT-I 
and ESCRT-III complexes (Strack et al. 2003). The ESCRT machinery is 
required for budding of most retroviruses, which interact with various ESCRT- 
components through different late domain motifs (Bieniasz 2006). So far, there 
is no evidence for ESCRT interaction with viral components other than Gag or 
matrix proteins equivalent to Gag in other viruses (compare Figure 1.6). It has 
been assumed that incorporation of Env into budding virions occurs either 
through concentration of Env in specific membrane domains (Nguyen and 
Hildreth 2000) or through direct interaction with Gag (Cosson 1996; Vincent et 
al. 1999; Hourioux et al. 2000).
HIV and SIV Envs contain a highly conserved motif GYxx0, which acts as an 
endocytosis motif in both viruses (Boge et al. 1998; Bowers et al. 2000). In HIV 
at least the motif is functionally redundant (see chapter 3). However, the 
GYxx0 motif is required for SIV pathogenesis in vivo (Fultz et al. 2001). These 
findings led to speculation that the GYxx0 motif may have functions other than 
trafficking and may be involved in regulating Env incorporation into budding 
virus. Further, the conserved GYxx0 motif in Env resembles a Yxx0 motif in
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the transferrin receptor (YTRF) that binds AIP1/Alix for exosomal sorting in 
reticulocytes (Geminard, De Gassart et al. 2004). In the Gag protein of the 
equine retrovirus EIAV a Yxx0 motif acts as the late domain through 
interaction with AIP1/Alix (Geminard, De Gassart et al. 2004).
On the basis of these findings I decided to investigate whether Envs can 
directly interact with the ESCRT machinery and if so, whether the GYxx0 motif 
is involved. I used a yeast-2-hybrid approach to search for potential protein- 
protein interactions between the HIV and SIV Env gp41 cytoplasmic domains 
and components of the ESCRT machinery. I found that both HIV and SIV Envs 
interact with Vps37B, a component of ESCRT-I, which directly binds to Tsg101 
and can recruit the remainder of the ESCRT machinery. The detected 
interaction was independent of the GYxx0 motif in Env, but may provide a 
direct link between the virus budding machinery and envelope proteins.
6.1. Yeast-two-hybrid analysis of ESCRT/Env interactions
6.1.1. Cloning of yeast-two-hybrid Env constructs
Despite their high structural and functional homology HIV and SIV Envs 
appear to be different in some aspects of intracellular trafficking. Both proteins 
contain a highly conserved GYxx0 motif, which appears to be essential for 
efficient endocytosis in SIV (Bowers et al. 2000), but not in HIV (see chapter 
3). However, in SIV this motif appears to function in pathogenesis (Fultz et al. 
2001). W e therefore speculated that this motif might be involved in Env 
integration into assembling virus. In order to address the question, whether the 
GYxx0 motif may be involved in a potential interaction with ESCRT 
components, a set of HIV and SIV Env cytoplasmic domain mutants were 
cloned into yeast-2-hybrid expression vectors. The cytoplasmic domain of 
gp41 (from either HIVHxb2 or S I V m a c 2 3 9 )  was amplified by PCR from the CD4- 
Env chimeras (see chapter 3). Subsequently, the PCR fragments were cloned 
into the multiple cloning site (MCS) of the yeast expression vectors from the 
Matchmaker 3 yeast-2-hybrid system (Clontech). The Env cytoplasmic 
domains were fused to both GAL4 activation domain (vector pGADT-7) and 
the GAL4 DNA binding domain (vector pGBKT-7) to test for interactions in both
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Figure 6.1. Cloning of Env constructs for yeast-2-hybrid analysis. The cytoplasmic 
domain of HIV HxB2 and SIV mac239 Env gp41 was amplified by PCR from CD4-Env 
chimeras (as described in Chapter 3) and ligated into the multiple cloning site of the Y2H 
expression vectors pGADT-7 and pGBKT-7 after the HA- or myc- tag sequence respectively 
under control of a T7 promoter fused to the GAL4 activation or DNA-binding domains (A). 
Mutations of potential protein-protein interaction motifs had been introduced previously into the 
CD4-Env constructs by Quickchange mutagenesis and were used to generate a set of mutants 
in both Y2H plasmids (B).
directions. The cloning strategy is summarised in Figure 6.1 A. In order to 
investigate the involvement of the GYxx0 motif, a set of mutants previously 
constructed in the CD4-Env chimera was cloned into the yeast-2-hybrid 
system (see Figure 6.1 B). For HIV Env a wt cytoplasmic tail, as well as a 
mutant with a non-functional GYxx0 motif (HIV Y712I) was used. For SIV Env 
the wt cytoplasmic tail and an analogous SIV Y721I mutant were cloned. We 
also used a GY-deletion construct (SIV dGY), as well as a cytoplasmic tail with
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a S/P mutation further downstream. This mutation had spontaneously arisen in 
monkeys infected with a dGY Env virus and rescued the pathogeneicity of the 
virus (Fultz et al. 2001).
6.1.2. Yeast-two-hybrid analysis
To identify potential interactions between Env cytoplasmic domains and the 
ESCRT machinery a series of directed yeast-2-hybrid experiments were 
performed. Vectors encoding the GAL4 activation domain or the GAL4 DNA 
binding domain fused to the coding sequence of a set of identified Vps proteins 
associated with the mammalian ESCRT machinery (compare Table 1.4) were 
obtained from Dr. W Sundquist, University of Utah, Salt Lake City, USA, and 
tested against the envelope constructs described above. All combinations of 
Env and ESCRT constructs were analysed in both directions, i.e. Env fused to 
activation and DNA binding domain of GAL4. Yeast strain AH109 was co­
transformed with pGADT-7 and pGBKT-7 vectors and grown on -Trp/-Leu 
plates to select for double transfected colonies. A selection of colonies from 
each transformation was picked and used to create master plates displaying 
an array of potential interactions. After two days the master plates were replica 
plated onto dropout media plates selecting for activation of reporter genes. 
Three different stringencies of selection were employed, nutritional selection 
for growth on -H is  plates (activation of HIS3), nutritional section for growth on 
-Ade/-His plates (activation of HIS3 and ADE2) and expression of a- 
galactosidase in addition to the nutritional selection (activation of HIS3, ADE2 
and MEL1). Expression of a-galactosidase leads to blue colonies on X-a-Gal 
indicator plates. Co-transformations with “empty” vectors only encoding the 
GAL4 activation or DNA binding domains were used as negative controls to 
identify self-activating proteins. As a positive control established protein- 
protein interactions were employed. Binding of SIV and HIV Envs to the p2- 
subunit of the clathrin adaptor AP-2 (AP50) had been demonstrated before 
using other systems (Boge et al. 1998; Bowers et al. 2000), and could be 
reproduced in the yeast system as a weak interaction (see Table 6.1). Other 
positive controls were the established interaction between the ESCRT-I 
components Tsg101 and Vps37B (Stuchell et al. 2004) and between
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AIP1/ALIX and CHMP4 (Katoh et al. 2003). Both interactions were detected in 
our yeast-2-hybrid system (Table 6.1).
When Env constructs were tested, positive interactions were only ever 
observed when Env was fused to the GAL4 activation domain. However, 
transformation of the construct was successful since growth of colonies on -  
Trp/-Leu plates was observed. It can therefore be assumed that the cause for 
the unidirectional interactions is based on expression or folding problems when 
Env was fused to the DNA-binding domain of GAL4. These unidirectional 
analysis indicated weak interactions between all Env constructs and Hrs as 
well as Vps28. The observed signal in Env and CHMP4B or CHMP5 co­
transformed colonies had to be neglected, since the same signal was found in 
the respective negative controls (Table 6.1). Most interestingly, a strong 
interaction between all analysed Env constructs and Vps37B was observed, 
compared to the weak self-activation in the respective negative control for 
Vps37B (Table 6.1 highlighted in pink). The interaction was reproducible and 
was detected in three independent experiments.
6.2. Vps37B binds to the Env cytoplasmic domain
6.2.1. Identification of a Vps37B/Env interaction
The potential interaction between the SIV and HIV Env cytoplasmic domains 
and the ESCRT-I component Vps37B described above was further analysed in 
several independent experiments in yeast and in vitro.
6.2.1.1. Analysis by yeast-two-hybrid
To reproduce the yeast-2-hybrid data presented above, yeast stain AH 109 was 
transformed with vector pGBKT-7 encoding Vps37B and vector pGADT-7 
encoding Env mutants, empty vectors were again used for control reactions. 
Interactions were analysed by replica plating of colonies onto -His/-Ade/ X-a- 
Gal indicator plates. After 3 days of incubation at 30°C the plates were 
scanned and analysed. A representative experiment is shown in Figure 6.2. 
Rapid growth was observed for all yeast colonies co-expressing Env 
constructs and Vps37B, while no colony growth was observed for negative
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controls containing Env constructs paired with empty vector and only marginal 
growth of a colony expressing Vps37B and empty vector was detected. 
Colonies expressing the constructs SIV Y and SIV dGY were intensively blue 
indicating secretion of a-galactosidase, and a blue rim started appearing 
around some of the other colonies as well. These results were indicative of a 
strong interaction between Vps37B and both the HIV and SIV Env cytoplasmic 
domains. They further suggested that the interaction was independent of the 
GYxx0 motif, since it was not abrogated when a GY deletion was introduced.
AD empty 
AD HIV Y 
AD HIV Y712I 
AD SIV Y 
AD SIV Y721I 
AD SIV dGY 
AD SIV S/P
Figure 6.2. Env/Vps37B interaction by Y2H. Yeast strain AH109 was co-transformed with 
pGADT-7 (AD) Env mutants and pGBKT-7 (DB) Vps37B, empty vectors were used as 
controls. Colonies were picked from -Leu/-Trp selective plates and replica plated onto -Leu/- 
Trp/-Hls/-Ade/X-a-Gal plates. The plate was scanned 3 days after replica plating.
6.2.1.2. Verification of the interaction by immunoprecipitation
Co-immunoprecipitation of in vitro transcribed and translated proteins was 
employed to verify the EnvA/ps37B interaction by alternative means. These 
experiments were performed by Claudia Gonzales-Lopez. The in vitro 
transcription/translation system takes advantage of the T7 promoter present in 
the yeast-2-hybrid vectors pGADT-7 and pGBKT-7, which can be used to 
express HA- and c-myc-tagged proteins respectively (compare Figure 6.1). We 
expressed proteins in vitro in the presence of 3H-leucine, to generate tritiated
200
c-myc tagged Env (from vector pGBKT-7) and HA-tagged Vps37B. C-myc 
tagged CHMP4B and Tsg101 were translated to use in control reactions. The 
proteins were subsequently mixed and immunoprecipitated with an antibody 
recognising the c-myc tag. Eluates from the precipitation were separated by 
SDS-PAGE and analysed by autoradiography.
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Figure 6.3. Env/Vps37B Co-precipitation. Schematic picture of Vps37B and its interactions 
with Tsg101 (A). Plasmids pGADT-7 encoding Vps37B and pGBKT-7 encoding Env constructs 
or Tsg101 or CHMP4B respectively were in vitro transcribed and translated in the presence of 
3H-leucine. The proteins were immunoprecipitated with antibodies against the c-myc tag in 
pGBKT-7 and the precipitates were separated by SDS-PAGE. An autoradiography of the 
precipitates shown (B) and individual protein bands are marked with arrowheads. The data in 
(B) were produced by C. Gonzales-Lopez (MRC LMCB).
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Tsg101 was used as a positive control to co-precipitate Vps37B. The two 
proteins have previously been reported to bind to each other using two 
interaction sites (Stuchell et al. 2004) (see Figure 6.3 A). As a negative control 
we used CHMP4B, which does not bind components of ESCRT-I (reviewed in 
Hurley and Emr 2006). Both controls clearly showed the expected results in 
the precipitation assay (Figure 6.3 B). When c-myc tagged Envs were 
assayed, Vps37B was co-precipitated with HIV Y, the mutant construct HIV 
Y712I and SIV Y. These findings confirm the results from the yeast-2-hybrid 
assays and show again that HIV and SIV Env can bind Vps37B independently 
of an intact GYxx0 motif.
6.2.2. Localisation of Vps37B and Env in cells
HIV Gag can recruit the ESCRT machinery to the plasma membrane through 
an interaction with Tsg101 to facilitate viral egress (Martin-Serrano et al. 
2001). Since an interaction of HIV and SIV Env cytoplasmic domains with 
Vps37B had been demonstrated in vitro and in yeast, a similar Env-mediated 
recruitment of Vps37B to membranes may be possible. I therefore chose to 
analyse the subcellular distribution of Vps37B with and without Env co­
expression in mammalian cells.
A first attempt to detect endogenous Vps37B by immunofluorescence using 
rabbit serum UT425 (obtained from Wesley Sundquist, University of Utah, Salt 
Lake City, US) failed in several tested cell lines. Instead, I chose to use a 
recombinant GST-Vps37B fusion protein (Juan Martin-Serrano, Kings College, 
London UK), which could be easily expressed in HeLa and HEK293T cells. In 
order to prove that the recombinant protein can be integrated into endogenous 
ESCRT-I, GST-pull down assays were performed using lysates of 293T cells 
transfected with GST-Vps37B or GST only as a control. When the eluates from 
the pull-downs were analysed by western blotting with an antibody against 
TSG101 it was observed that Tsg101 was precipitated with Vps37B but not in 
the control samples (Figure 6.4), indicating an interaction of recombinant 
Vps37B with endogenous Tsg101.
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Figure 6.4. GST-Vps37B interacts with endogenous Tsg101. 239T cells were transfected 
with GST-Vps37B or GST only using lipofectamine, grown for 48 h and then lysed. Lysates 
were precipitated with glutathione-Sepharose beads (GST pull down). Fractions bound to 
beads were eluted and separated on SDS-PAGE with the supernatants and the original lysate. 
Proteins were blotted onto membranes and the blots were probed with either anti-Tsg101 or 
anti-GST as indicated.
Subsequently, HeLa cells expressing CD4-HIV Env chimeras (as described in 
chapter 3) were transfected with GST-Vps37E3 and the subcellular distribution 
analysed with anti-GST and anti-CD4 antibodies by immunofluorescence. In 
cells that were not expressing any CD4-Env, GST-Vps37B was dispersed 
through the cytoplasm. This distribution remained unchanged when CD4-Env 
was expressed in the cells (Figure 6.5). These results suggest that the 
cytoplasmic domain of HIV Env may not be sufficient to recruit Vps37B to 
membranes in a cell system. However, it has to be considered that GST- 
Vps37B may not be representing the correct localisation of endogenous 
Vps37B, even though an interaction with Tsg101 had been demonstrated. 
Further, interactions in the cell may be transient and missed by the 
immunofluorescence method and there is need for a model system closer to 
the physiological situation.
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Figure 6.5. Colocalisation of CD4-Env and GST-Vps37B. HeLa cells expressing CD4-Env Y wt 
chimera were transfected with GST-Vps37B using Lipofectamine. The cells were fixed and 
permeabilised 48 hr post-transfection and stained with Q4120 anti-CD4 and anti-GST. The 
antibodies were detected with anti-mouse Alexa-Fluor 594 (red) and anti-rabbit Alexa-Fluor 
488 (green), respectively. Single confocal sections are shown. Scale bars = 10 pm.
6.3. Functional analysis of the HIV Env/Vps37B interaction
6.3.1. Strategy for functional analysis
If the Env cytoplasmic domain can bind components of ESCRT-I, it might itself 
be capable of recruiting the ESCRT machinery to facilitate virus budding. 
Previous experiments have shown that a mutation in the late domain of Gag 
can be compensated for by fusion of an ESCRT-I component to the C- 
terminus of Gag. Stuchell and colleagues demonstrated that when the PTAP 
motif in HIV-1 Gag was changed to URL, budding of virus like particles (VLPs) 
was abrogated. However, budding was rescued by fusion of Vps37B to Gag, 
which binds Tsg101 and can thereby recruit the rest of the ESCRT-machinery 
required for budding (Stuchell et al. 2004).
We decided to employ a similar strategy to test whether an interaction between 
Env and Vps37B is sufficient to recruit the remaining ESCRT-machinery, and
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Figure 6.6. Gag-Env fusion constructs. Schematic depiction of Gag-GFP and Gag-Env 
fusion proteins. The Env gp41 cytoplasmic tail was fused to the C-terminus of PTAP/LIRL 
mutant Gag constructs or to p6 deficient Gag constructs (Gag dp6). Additionally, a 
myristoylated (Myr) p6 domain was cloned into the pEGFP-N1 expression vector. The cloning 
procedure is detailed in Materials and Methods (Chapter 2).
thus facilitate virus budding. A mutation or deletion in the Gag p6 domain 
should be compensated for by the fusion of the HIV Env cytoplasmic domain to 
the C-terminus. To this end six different HIV Gag constructs were generated 
(see Figure 6.6). A full-length Gag construct fused to GFP (Gag wt-GFP), 
which has been described previously, is capable of recruiting the ESCRT 
machinery and can form VLPs (Hermida-Matsumoto and Resh 2000). When 
the PTAP motif in the late domain of the same Gag was mutated (Gag LIRL- 
GFP) the formation of VLPs was inhibited, since binding to TSG101 was no 
longer possible (Stuchell et al. 2004). As an additional negative control a Gag- 
GFP construct with a completely deleted p6 domain (Gag dp6-GFP) was used. 
To test the ability of Env to recruit ESCRTs, we replaced the GFP coding 
sequence in the budding deficient Gag LIRL-GFP and Gag dp6-GFP with the 
coding sequence for the cytoplasmic domain of HxB2 Env. In addition, we 
cloned an intact myristoylated Gag p6 domain fused to GFP (p6-GFP), which 
should be directed to membranes and be capable of binding Tsg101 and 
recruiting ESCRT. However, this construct cannot oligomerise with other Gag 
proteins and can solely be used to target ESCRT components to membranes
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and facilitate their interaction with the constructs described above. The 
constructs were then tested for their ability to produce VLPs.
6.3.2. VLP release assays
Experiments presented in this section were conducted in collaboration with 
Claudia Gonzales-Lopez. The above-described Gag-GFP and Gag-Env 
chimera were tested for expression in HeLa and HEK293T cells. Western 
blotting with antibodies against GFP and capsid (p24) demonstrated that all 
constructs were efficiently expressed at their respective correct sizes (Figure 
6.7 A). VLP release assays were then performed to analyse the capability of 
the constructs to trigger particle budding. Various cell lines were transfected 
with the Gag constructs using lipofectamine and the supernatant tissue culture 
medium was collected at several different time points post-transfection. VLPs 
were purified from the supernatant by centrifugation through a 20% sucrose 
cushion. In parallel, the cells were lysed to control for protein expression. VLPs 
and lysates were analysed by SDS-PAGE and subsequent western blotting for 
p24. It was confirmed that Gag wt-GFP transfection led to efficient VLP 
formation (Figure 6.7 B, second band from the left in left hand panel). The 
negative controls however, proved to be problematic. VLP production was only 
abrogated for the Gag LIRL-GFP construct in HeLa cells as early as 19 hr 
post-transfection. At later time points or in HEK293T or COS cells VLPs were 
produced despite the mutation in the Tsg101 binding motif. Over- expression 
of the construct provides a potential explanation for this phenomenon. In the 
same experiment VLP production in cells transfected with Gag dp6-GFP was 
reduced but not abrogated (Figure 6.7 B). Fusion of the Env cytoplasmic 
domain to Gag LIRL did not rescue VLP budding and the amount of VLPs 
produced when the cells were expressing a Gag dp6-Env construct was minor 
and did not differ from the amount of VLPs when Gag dp6-GFP was used 
under the same conditions. Co-expression of p6-GFP did not aid the 
production of VLPs (Figure 6.7 B right hand panel). Thus, it was concluded 
that in this unusual scenario Env could not recruit the ESCRT machinery and 
rescue VLP budding.
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Figure 6.7. VLP-release assay. HeLa cells grown in 6-well dishes were transfected with 0.5 
pg DNA per well as indicated for individual samples using Lipofectamine. For (A) the cells 
were lysed 19 hr post-transfection, lysates separated by SDS-PAGE and blotted. Blots were 
probed with anti-GFP or anti-p24 as indicated to detect protein expression. For panel (B) the 
cell supernatant was collected 19 hr post-transfection and VLPs were purified through a 20 % 
sucrose cushion. The cells were subsequently lysed. Both, lysates (L) and VLPs (VLP) were 
run on SDS-PAGE and blotted. Blots were probed with anti-p24. Arrowheads indicate relevant 
protein bands. This experiment was performed by C. Gonzales-Lopez.
A potential cause for Env not rescuing VLP budding may be a lack of, or 
reduced expression of Vps37B in the cell lines used for the VLP release 
assays. It was therefore considered that co-expression of recombinant Vps37B 
may be of help. Therefore cells were co-transfected with Gag-Env chimeras
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and GST-Vps37B, which can bind endogenous Tsg101, as previously 
demonstrated. However, no production of VLPs from a Gag LIRL-Env was 
seen.
6.4. Discussion
The cellular machinery required for retrovirus budding has been well 
characterised in recent years, and it was shown how Gag proteins interact with 
components of the ESCRT machinery to facilitate viral egress (see section 
1.5). Despite this progress, it is not understood how envelope proteins are 
incorporated into newly forming virus particles. However, integration of Env is 
essential for the generation of infectious virus and mechanisms must exist that 
regulate it. Since the Env cytoplasmic domain comprises a conserved 
sequence motif GYxx0, which is similar to motifs responsible for interaction 
with ESCRT components on viral Gag and cellular proteins, I decided to 
investigate whether a direct link between Env and ESCRT exists, which may 
facilitate Env incorporation into budding virus.
I employed directed yeast-2-hybrid analysis to test for interactions between 
HIV and SIV Env cytoplasmic domains and all Vps proteins identified to be 
associated with the ESCRT-machinery (see Hurley and Emr 2006). I found 
that both HIV and SIV Envs bind the ESCRT-I component Vps37B, and the 
interaction was further confirmed by co-immunoprecipitation analysis. Vps37B 
is one of four proteins of the mammalian Vps37 family, which is homologous to 
the yeast Vps37p (Stuchell et al. 2004). Two other members of this family, 
Vps37A (Bache et al. 2004) and Vps37C (Eastman et al. 2005) have also been 
associated with ESCRT-I, while Vps37D awaits further analysis. Vps37A, C 
and D were subsequently analysed for interaction with Envs, but while Vps37A 
proved to be a self-activator in the yeast system, no interaction with Vps37C or 
D was observed either by yeast-2-hybrid or by co-immunoprecipitation 
experiments (data not shown). These results suggest that the Env Vps37B 
interaction is highly specific and may be indicative of Vps37B being 
preferentially expressed over other members of the Vps37 family in HIV target 
cells. I therefore conducted a western blot protein expression screen in various
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cells lines and primary cells. Initial data suggests that Vps37B may be highly 
expressed in primary macrophages as well as in a PMA differentiated form of 
the pro-monocyte U937. No expression was detected in primary T-cells, or the 
cell lines HeLa, COS or HEK293T (data not shown). However these results 
were poorly reproducible and an analysis by PCR amplification of mRNA 
indicated that all four forms of Vps37 are expressed ubiquitously (Ezequiel 
Ruiz-Mateos, MRC LMCB personal communications). Though it cannot be 
excluded that protein expression of certain members of the Vps37 family is 
tissue specific due to post-translational modification or degradation of proteins.
We analysed different mutant constructs of HIV and SIV Envs to investigate 
whether the conserved membrane proximal GYxx0 motif is involved in 
Vps37B binding. Both yeast-2-hybrid and co-immunoprecipitation experiments 
showed that this is not the case and neither mutation of Y 712I in HIV or a 
deletion of GY in SIV abrogates the interaction. Further analysis by alanine 
scanning of the entire cytoplasmic tail is therefore required to map the 
interaction site. Unfortunately, attempts to map the interaction site on Vps37B 
using fragments consisting of aa 1-64, 65-198 or 199-C-terminus (Stuchell et 
al. 2004) were unsuccessful due to self-activation in the yeast system.
If Env can bind Vps37B, it should be able to recruit the ESCRT machinery 
through the interaction of Vps37B with the other ESCRT-I components. Thus, 
it should be possible to rescue budding of VLPs from late domain deficient 
Gag proteins. We used a system, where the Env cytoplasmic tail was fused to 
the C-terminus of either PTAP-mutant or p6-deficient Gag constructs and 
analysed VLP release in different cell systems. We did not observe any rescue 
of VLP budding with either of the constructs used. Also, no budding was 
observed, when myristoylated p6 was co-expressed to facilitate ESCRT 
targeting to membranes, or when recombinant Vps37B was added to increase 
the cellular pool. This may indicate that the EnvA/ps37B interaction observed 
in yeast and in vitro cannot be formed in a cellular background, or that it is not 
sufficient to recruit the remainder of the ESCRT machinery. However it is also 
possible that the Gag-Env chimeras do not form VLPs due to impaired
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oligomerisation and that it may be necessary to co-express Gag-mutants with 
no added Env to induce formation of mixed particles. Also, other cellular 
factors may be required, which cannot be recruited when only the cytoplasmic 
domain of Env is present. Further analysis by alternative means is therefore 
needed in order to identify whether an interaction between Env and Vps37B is 
functionally relevant. These methods may include knockdown of Vps37B or the 
mutation of interaction sites on both proteins, which can then subsequently be 
used to analyse incorporation of Env into virus particles.
Apart from an interaction with Vps37B we detected weak binding of Env 
cytoplasmic tails to Hrs and Vps28 in the yeast-2-hybrid system. Both of these 
are interesting in the light of recent discoveries. Hrs is responsible for targeting 
ubiquitinated cargo proteins to multivesicular bodies for sorting into internal 
vesicles (Babst 2005), which are topologically equivalent to intracellular 
budding virus particles. An interaction with Hrs may therefore provide a means 
for targeting Env to the site of viral assembly and provide a link to Gag and the 
ESCRT machinery. Vps28 has recently been found to play a role in the 
budding of influenza virus (Hui et al. 2006), and its role in viral assembly 
awaits further elucidation. The functional relevance of an interaction between 
Env and these two proteins is under investigation.
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7. Interactions between SIV envelope proteins and E3 
Ubiquitin ligases
Incorporation of Env into virions is crucial for viral pathogenesis, since the 
protein is required for binding to the viral receptors, fusion with the target cell 
membrane and therefore spread of the virus. In the previous chapter I 
demonstrated that a direct interaction between the HIV and SIV Env 
cytoplasmic domains and Vps37B, a component of the ESCRT-I complex, may 
play a role in Env incorporation into budding virions. However, the interaction 
itself was not sufficient to rescue budding of late domain mutant Gag proteins, 
suggesting that other factors are required.
As previously discussed (see section 1.4.2.1), the membrane proximal GYxx0 
motif has been implicated in SIV pathogenesis (Fultz et al. 2001). When 
rhesus macaques were inoculated with SIVmaC239 containing a GY72i deletion, 
an initial burst of viral replication was observed, but then plasma RNA levels 
declined to barely detectable and two from three animals remained healthy. 
However, one animal developed a high viral load and progressed to AIDS. 
Surprisingly, when virus isolated from this animal was analysed, it was noticed 
that the deletion in the G Yxx0 motif persisted, but a novel compensatory 
mutation had occurred further downstream changing serine727 to a proline 
(Fultz et al. 2001). Sequence analysis revealed that this proline was positioned 
just upstream of an amino acid sequence PPSY. PPxY motifs have been found 
to bind WW-domains, a protein module present in the Nedd4 family of HECT 
E3-ubiquitin ligases (Dunn and Hicke 2001; Hicke 2001). These proteins tag 
substrates with ubiquitin to direct them into the intralumenal vesicles of MVBs. 
In addition, HECT-ubiquitin ligases have been shown to facilitate retrovirus 
budding (Martin-Serrano et al. 2005). PPxY motifs are present in the Gag 
proteins of Rous Sarcoma Virus (RSV) (Kikonyogo et al. 2001), Mason-Pfizer 
Monkey Virus (MPMV) (Yasuda et al. 2002) and HTLV-1 (Bouamr et al. 2003) 
and mutations in the motif lead to a decrease in virus release (see section
1.5.2.2.). While no direct interaction between the Gag proteins of these viruses 
and ESCRT-components was observed, the HECT-ubiquitin ligases may 
provide a means of targeting them to virus budding sites and linking them to
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the ESCRT-machinery possibly through ubiquitination (Blot et al. 2004). In 
addition, HECT-ubiquitin ligases display some characteristics of the 
mammalian class E proteins (compare section 1.5.1) and are recruited to 
endosomal membranes when dominant negative Vps4 mutants are expressed 
(Martin-Serrano et al. 2005). The Ser/Pro mutation preceding the PPxY motif 
in the cytoplasmic domain of SIV Env may expose or enhance this motif, 
facilitating an interaction with HECT-ubiquitin ligases. Thus the mutation may 
lead to an alternative mechanism for Env incorporation into budding virus by 
establishing a novel link to the ESCRT-machinery, compensating for an 
interaction that has been destroyed by the loss of the GYxx0 motif.
To test this hypothesis I have employed a yeast-2-hybrid candidate screen to 
identify potential interactions between SIV Env and HECT-ubiquitin ligases of 
the Nedd4-family. I found that SIV Env specifically interacts with the E3 ligase 
WWP2. GST-pull down analysis confirmed the interaction and revealed that 
the E3-ligase was bound in a PPxY motif dependent, but GYxx0 independent, 
manner. A detailed analysis of SIV Env ubiquitination and experiments using 
dominant negative proteins were then used to try and establish a mechanism 
for W W P2 mediated integration of Env into budding virions.
7.1. Env cytoplasmic domain sequence alignment
Both HIV and SIV Env cytoplasmic domains contain several highly conserved 
regions. The GYxx0 motif (see chapter 3) for example is conserved among all 
HIV-1, HIV-2 and SIV strains. However, the viruses appear to be different in 
some aspects, the C-terminal dileucine motif, which is also highly conserved, 
mediates endocytosis in HIV Env but not SIV Env (see chapter 3), where a 
second endocytosis motif has not yet been clearly identified (Bowers et al.
2000). Fultz and colleagues have shown a serine to proline change in 
SIVmac239 Env was affecting viral pathogenesis. The mutation preceded a PPxY 
motif, which agrees with the consensus sequence for HECT-ubiquitin ligase 
binding. However, the function of the motif in SIV Env has not yet been 
examined and it is not known whether it may play a general role for the biology 
of the virus.
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Figure 7.1. Sequence alignment of HIV and SIV Env cytoplasmic domains. Amino acid 
sequences for HIV and SIV strains were obtained from the LANL HIV sequence database 
(http://hiv-web.lanl.gov). Accession numbers are as follows: HIV-1 HxB2 = K03455; HIV-1 BaL = 
M68893; HIV-2Rod = M30502; SIVcpz = AF103818; SIVmac239 = M33262; SIVmac251 = 
D01065; SIVsmm = M80194; SIVstm = M83293. Boxes indicate regions discussed in the text. 
Amino acids conserved in all analysed HIV-1, HIV-2 and SIV strains are shaded in yellow, 
amino acids conserved in HIV-1 and SIVcpz in blue and amino acids conserved in HIV-2 and 
SIV strains in pink.
I conducted a sequence alignment comparing the Env cytoplasmic domains of 
several SIV strains to HIV-1 and HIV-2. Sequences for the X4-tropic HIV-1 Hxb2 ,
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the R5-tropic H I V -1 BaL, H I V - 2R o d ,  S I V c p z  (chimpanzee), S I V m a c 2 3 9  and S I V m aC 2 5 i  
(macaque), S I V s m m  (sooty mangabey) and S I V s tm  (stump-tailed macaque) were 
obtained from the Los Alamos National Laboratory (LANL) HIV Sequence 
Database (http://hiv-web.lanl.aov1 and aligned using the MegAlign module in 
the DNAStar software. The sequence alignment is depicted in Figure 7.1. 
Sequences conserved in all analysed strains are highlighted in yellow, 
sequences conserved in the closely related SIVcpz and HIV-1 strains in blue 
and sequences conserved in the related HIV-2 and rest of SIV strains in pink. 
The alignment immediately shows the high similarity between SIVcpz and HIV- 
1, as well as the difference between H I V -1 and H I V -2 strains. As mentioned 
above, the G Yxx0 consensus motif is conserved in all analysed strains (see 
first box) and the sequences are exactly conserved within the two groups of 
viruses. The PPxY motif (see second box in Figure 7.1) is present in both 
S I V m a c  and HIV-2, indicating a certain degree of conservation. A variation was 
observed for S I V s tm  and potentially S l V s m m , where the residue in the Y-position 
is unidentified. However, the di-proline and preceding serines are conserved in 
all HIV-2 and SIV strains tested. This high degree of sequence conservation 
and the fact that the entire motif is absent in HIV-1 and SIVcpz suggests that the 
PPxY sequence may be of importance to SIV biology and constitute one of the 
differences between SIV and HIV-1.
Further downstream two leucines in a sequence of four amino acids (LxxL) are 
conserved in all analysed strains. This motif is similar to a motif found in the 
HIV Gag p6 domain responsible for binding to AIP1/Alix (Strack et al. 2003; 
von Schwedler et al. 2003). However, the function of this motif remains 
unknown, in an initial yeast-2-hybrid screen no interaction between Env and 
AIP1/Alix was identified (see Table 6.1).
A motif YW  is conserved in HIV-1 and SIVcpz strains (see Figure 7.1 fourth 
box) and has been demonstrated to bind to TIP47 and play a role in viral 
pathogenesis (Blot et al. 2003). Both residues are present in HIV-2 and SIV, 
but they are intercepted by three additional residues, and it is not known, 
whether the motif has any functional role. It is striking that, while HIV-2 and
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S I V m a c  contain a PPxY motif with implications in pathogenesis, the group of 
SIVcpz and HIV-1 strains possesses a YW  motif with a potential role in 
pathogenesis absent in the other group of strains.
A dileucine motif present in HIV-1 strains and SIVcpz ( L L s u / s i s  in HxB2) was 
analysed previously (see chapters 3 and 4) and was found not to have a direct 
effect on Env trafficking despite its in vitro interaction with AP-1 (Wyss et al.
2001). This dileucine is not conserved in other SIV or HIV-2 strains (see Figure 
7.1 fifth box). A high degree of conservation is found in the C-terminus of all 
analysed Envs. Interestingly, there appear to be differences in the functional 
relevance of these residues despite the conservation. The C-terminal dileucine 
is acting as an endocytosis motif in HIV (see chapter 3) but not in SIV (Bowers 
et al. 2000) and the endocytotic properties of the dileucine were not affected 
by a preceding conserved glutamic acid residue (see chapter 3). However, the 
highly conserved 7 amino acid stretch N-terminal of the dileucine (Figure 7.1 
sixth box) appears to have a function in HIV and SIV Envs in modulating Env 
structure and affecting the S U -TM  interaction stability (Affranchino and 
Gonzalez 2006).
Taken together, the sequence alignment shows that while there are several 
amino acid stretches conserved in HIV-1, HIV-2 and SIV with mostly identified 
functions, there are also sequences, which are specifically conserved in either, 
only HIV-1 and SIVcp2 or in HIV-2 and other SIV strains. Since some may play 
a role in pathogenesis of the virus, it will be intriguing to see, whether the two 
groups of viruses have evolved different mechanisms for Env incorporation 
into budding virions.
7.2. Yeast-two-hybrid screen for SIV Env/E3-ligase interactions
7.2.1. Constructs for yeast-2-hybrid screen
In order to test whether the S I V  Env cytoplasmic domain can interact with 
members of the Nedd4-family of HECT-ubiquitin ligases I employed a yeasty- 
hybrid analysis. The S I V m a c 2 3 9  Env cytoplasmic domain from CD4-Env 
chimera, as previously described (see Materials and Methods and Bowers et
215
al. 2000), was inserted into the yeast-2-hybrid expression vectors pGADT-7 
and pGBKT-7 fused to HA- and myc-tags, respectively (Figure 7.2 A), as 
explained in section 6.1.1. and Materials and Methods.
A
CD4-Env CD4 lumenal domain CD4TM gP41 cyt
G A L4A D PT7 HA gP41 cyt M  LEU
ApGBKT-7 Env (DB) G A L4D B D  PT7 > myc |  gP4 i cyt
B
CD4/AD/DB SIV Y  GYxx0......SPPxY..
CD4/AD/DB SIV dGY ......- - xx0........SPPxY..
CD4/AD/DB SIV S/P ......- - xx0........PPPxY..
CD4/AD/DB SIV Y PP/AA  GYxx0.......SAAxY.
CD4/AD/DB SIV Y xY/AA  GYxx0.......SPPAA.
CD4/AD/DB SIV dGY PP/AA .......- - xx0........SAAxY.
CD4/AD/DB SIV dGY xY/AA .......- - xx0........SPPAA.
Figure 7.2. Cloning of Env constructs for yeast-2-hybrid analysis. The cytoplasmic 
domain of SIVmac239 Env gp41 was fused to the ecto- and transmembrane domains of CD4 
or ligated into the multiple cloning site of the Y2H expression vectors pGADT-7 and pGBKT-7 
after the HA- or myc- tag sequence respectively, under control of a T7 promoter fused to the 
GAL4 activation or DNA-binding domains (as shown in Figure 6.1) (A). Mutations of potential 
protein-protein interaction motifs were introduced into the constructs by Quickchange 
mutagenesis to generate a set of mutants in both, the CD4-Env chimera and the Y2H plasmids 
(B).
To investigate if a potential interaction is dependent on the PPxY motif or the 
S/P change that occurred as a compensatory mutation (Fultz et al. 2001), a set 
of mutant constructs was created in both, the CD4-Env chimera and in the
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Y2H vectors using QuickChange mutagenesis (see Figure 7.2 B). Constructs 
encoding a wt cytoplasmic tail (SIV Y), a deletion in the GYxx0 motif (SIV 
dGY) or a deletion combined with the S/P change (SIV S/P) were the same as 
used previously to test SIV Env/ESCRT interactions (see Figure 6.1). In 
addition, the PPxY motif was mutated by a PP/AA and a xY/AA change both, 
in the context of a wt tail (SIV Y PP/AA and SIV Y  xY/AA) or in the context of 
the GY-deletion (SIV dGY PP/AA and SIV dGY xY/AA). Subsequently, the 
expression of CD4-SIV Env mutants was tested in HeLa cells and the Y2H 
mutant constructs were used to transform yeast strain AH 109.
7.2.2. Yeast-2-hybrid screen overview
To identify potential interactions between the SIV Env cytoplasmic domain and 
Nedd4-family HECT-ubiquitin ligases a series of yeast-2-hybrid experiments 
were performed in yeast strain AH 109 as described in section 6.1.2. Yeast 
vectors encoding the E3-ligases WWP1, WWP2 and Itch were obtained from 
Dr. W  Sundquist (University of Utah, Salt Lake City, USA) and the respective 
vectors encoding the ligase Nedd4 or the WW-domains of Nedd4 L, BuL1, 
Smurfl and Smurf2 were received from Dr. J. Martin-Serrano (Kings College, 
London, UK). All ligases were tested against the SIV Env constructs described 
above. Whenever possible, interactions were analysed in both directions, i.e. 
Env fused to activation and DNA binding domain of GAL4. Co-transformation 
with “empty” vectors only encoding the GAL4 activation or DNA binding 
domains was used as a negative control to identify self-activating proteins. Co­
transformed yeast colonies were analysed on selective -Trp/-Leu/-His plates 
and on X-a-Gal indicator plates. The results of several experiments are 
summarised in Table 7.1.
A strong interaction was detected between all three tested SIV Env constructs 
and WWP2. The interaction was reproducible in several independent 
experiments, but it was only observed when the Env cytoplasmic tail was fused 
to the GAL4 activation domain. Weak signals were observed with WWP1, as 
well as Itch, of which the later at least appeared to be caused by auto­
activation. No interaction was found with other ligases or their WW-domains.
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However, these results have to be interpreted with care since most of the 
interactions were only tested in one direction.
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AD Smurf 1 WW - - - -
AD Smurf 2 WW - - - -
Table 7.1. Yeast-2-hybrid analysis of SIV Env cytoplasmic tail interaction with HECT E3 
ubiquitin ligases. Summarised results from several yeast-2-hybrid experiments. Strong Env 
interactions are shaded in pink. Negative results are marked with (-), weak interactions (growth 
on -His only) with (+), strong interactions (growth on -Ade/-His and blue colonies on X-Gal) 
with (+++). For some of the E3 ligases only the WW-domains were used in the Y2H constructs 
(indicated with WW).
7.3. WWP2 interacts with the cytoplasmic domain of SIV Env
7.3.1. Identification of a SIV Env/WWP2 interaction by yeast-2-hybrid
Preliminary results from X-a-Gal screening suggested that SIV Env interacts 
with the Nedd4-family HECT-ubiquitin ligase WWP2. To further confirm this 
result, the yeast-2-hybrid analysis was repeated testing the SIV Y and SIV S/P 
constructs fused to the GAL4 activation domain against the ligases WWP1, 
WWP2 and Itch fused to the GAL4 DNA-binding domain. As an alternative
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method of analysis, filter assays detecting intracellular p-galactosidase were 
used (see Materials and Methods section 2.13.6.)- An interaction between two 
proteins leads to the expression of (3-galactosidase, which, following cell 
disruption, can turn an X-Gal substrate blue.
Co-transfection of yeast strain AH 109 with SIV Env constructs and WWP2 led 
to strong p-galactosidase expression in both the wt SIV cytoplasmic domain 
and the S/P mutant. No expression was observed in negative controls using 
empty Y2H vectors or when the cells were co-transfected with WWP1 or Itch 
(Figure 7.3). These results confirmed the previously observed interaction with 
WWP2 and further emphasised the specificity of the interaction with this ligase.
DB WWP1
DB WWP2
DB Itch
DB empty
-Trp/-Leu master plate X-gal assay
Figure 7.3. Yeast-2-hybrid analysis of SIV Env I HECT E3-ligase interactions. Yeast 
strain AH109 was co-transformed with vectors pGBKT-7 encoding E3-ligases and pGADT-7 
encoding SIV Env constructs. Empty vectors were used as controls. Colonies growing under 
selection for both vectors were replated onto a master plate (left panel) and grown for 2 days. 
The colonies were transferred onto a filter and assayed for intracellular beta-galactosidase 
expression as described in Materials and Methods (right panel).
7.3.2. GST-pull down analysis
Alternative assays independent of yeast were required to confirm the 
interaction between WWP2 and the SIV Env cytoplasmic domain. We chose to 
employ a GST-pull down approach, and the WW-domain of WWP2 fused to
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GST was obtained from Dr. J. Martin-Serrano (Kings College, London, UK). 
Experiments in this section were performed by Dr. C. Gonzales-Lopez, MRC 
LMCB.
7.3.2.1. Verification of a SIV Env/WWP2 interaction
To test whether an interaction between Env cytoplasmic domain constructs 
and WWP2 occurs in cells, HEK293T cells were transfected with CD4-SIV Env 
constructs and either GST alone or the WW-domain of WWP2 fused to GST. 
The cells were lysed 48 hr post-transfection and the lysates precipitated with 
glutathione-sepharose beads. Eluates of the pull-downs were blotted with anti- 
CD4 Q4120. Figure 7.4 shows that constructs containing the wt Env 
cytoplasmic domain as well as the dGY and the S/P mutants co-precipitated 
with the WW-domain in agreement with the results from the yeast-2-hybrid 
analysis. No precipitation was detected with either GST alone or from single 
CD4-Env transfected cells, indicating that there was no unspecific binding of
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Figure 7.4. GST pull-down of CD4-SIV Env and WWP2. 293T cells were transfected with 
CD4-SIV Env constructs and empty GST vectors or the WWP2 WW-domain fused to GST. 
The cell lysates were precipitated with Glutathione-Sepharose 48 hr post-transfection. Eluates 
were separated by non-reducing SDS-PAGE and blotted. Blots were probed with Q4120 anti- 
CD4. Data was produced by C. Gonzales-Lopez.
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Figure 7.5. WWP2 binding is dependent on a PPxY motif. HEK293T cells were transfected 
with CD4-SIV Env constructs and GST or the WW-domain of WWP2 fused to GST. Lysates of 
cells were blotted for CD4 and GST at 48 hr post-transfection as indicated (A), or precipitated 
with glutathione-Sepharose and the eluates blottedfor CD4 (B). Experiments wereperformed 
by C. Gonzales-Lopez.
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CD4-Env to either GST or the glutathione-Sepharose beads. This data 
suggests that wt SIV Env cytoplasmic domains can bind WWP2 and that the 
G Yxx0 motif is not involved in the interaction, since deletion of the GY codons 
did not abrogate binding.
7.3.2.2. Binding is dependent on a PPxY motif
Next, we wanted to investigate whether the PPxY motif was essential for the 
interaction with W W P2. Another set of GST-pull down assays was therefore 
performed including PP/AA and xY/AA mutants in the context of wt and GY- 
deleted cytoplasmic domains as previously described (compare Figure 7.2). 
The mutants were expressed in HEK293T cells together with either the WWP2 
WW-domain fused to GST or GST alone. The lysates were blotted to analyse 
expression of the proteins using antibodies against CD4 or GST, before they 
were subjected to GST-pull downs. All constructs were expressed efficiently 
and to a similar extent (Figure 7.5 A). When the lysates were subjected to 
GST-pull downs and eluates were blotted for CD4, a clear signal was again 
obtained with SIV Y, SIV dGY and SIV S/P constructs. However, the 
interaction was completely abrogated when residues of the PPxY motif were 
mutated (Figure 7.5 B). None of the constructs co-precipitated with GST alone 
(data not shown).
These findings show a clear dependency of the Env/WWP2 interaction on the 
PPxY motif and further demonstrate that the prolines as well as the tyrosine 
residues are essential for function. The PPxY motif appears to operate 
independently of the G Yxx0 motif, since mutations in PPxY led to a loss of 
interaction even when the GYxx0 motif remained unchanged.
7.3.2.3. An S/P mutation increases WWP2 binding
The fact that the S/P change in front of the PPxY motif can compensate for a 
GY-deletion with respect to viral pathogenesis (Fultz et al. 2001) suggests that 
an alternative mechanism of Env incorporation may be used that is not 
normally present. However, the data presented here indicates that PPxY motif 
mediated binding to WWP2 is also present in the context of an intact GYxx0  
motif and is not exclusive to S/P mutants. It may however be possible that
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Figure 7.6. Quantification of CD4-SIV Env/WWP2 binding. HEK293 T cells were 
transfected with CD4-SIV Env and GST-WW constructs, and lysates were processed for GST 
pull-down 48 hr post-transfection. Eluates were blotted for CD4 (A). The density of bands was 
analysed using QuantityOne software and plotted. Averaged values from 4 experiments are 
shown in (B), error bars represent the standard deviation. This experiment was performed by 
C. Gonzales-Lopez.
binding is enhanced when an additional proline is present. We therefore 
compared the results from five independent GST-pull down experiments, all 
showing interactions between SIV Env constructs and WWP2. We observed 
that in three from five experiments, the bands representing the SIV P/S 
mutants were stronger than bands for SIV Y or SIV dGY constructs (see 
example in Figure 7.6 A). We subsequently quantified the bands from four of 
these experiments by densitometry and plotted the average intensity of bands 
indicating CD4-Env binding to WWP2 for all three constructs compared. The
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values obtained were normalised to the band for the wt SIV Env cytoplasmic 
domain (SIV Y). Figure 7.6 B shows that SIV S/P binds WWP2 with 1.5 times 
higher efficiency than the wt SIV Y. The binding efficiency of the dGY mutant 
was comparable to the wt, again reinforcing the independency of the 
interaction of the G Yxx0 motif. The variability in these values was high, since 
experiments that showed equal binding of all constructs were included in the 
calculations. Further, it has to be considered that the binding efficiency was 
determined using CD4-Env constructs and full length Env might bind 
differently.
7.3.3. Immunofluorescence analysis of SIV Env/WWP2 binding
The previous data demonstrated that the SIV Env cytoplasmic domain 
interacts with W W P2 in a yeast-2-hybrid system and in cell lysates. However, it 
remains to be shown that the PPxY motif can recruit the ubiquitin ligase in a 
cell system, as was previously demonstrated for the PPxY motifs in the Gag 
protein of MLV and the Ebola matrix protein (Martin-Serrano et al. 2005). To 
this end I decided to test, whether the expression of CD4-SIV Env constructs 
can alter the subcellular distribution of the ubiquitin ligases. Martin-Serrano 
and colleagues reported that Nedd4 ubiquitin ligases lacking their C2 domain, 
or single WW-domains localise to the nucleus and can be redistributed to 
membranes upon co-expression of a membrane-associated interactor (Martin- 
Serrano et al. 2005). Co-expression of SIV Env and the WWP2 WW-domain 
should therefore lead to the same observation, if the interaction with the Env 
PPxY motif is sufficiently potent.
To avoid double transfections, HeLa and PA317 cells stably expressing CD4- 
SIV Env constructs were used. A construct encoding the WWP2 WW-domain 
fused to YFP was obtained from Dr. J. Martin-Serrano. When HeLa cells were 
transfected with the YFP-W W  construct, strong fluorescence was observed 
almost exclusively in the nucleus (Figure 7.7 top panel). Transfection of HeLa 
cells expressing CD4-SIV Y constructs, which localised to a perinuclear area, 
did not change the nuclear pattern of the YFP signal. The YFP-WW distribution 
also remained practically unchanged, when the cells were stably expressing 
CD4-SIV dGY. In contrast, in cells expressing CD4-SIV S/P a fraction of the
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Figure 7.7. Relocalisation of WW-domains by CD4-SIV Env expression. HeLa (top two 
rows) and PA317 cells (bottom two rows) stably expressing CD4-SIV Env constructs as 
indicated, were transfected with the WW-domain of WWP2 fused to YFP. The cells were fixed, 
permeabilised and stained with anti-CD4 Q4120 and secondary anti-mouse Alexa-Fluor 594 
(red) reagent. Single confocal sections are shown. Insets represent 3x magnifications of the 
framed areas. Scale bars = 10 pm.
YFP-WW was observed in patches at the plasma membrane and on 
cytoplasmic organelles, which colocalised with the Env construct. This 
suggested that CD4-SIV S/P may be able to recruit the WWP2 WW-domain
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merge
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construct in intact cells and supports the notion that binding to the S/P variant 
may be stronger than binding to the wt Env cytoplasmic domain.
7.4. Ubiquitination of the SIV Env cytoplasmic domain
Previous studies demonstrated that the presence of a PPxY motif and 
recruitment of an E3-ligase can lead to ubiquitination of a protein in a context 
independent manner (Martin-Serrano et al. 2004). In the case of retroviral Gag 
proteins ubiquitination may contribute to the viral budding and release 
(Gottwein and Krausslich 2005), and inhibition of ubiquitination by proteasome 
inhibitors leads to an intracellular retention of immature virus particles (Blot et 
al. 2004). Since ubiquitination is required for delivery of cargo protein to the 
ESCRT-machinery (see section 1.5.1.3), similar mechanisms might also be 
involved in Env sorting to viral assembly sites. As the PPxY motif in Env 
appears to recruit a HECT ubiquitin ligase, I investigated whether this 
interaction leads to ubiquitination of SIV Env.
7.4.1. SIV Env ubiquitination
To test whether the cytoplasmic domain of SIV Env is ubiquitinated the set of 
CD4-Env constructs described in Figure 7.2 was used. HEK239T cells were 
transiently transfected with the constructs and the cells lysed two days later. 
The lysates were subjected to immunoprecipitation with antibodies against 
CD4 and the eluates were subsequently blotted for CD4, to control the 
presence of the chimera in the precipitates, and with an antibody against 
ubiquitin. The lower panel in Figure 7.8 A shows that the wt SIV cytoplasmic 
domain (SIV Y) as well as the GY-deletion mutant (SIV dGY) and the S/P 
mutant (SIV S/P) were strongly ubiquitinated (lanes 1, 4 and 7). The ubiquitin 
blot displayed a single band suggesting only one most possibly mono- 
ubiquitinated form of the proteins was present (the size of CD4-SIV Env is 76 
kD). The strong band at the top of the blot is the mouse IgG used for the IP, 
which was recognised by the secondary anti-mouse HRP reagent.
Subsequently, the effects of WWP2 on CD4-Env ubiquitination were analysed 
by co-expression of YFP-WWP2 or the YFP-WW-domain. WW-domains on 
their own bind strongly to PPxY motifs and may inhibit binding of the
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Figure 7.8. Ubiquitination of CD4-SIV Env constructs. HEK293T cells were transfected with 
CD4-SIV Env constructs and YFP-WWP2 or the YFP-WW-domain as indicated. Lysates were 
immunoprecipitated 48 hr post-transfection with anti-CD4 #19. Eluates were blotted against 
CD4 with Q4120 (upper panels) or with anti-ubiquitin P4G7 (lower panels). Panel (A) shows 
effects of WWP2 and the WW-domain on ubiquitination of the CD4-chimeras, while panel (B) 
shows ubiquitination of PPxY mutant constructs. Co-expression of WW-domains is indicated 
with “+’ in panel (B). Arrows indicate bands for CD4-SIV Env in all panels.
catalytically active HECT ubiquitin ligase; they also inhibit the budding of 
retroviruses using PPxY type L-domains (Martin-Serrano et al. 2005). 
However, in this system dominant negative effects were hard to detect. The 
bottom panel in Figure 7.8 A shows that ubiquitination of SIV S/P, but not the 
other two constructs analysed was slightly enhanced, when VWVP2 was 
expressed (lane 8). Expression of the WW-domain led to a reduction of the 
signal for SIV Y-ubiquitin and possibly also SIV S/P-ubiquitin (lanes 3 and 9), 
but these results were difficult to reproduce. Preliminary experiments analysing 
the incorporation of recombinant HA-ubiquitin suggested that an enhancing 
effect of WWP2 and an inhibitory effect of the WW-domain respectively, may 
exist for ubiquitination of the SIV S/P construct (data not shown).
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In order to investigate whether ubiquitination is influenced by the PPxY motif, a 
CD4-Env construct with a PP/AA mutation was expressed and analysed for 
ubiquitin by western blots in parallel with the previously tested constructs. 
Surprisingly, a strong band for an ubiquitinated variant of the protein was 
detected (Figure 7.8 B lane 7). The signal was not markedly reduced when the 
WW-domain of W W P2 was co-expressed. The reduction observed in the blot 
was due to a smaller amount of protein as detected in the blot for CD4 
(compare lanes 8 in top and bottom panels in Figure 7.8 B). These results 
suggest that the PPxY and potentially also WWP2 have no direct influence on 
ubiquitination of the CD4-SIV Env chimera. However, it has to be considered 
that the proteins were over-expressed in these experiments and that ubiquitin 
may be incorporated by other ligases.
7.4.2. Mono- versus poly-ubiquitination
The results in Figure 7.8 suggested that CD4-SIV Env chimera were 
ubiquitinated independently of the PPxY motif and possibly also WWP2. 
Analysis of the band size in Figure 7.8 indicated that only one ubiquitin moiety 
was incorporated into each protein. However, it was possible that the antibody 
labelling was non-specific. The experiments were therefore repeated using two 
alternative antibodies for the detection of ubiquitination. Antibody FK1 
recognises exclusively poly-ubiquitin chains, while antibody FK2 can recognise 
both poly- and mono-ubiquitin. The CD4-Env constructs SIV Y and the PPxY 
mutant SIV Y PP/AA were analysed. Blotting with antibody P4G7 as used in 
the experiments described above showed strong bands for both constructs 
(Figure 7.9 A). Both bands almost completely disappeared when FK1 was 
used for blotting, even though eluates from the same IP were used (Figure 7.9 
B). When the samples were blotted with antibody FK2 bands for both CD4-Env 
constructs were detected (Figure 7.9 C). These results suggest that antibody 
P4G7 used in the previous experiments (Figure 7.8) did indeed recognise 
ubiquitin moieties, and they further confirm that CD4-Env constructs may be 
mono-ubiquitinated.
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Figure 7.9. Mono- vs. Polyubiquitination of CD4-SIV Env chimera. HEK293T cells were 
transfected with CD4-SIV Env constructs as indicated. The cells were lysed 48hr post­
transfection and the post-nuclear supernatants immunoprecipitated with anti-CD4 #19. Eluates 
were blotted with either anti-ubiquitin P4G7 as shown before (A), anti-ubiquitin FK1 
recognising only poly-ubiquitination (B) or anti-ubiquitin FK2 recognising mono- and poly­
ubiquitination (C). CD4-SIV Env bands are marked with an arrow.
7.4.3. Analysis of potential ubiquitination sites
Ubiquitination of proteins usually occurs via a covalent linkage of ubiquitin 
moieties to lysine residues. However, only two lysines are present in the 
cytoplasmic domain of SIV Env and neither of them is conserved (see Figure 
7.10 A, shaded in blue). It was recently reported that a viral E3 ligase can 
catalyse ubiquitination of cysteine residues (Cadwell 2005). One single 
conserved cysteine is present in the Env cytoplasmic tail (see Figure 7.10 A, 
shaded in pink, and compare Figure 7.1). Apart from this, a cysteine is found in 
the spacer sequence introduced into the CD4-Env chimera. Cadwell and 
colleagues also demonstrated that cysteine-ubiquitination but not lysine- 
ubiquitination is sensitive to reduction by fc-mercaptoethanol. Thus, I 
performed an experiment where lysates from SIV Y or SIV S/P transfected 
HEK293T cells were precipitated in two parallel reactions with anti-CD4. One 
reaction was eluted at non-reducing conditions and neutral pH, while the other 
reaction was eluted in the presence of fe-mercaptoethanol at pH 11. The 
samples were blotted with anti-CD4 and anti-ubiquitin P4G7. Strong bands for
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both constructs were observed under the first condition (Figure 7.10 C). Under 
the second condition both, the band for SIV Y-ubiquitin and SIV S/P-ubiquitin 
disappeared. A band observed at a molecular weight of 50 kD represented the 
reduced antibody heavy-chain.
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Figure 7.10. Lysine versus Cysteine Ubiquitination. The sequence of CD4-SIV Env chimera is 
shown in (A). The CD4 transmembrane domain and the 4 aa spacer (see Fig. 3.3) are 
depicted in green, lysines are highlighted in blue and cysteines in pink. For panels B, C and D 
HEK293T cells were transfected with CD4-SIV Y or CD4-SIV S/P chimera as indicated. The 
cells were lysed 48 hr post-transfection and lysates were precipitated with anti-CD4 #19 on 
ProteinA -sepharose beads. Proteins were eluted from the beads with non-reducing sample 
buffer at neutral pH (B and C) or with reducing sample buffer at pH 11 (D). Eluates were blotted 
with anti-CD4 Q4120 (A) or with anti-ubiquitin P4G7 (C and D). Bands for CD4-SIV Env are 
indicated with arrows.
These preliminary results suggest that cysteine-ubiquitination may occur in 
both the wt SIV Env cytoplasmic domain and in the mutant that binds stronger
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to W W P2. To confirm these findings we are currently mutating lysines as well 
as cysteines in the CD4-SIV Env chimera.
7.5. Functional analysis of the WWP2/SIV Env interaction
The above data showed that the SIV Env cytoplasmic domain binds to the 
HECT ubiquitin ligase W W P2 in a PPxY dependent manner. The interaction is 
enhanced when a serine preceding the PPxY motif is mutated to proline. Such 
a mutation had spontaneously occurred in a virus with a deletion in the GYxx0  
motif and was crucial for pathogenesis (Fultz et al. 2001). One possible way of 
affecting pathogenesis would be, that a WW P2 interaction plays a role in Env 
incorporation into budding virus and therefore ensures infectivity.
Functional assays to test this hypothesis are currently in progress. It was 
previously shown that co-transfection of proviral plasmids and YFP-fusion 
proteins of HECT ubiquitin ligases can be used to analyse the ability of the 
ligases to enhance or inhibit viral budding (Martin-Serrano et al. 2005). We will 
attempt to use a similar assay to analyse Env incorporation into virions. 
HEK293T cells will be transfected with SIV proviral plasmids encoding wt Env 
or mutants with a deletion in the G Yxx0 motif, the deletion plus an S/P 
change, or PP/AA changes in the PPxY motif. Together with the proviral 
plasmids we will transfect YFP-fusion proteins of either full length WWP2 or 
the inhibitory WW-domain, as described above. Viral particles will be 
harvested from the cell supernatant and purified by centrifugation through a 
20% sucrose cushion. The viral proteins will then be analysed by western 
blotting against SIV Gag and Env, and the ratio of these two proteins will be 
used as a read-out for Env incorporation.
It is possible that wt Env will be incorporated into virions independently of 
WWP2, since alternative mechanisms, potentially mediated by the GYxx0 
motif, may be present. Incorporation of a GY deletion mutant is believed to be 
reduced based on the results by Fultz et al., again independently of WWP2. 
However, a deletion mutant with the S/P change should rescue Env 
incorporation in a manner that can be inhibited by the dominant negative YFP-
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WW-domain. An effect of PPxY mutations is expected to be seen in 
combination with a GY deletion and the S/P change, but possibly not in the 
context of the wt Env.
7.6. Discussion
Chapter 6 of this study provided some insight into potential mechanisms 
underlying Env incorporation into budding virus. However, while the ESCRT 
machinery might facilitate sorting of Env onto the membrane of virions, it is not 
understood how Envs are brought into proximity of ESCRTs, and direct 
recruitment of ESCRT-I components by Env itself was not observed (see 
chapter 6). Trafficking data collected using HIV Env (see chapter 4) provided 
evidence that Env contains determinants that can directly target it to sites of 
virus assembly independently of other viral components, but no such evidence 
has been shown for SIV Env yet. Previous studies suggested that the 
membrane proximal G Yxx0 motif in the Env cytoplasmic domain has a direct 
effect on viral pathogenesis. Deletions in this motif were compensated for by a 
novel S/P mutation, which rescued pathogenic effects of SIV in an infected 
macaque (Fultz et al. 2001). The mutation occurred in an amino acid directly 
preceding a sequence PPSY, which is partially conserved in HIV-2 and SIV 
strains but not in HIV-1 or SIVCpZ. PPxY is a consensus motif that can bind to 
the WW-domains of Nedd4-family HECT ubiquitin ligases.
I performed a directed yeast-2-hybrid analysis and demonstrated that SIV Env 
cytoplasmic domains can indeed bind a HECT ubiquitin ligase, namely the 
Nedd4-family member WWP2. This binding appears to be very specific, since 
no binding to other Nedd4 ligases was detected. Recently, it was shown that 
W W P2 also plays a role in the budding of viruses carrying PPxY motifs as a 
late domain (Martin-Serrano et al. 2005). However, the activity of this motif 
appeared to be context dependent, and it was non-functional when 
transplanted into some other viruses (Martin-Serrano et al. 2004). I therefore 
speculated that in an in vivo situation the PPxY motif in SIV Env may only be 
used when it is preceded by a proline, as seen in the compensatory S/P 
mutation discovered in the monkey experiment. Further, it was shown that the
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interaction with Nedd4 ubiquitin ligases can be crucial for targeting viral Gag 
proteins to endosomal membranes and facilitating interaction with components 
of the ESCRT-I complex (Blot et al. 2004). W W P2 is therefore a strong 
candidate for Env targeting to virus assembly sites.
We used GST-pull down experiments to verify the Env-WWP2 interaction in a 
yeast-independent system and showed that even though wt SIV Env or 
mutants carrying a deletion in the G Yxx0 motif bind WWP2, the interaction is 
stronger when a S/P mutation is present. In either case though, binding is 
clearly dependent on the PPxY motif and is abrogated by mutation of either the 
di-proline or the tyrosine residue. This suggests that the S/P change may lead 
to exposure of the PPxY motif and then either promote the use of an 
alternative pathway for Env targeting to assembly sites or at least favour the 
use of an already existing mechanism. This hypothesis is further supported by 
the observation that SIV Env S/P, but not the wt is able to recruit WW-domains 
in a cell system.
Further, I showed that CD4-SIV Env chimeras are strongly mono-ubiquitinated, 
a result that was expected, since PPxY sequences can promote ubiquitination, 
even when taken from their original context (Martin-Serrano et al. 2004). 
Surprisingly, ubiquitination appears to be independent of the PPxY motif, and 
little evidence of an involvement of WWP2 was found, suggesting that another 
E3 ligase induces ubiquitination, and that interaction with WWP2 may have 
only a targeting function. Interestingly, ubiquitination is no longer detected after 
treatment of samples with the reducing agent fc-mercaptoethanol, which has 
been reported to remove cysteine-linked ubiquitin-moieties (Cadwell 2005). 
Since we are not aware of any viral ligases in our system, this would be the 
first indication of a cellular E3-ligase conjugating ubiquitin to cysteine. It is also 
striking that, while no lysines are conserved in the SIV Env cytoplasmic 
domain, there is one cysteine residue conserved in HIV-2 and the majority of 
SIV strains tested in our sequence alignment (compare Figure 7.1).
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Functional assays are now required to test whether an interaction with WWP2 
is essential for, or can enhance Env incorporation into virions. They will further 
elucidate whether the ligase has a functional role in targeting wt proteins to 
virus assembly sites or whether it is exclusively involved in an alternative 
pathway taken by the S/P mutant. These results will help to understand the 
mechanisms underlying Env incorporation into budding virus and extend our 
knowledge of how infectious viruses are formed.
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8. General Discussion
The Env protein of lentiviruses is required for binding the viral receptors and 
co-receptors and fusion with the host cell membrane. Hence, its integration 
into budding virions is essential for the generation of infectious virus and viral 
pathogenesis. It is therefore crucial that Env is transported to the site of virus 
assembly in the host cell. Despite the recent progress in understanding HIV 
assembly and budding, the mechanism of Env incorporation into virions is not 
well understood, and most work focussed on the Gag protein. This thesis 
concentrates on Env trafficking and targeting, and it provides evidence that 
Env is routed via the plasma membrane and re-endocytosed by interaction of 
two internalisation motifs in its cytoplasmic domain with the clathrin machinery 
(Chapter 3). Moreover, Env contains determinants that allow it to be targeted 
to the virus assembly site, an endocytic compartment characterised by the 
tetraspanin CD81, independently of other viral proteins (Chapter 4). This 
compartment appears to be different from a CD63 positive late endosome 
(Chapter 5). Initial observations suggest that both, HIV-1 and SIV Env 
cytoplasmic domains may interact with components of the ESCRT machinery 
required for virus budding that could facilitate Env incorporation into virions 
(Chapter 6). A motif in the SIV Env cytoplasmic domain additionally binds the 
HECT E3-ubiquitin ligase WWP2, and may enable Env delivery to the budding 
machinery, although a mechanism for this process remains to be 
demonstrated (Chapter 7). The different aspects of these findings and their 
importance for understanding the molecular mechanisms underlying HIV and 
SIV pathogenesis will be discussed.
8.1. HIV Env endocytosis
As an enveloped virus, HIV assembles at a membrane interface where 
oligomerisation of Gag complexes is co-ordinated with the incorporation of Env 
into budding viral particles. Thus it is essential that Env be targeted to the 
correct sites in the cell, where virus assembly and budding occur. However, 
the precise site of assembly appears to vary in different HIV target cells. In T 
cells assembly occurs predominantly at the plasma membrane, while in
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macrophages HIV assembles on intracellular membranes of a multivesicular 
organelle (Raposo et al. 2002; Pelchen-Matthews et al. 2003). Thus Env must 
contain trafficking signals, and follow cellular trafficking pathways that allow 
infectious particle assembly in apparently distinct locations. Previously, a 
number of labs have identified trafficking signals in HIV and SIV Env that 
mediate endocytosis (LaBranche et al. 1995; Rowell et al. 1995; Bowers et al. 
2000; Wyss et al. 2001), polarised sorting (Lodge et al. 1997) and recycling to 
the TGN (Blot et al. 2003), through interaction with diverse components of the 
vacuolar trafficking machinery including the clathrin-adaptor complexes AP-1 
and AP-2 and the putative late endosome-Golgi recycling protein TIP47. Of 
these motifs, the highly conserved membrane proximal GYxx0 motif (Y712 in 
HIVHxb2 and Y721 in S IVmac239) is the most extensively characterised. This motif 
binds both AP-1 and AP-2 adaptors (Ohno et al. 1997; Boge et al. 1998; 
Berlioz-Torrent et al. 1999; Bowers et al. 2000; Wyss et al. 2001) and 
mediates both, endocytosis from the cell surface (LaBranche et al. 1995; 
Rowell et al. 1995; Bowers et al. 2000; Wyss et al. 2001) and polarised sorting 
when expressed in MDCK cells (Lodge et al. 1997). It was demonstrated that 
Env endocytosis is fast and thus surface expression levels are generally low. 
(Bowers et al. 2000). Apart from its targeting function the GYxx0 motif in SIV 
Env is essential for pathogenesis (Fultz et al. 2001).
Previous experiments with SIVmac239 Env suggested that apart from the 
conserved G Yxx0 signal, additional endocytosis information is present in the 
full-length Env protein (Bowers et al. 2000). Here I show the same is true for 
HIVHxB2 Env, and I identify the C-terminal dileucine as the relevant motif. 
Dileucine motifs have previously been demonstrated to act as endocytosis and 
trafficking motifs in studies with a range of cellular proteins including MHC-II, 
CD4 and CI-M6PR, and are believed to interact with clathrin adaptor 
complexes (Marks et al. 1996), though the mode of binding is different to that 
of Yxx0 motifs (Bonifacino et al. 1996). The C-terminal dileucine motif is highly 
conserved in SIV and HIV Env (compare Figure 7.1), however, it was 
suggested that it plays no role in SIVmac239 Env endocytic trafficking (Bowers et 
al. 2000), while I show here that the motif in HIVHxb2 Env clearly acts as an
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endocytosis signal that operates through clathrin AP-2 adaptors. This signal is 
independent of the membrane G Yxx0 motif, but is equally efficient, and I show 
that these two motifs account for all the endocytosis information present in the 
HxB2 Env cytoplasmic domain.
The presence of two endocytosis signals indicates that the virus has 
developed a belts and braces mechanism to ensure internalisation of envelope 
proteins, suggesting that control of cell surface levels of Env may well 
contribute to viral evasion of humoral immune responses. As an external 
component of viral particles, Env is a primary target for host immune 
responses (Wyatt and Sodroski 1998), and Env expression on the surface of 
infected cells can lead to recognition by antibodies and subsequent killing of 
the cell before new virus can be formed and released. Internalisation of Env 
may therefore be crucial not only for targeting to assembly sites in 
macrophages, but also to ensure long-term infection and turn cells into viral 
fortresses. In addition, Env internalisation will limit Env-mediated cytopathic 
effects, such as cell-to-cell fusion.
The experiments presented in this thesis underline the notion that the 
trafficking of HIV Env, and presumably SIV Env as well, is tightly regulated and 
likely to be important for the correct assembly of infectious virus particles and 
therefore for pathogenesis (Fultz et al. 2001). Significantly, my results suggest 
that there are differences in the trafficking signals in SIV and HIV Env, which 
may explain why short tail Env variants emerge during SIV propagation in 
cultured human T cell lines but similar HIV variants do not. Nevertheless, a full- 
length Env protein does appear to be required for SIV infection and 
pathogenesis in vivo (Kodama et al. 1989). How exactly the signals studied 
here in the model system of a HeLa cell operate in relevant host cells remains 
to be established.
In the main, HIV is thought to assemble at the plasma membrane of T cells. 
The finding that the two endocytosis signals keep the plasma membrane levels 
of Env low may explain why HIV particles collected from cultured T cell lines
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have relatively low levels of Env protein (av. 7-10 spikes/virion; (Chertova et al. 
2002; Zhu et al. 2003). By contrast, the conserved signals may have a more 
significant role in infected macrophages, where HIV assembles on endocytic 
membranes and not at the plasma membrane. Preliminary results in our lab, 
based on immuno labelling of cryosections suggest that Env levels in 
macrophage-derived HIV may be higher than those in T cell-derived virus 
(Pelchen-Matthews et al. unpublished). Whether the GYxx0 and/or the 
dileucine motif contribute to this increased incorporation remains to be 
established, Moreover, the fact that SIVmaC239 carrying GYxx0 mutations is 
non-pathogenic, even though these proteins continue to undergo endocytosis 
through the activity of a second, yet to be identified, signal (Bowers et al. 
2000), suggests the G Yxx0 signal has roles in addition to its activity as an 
endocytosis signal. The genetic conservation of trafficking signals throughout 
the primate lentiviruses, plus selection for wt sequences in animals infected 
with mutant viruses (Fultz et al. 2001) indicates Env endocytosis and trafficking 
is important, if not essential, for lentiviral infectivity and pathogenesis.
8.2. Intracellular Env trafficking and targeting to virus 
assembly sites
As previously discussed, the formation of new infectious virions requires the 
spatially and temporally coordinated transport of all viral components, in 
particular Env and Gag, to assembly and budding sites within an infected cell. 
However, it is still unknown how the location for particle production is chosen 
and regulated, and it is not clear whether Gag or Env specify the primary site 
of virus assembly. It has been reported that Gag can recruit Env to distinct 
membrane areas (Hermida-Matsumoto and Resh 2000), while Env seems to 
increase Gag accumulation in others (Nydegger et al. 2006). For many 
retroviruses budding has long been known to occur at the plasma membrane, 
and it has been believed that Env plays a key role in targeting virus assembly 
to certain membrane domains. Accordingly, in polarised cells the GYxx0 
sorting signal in the Env cytoplasmic domain was shown to promote virus 
release from basolateral membranes (Lodge et al. 1997). However, the 
findings that in macrophages HIV is budding into an endosomal compartment,
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and the observation that Env is rapidly internalised from the plasma membrane 
and resides in a perinuclear compartment at steady state put this theory in 
question.
Previously, it was demonstrated that Gag expression is not only essential, but 
also sufficient for particle formation, and Gag can directly target membranes, 
from which VLPs are then released. HIV-1 Gag is primarily localised to the 
plasma membrane in T cells and model systems, such as HeLa or COS-1 cells 
(Hermida-Matsumoto and Resh 2000), while in macrophages a multivesicular 
endosomal compartment is clearly the site for Gag localisation and particle 
production (Raposo et al. 2002; Pelchen-Matthews et al. 2003). Several 
potential mechanisms for Gag targeting to these sites have been suggested 
recently. The presence of certain molecules in a membrane may trigger Gag 
accumulation and it has been shown that Gag distribution is influenced by the 
phospho-inosite PI(4,5)P2. Depletion of this molecule leads to a decrease in 
virus release. Even though in general PI(4,5)P2 seems to target Gag to the 
plasma membrane, it has been observed together with Gag on late 
endosomes (Ono et al. 2004).
Another theory is that Gag multimerisation and capsid assembly, which is 
believed to happen in the cytosol in an ATP-dependent way (Lingappa et al. 
2006), may lead to a myristoylation-dependent localisation to membrane 
regions of lipid rafts and the formation of so-called membrane barges 
(Lindwasser and Resh 2001). Evidence has further been given for HIV budding 
from raft-like membrane domains (Nguyen and Hildreth 2000), and lipid rafts 
containing cholesterol are required for the formation of viral synapses between 
T cells (Jolly and Sattentau 2005). Localisation to detergent resistant 
membrane domains has also been proposed for Env, dependent on 
palmitoylation of a cysteine residue (Yang et al. 1995; Rousso et al. 2000; 
Bhattacharya et al. 2004), but recently it has been suggested that this targeting 
may indeed be regulated by an interaction with Gag (Bhattacharya et al. 2006).
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In order to reach specific membranes both Gag and Env must hijack the 
cellular trafficking machinery. Intracellular pathways have been suggested for 
the routing of Gag, and it was demonstrated that the protein passes from a 
diffuse cytoplasmic distribution to a perinuclear area and transits MVBs before 
reaching the plasma membrane (Perlman and Resh 2006). Such a pathway 
would be compatible with MVB and plasma membrane budding models, if Gag 
containing MVBs constantly exocytose. In agreement with this theory is the 
observation that HIV Gag can bind the clathrin adaptor AP-3, which is required 
for MVB targeting from the TGN and particle release (Dong et al. 2005). In 
addition, Gag contains a dileucine signal that binds to AP-2 and mediates 
endocytosis from the plasma membrane (Lindwasser and Resh 2004), it may 
therefore be possible that the protein is recycling and transiently passing 
potential budding sites. Interaction with certain membrane components, parts 
of the budding machinery or even Env may then trigger arrest and lead to 
budding.
In this thesis I show that Env is also hijacking the cellular trafficking machinery 
to recycle between the plasma membrane and intracellular compartments. 
After de novo synthesised protein is exported to the plasma membrane, it is 
internalised to the endocytic pathway through an interaction with AP-2, it 
passes through early endosomes and eventually reaches a compartment, 
characterised by the tetraspanin CD81 and similar to the MVBs targeted by 
Gag, where it is predominately observed at steady state. Like Gag, Env is 
transported to perinuclear areas positive for TGN markers and can be recycled 
back to the plasma membrane. The determinants for MVB targeting are 
different from the signals responsible for internalisation, but remain elusive to 
date. An interaction between Env and AP-3 has been detected earlier (Ohno et 
al. 1997) raising the possibility that Gag and Env may use the same adaptor 
protein for MVB targeting, consistent with the presence of infectious particles 
in this compartment (Pelchen-Matthews et al. 2003). However, I can exclude 
that an interaction between Gag and Env is necessary to promote AP-3 
binding and delivery to MVBs, since no other viral components are essential 
for Env colocalisation with CD81. Neither does co-expression of Gag alter the
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distribution of Env lacking internalisation signals and therefore residing at the 
plasma membrane. I therefore suggest that both Gag and Env contain their 
own intrinsic targeting information, which delivers them to the correct sites of 
viral assembly. This site most possibly depends on the type of the cell and the 
composition of membranes. Trafficking through assembly sites may be 
transient and only be arrested, when Gag and Env are present in the correct 
membrane environment at the same time. Support for this hypothesis is given 
by earlier observations suggesting that Gag can trap Env at the plasma 
membrane inhibiting internalisation, possibly by masking of endocytosis 
signals (Egan et al. 1996).
In the model system of a HeLa cell, as well as in macrophages, Env targets a 
compartment that is enriched in the tetraspanin CD81, but not the classical late 
endosomal marker CD63. Even though the morphology of the compartment 
appears different in the two cell types, it is similar in relation to other endocytic 
compartments. Colocalisation with CD81 is found in cells transiently 
expressing Env as well as in infected cells, surprisingly though, while CD63 is 
excluded from the Env localisation site in cells expressing solely Env, it is 
present in virus containing compartments, and is even incorporated into the 
envelope of de novo formed virions (Pelchen-Matthews et al. 2003). It is thus 
possible that the virus may not use a pre-existing compartment for budding, 
but modify it through recruitment of different membrane proteins. Further 
evidence for this theory is provided by the fact that AP-3 is involved in CD63 
trafficking (Dell'Angelica et al. 1999; Rous et al. 2002) and Gag and CD63 may 
traffic to late endosomal compartments together. A modification of the budding 
membrane by HIV may also explain why the virus is budding from so-called 
tetraspanin-enriched microdomains (TEMs) at the plasma membrane 
containing CD63 in combination with CD81 and/or CD9, even though surface 
CD63 expression is generally low (Nydegger et al. 2006).
Whether TEMs are present at MVB budding sites is questionable. Light 
microscopy detects colocalisation of Env and Gag with the teraspanins CD63, 
CD81 and CD9 in infected cells, ultrastructural analysis however shows that,
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while the viral proteins are localised to the limiting membrane of MVBs, the 
tetraspanins are predominately found on internal membranes. At first glance, it 
also seems that involvement of TEMs and lipid raft domains in HIV budding 
are mutually exclusive, since markers for detergent resistant membrane 
domains are not found in TEMs (Nydegger et al. 2006). HIV though seems to 
modify the membranes from where it buds, and it may be possible that either 
rafts are only formed upon Gag polymerisation, or tetraspanins are included 
into membrane regions positive for lipid raft markers, where they do not 
normally localise. Both types of microdomains are believed to form large 
integrated signalling platforms, and even though they exist as separate 
entities, they have been shown to interact physically and functionally 
(Cherukuri 2004; Delaguillaumie 2004).
Despite the uncertainty about HIV budding association with TEMs, 
tetraspanins may play a role in the biology of the virus, and there are several 
examples of tetraspanin involvement in the life cycles of other viruses. CD81 is 
a potential receptor for HCV and may interact with the viral envelope protein 
E2 (Pileri et al. 1998), in addition, an interaction between E2 and CD81 also 
seems to lead to an incorporation of E2 into TEMs facilitating glycoprotein 
translocation into exosomes during viral exit (Masciopinto et al. 2004). Similar 
mechanisms may thus exist for tetraspanins and HIV, since HIV budding bears 
similarities to exosome biogenesis and tetraspanins are enriched on 
multivesicular bodies. Further, mechanisms involving tetraspanins may not 
only be relevant in intracellular MVB budding, but also where HIV is budding 
from the cell surface. It has recently been demonstrated that Gag is associated 
with endosome-like domains at the plasma membrane (Booth et al. 2006). A 
role for tetraspanins in the HIV lifecycle in both types of target cells would 
further support the hypothesis that targeting of viral proteins to assembly sites 
and subsequent budding follow the same principles in both, macrophages and 
T cells. The decision of whether to bud intracellularly or at the cell surface may 
be entirely due to where membrane domains with a certain protein and lipid 
composition are located in the different cell types. The location of these
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domains may depend on secretory mechanisms present in the cell and on the 
cells role in host biology.
8.3. Mechanisms for Env incorporation into budding virions
I have shown in this thesis that Env contains determinants that enable its 
delivery to the compartment of virus assembly independently of other viral 
components. However, how Env is arrested in this compartment or how it is 
sorted to the correct membrane domains remains unclear. Potential 
mechanisms include the direct interaction between Env and Gag or the 
enrichment in defined membrane domains caused by post-translational 
modifications, e.g. palmitoylation, as discussed above. It may also be possible 
though that Env can directly interact with parts of the ESCRT-budding 
machinery, facilitating a highly regulated sorting and efficient incorporation into 
viral particles.
Indeed, both HIV and SIV Envs contain amino acid motifs in the cytoplasmic 
domain of gp41 that are similar to consensus late domain sequences found in 
retroviral Gag proteins (compare Figure 7.1 and Bieniasz 2006). A Yxx0 type 
motif and an LxxL motif are present in all strains of HIV-1, HIV-2 and SIV 
analysed in a sequence alignment, while a PPxY motif is exclusively found in 
HIV-2 and some SIV strains but not HIV-1 or SIVcpz. The Env cytoplasmic 
domains were tested for potential interactions with ESCRT components, and I 
indeed found that both HIV and SIV Envs bind the ESCRT-I protein Vps37B. In 
addition, SIV Env binds to the Nedd4-family HECT ubiquitin ligase WWP2, 
which has previously been implicated in retrovirus assembly (Martin-Serrano et 
al. 2005). HECT ligases are involved in the ubiquitination of cellular protein 
cargos and directing them to MVBs (see section 1.5.1.3.), but they can also 
link viral Gag proteins to the ESCRT-I complex (Blot et al. 2004). The 
presence of an additional L domain-like motif in SIV Env suggests that 
differences between SIV and HIV are not only found in terms of endocytosis 
(see above), but also in the mechanisms for Env incorporation into virions and 
that, despite the high degree of sequence conservation, the viruses have 
evolved their own strategies to exploit the machineries of the host cell.
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Based on the discovered interactions, I propose that incorporation of envelope 
proteins into budding virions is a multi-step process with distinct features for 
HIV and SIV. Initially the Envs of both virus types are sorted to the plasma 
membrane, from where they can be internalised through interactions with the 
clathrin adaptor complex AP-2 and are fed into the endocytotic pathway. 
Differences between the two virus types at this stage of sorting have been 
discussed above. HIV and SIV Envs are then targeted to a perinuclear 
compartment from where they can recycle to the surface. However, after 
internalisation from the plasma membrane the pathways taken by HIV and SIV 
Envs may be dividing. I have shown that SIV Envs can interact with WWP2 
through their PPxY motifs and may be concomitantly ubiquitinated either by 
W W P2 itself or by another cellular E3 ubiquitin ligase. Since I could not show a 
dependency of ubiquitination on the PPxY motif, this step remains unclear, and 
it is possible that ubiquitination may be completely independent of the WWP2 
interaction and that W W P2 is binding to the already ubiquitinated Env. 
Subsequently, Env is targeted to the membranes of an endosomal 
compartment, where Gag is localised and to where the ESCRT-machinery is 
recruited. A direct interaction either with Gag and/or ESCRT components, 
possibly Vps37B, then leads to an arrest of Env at these particular membranes 
and possibly deubiquitination, as previously observed for Gag (Martin-Serrano 
et al. 2004). This potential mechanism shows analogies to a targeting 
mechanism previously discovered for HTLV-1 Gag, where an interaction with 
Nedd4.1 and subsequent ubiquitination lead to internalisation of the protein 
and delivery to membranes of an MVB-like endosome. Binding to Tsg101 and 
deubiquitination then trigger budding of the virus (Blot et al. 2004). While for 
HTLV-1 Gag the encounter of the HECT ubiquitin ligase happens at the 
plasma membrane, it is unclear where SIV Env meets WWP2. Since Envs are 
permanently internalised and their expression at the cell surface is low, it is 
likely that the interaction happens in the endocytotic pathway. There is also no 
indication of W W P2 mediating endocytosis of Env, since mutation of the PPxY 
motif in combination with a deletion in the GYxx0 endocytosis signal did not 
lead to an accumulation at the plasma membrane.
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Figure 8.1. Mechanism for Env targeting to virus assembly sites. (A) Targeting of SIV 
Env, individual steps are numbered. 1: AP-2 mediated endocytosis, 2: WWP2 facilitates 
transport to assembly compartment, possibly via ubiquitination, 3: interaction with ESCRT-I 
and/or Gag leads to incorporation into virions. A potential mechanism for a dGY S/P mutant is 
boxed and indicated with dashed lines, 4: direct WWP2 mediated targeting from plasma 
membrane to assembly sites. (B) targeting of HIV Env, steps 1 and 3 are as described for SIV, 
step 2 shows TIP47 mediated targeting to assembly sites. Red arrows depict protein-protein 
interactions, black arrows show trafficking pathways.
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Fultz and colleagues showed that a deletion in the GYxx0 motif, which is 
detrimental for pathogenesis of SIV, can be compensated for by a S/P change 
directly preceding the PPxY motif (Fultz et al. 2001). I found that this mutation 
enhances the binding of SIV Env to WWP2, and can promote recruitment of 
the ubiquitin ligase in cells. The consequence of this stronger affinity for 
W W P2 may lead to protein-protein interaction at locations, where it does not 
normally occur. It may thus not be necessary for Env to be internalised before 
WW P2 is encountered, and an interaction with VWVP2 at the cell surface may 
facilitate direct targeting to budding sites on MVBs or at the plasma 
membrane. Assuming that endocytosis is essential for wt Env targeting to virus 
budding sites, a G Yxx0 deletion would affect pathogenesis in viruses 
encoding Env with short cytoplasmic domains, as used by Fultz and 
colleagues. Binding to W W P2 at the plasma membrane through the 
spontaneous S/P mutation could then rescue this defect without directly 
afflicting endocytosis. In summary, I suggest a three-step mechanism for SIV 
Env targeting to budding virions: Env is entering the endocytotic pathway via 
an AP-2 interaction, can then bind to WWP2 and is targeted to viral assembly 
sites, where it binds to components of the ESCRT-machinery (see Figure 8.1 
A).
The PPxY motif is not present in HIV-1 or SIVcpz, indicating that different 
means of targeting to assembly sites must exist. Recent studies have shown 
that HIV-1 Env can bind to TIP47, a protein which is responsible for transport 
between late endosomal compartments and the TGN, and it has been 
suggested that disruption of this interaction affects Env trafficking to late 
endosomes and viral infectivity (Blot et al. 2003). TIP47 binds to a motif YW  
that is conserved in HIV-1 and SIVcpz, but is disrupted by additional amino 
acids in SIV and HIV-2 (compare Figure 7.1). I thus suggest that TIP47 binding 
to the YW-motif may act in a similar way to WWP2 binding to PPxY, and 
provide a means of delivering Env to viral assembly sites. A three-step process 
similar to the one proposed for SIV can therefore be hypothesised for targeting 
of HIV-1 Env: Env is fed into the endocytotic pathway through an interaction 
with AP-2, subsequently binds TIP47 in an intracellular compartment, possibly
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the TGN, and is then transported to viral assembly sites, where it can bind to 
either Gag or components of the ESCRT-machinery (see Figure 8.1 B).
8.4. Future perspectives
This work demonstrates that targeting of both HIV and SIV Env is a highly 
regulated process, which is on the one hand determined by multiple trafficking 
signals in the gp41 cytoplasmic domain, and on the other by a strong 
dependence on several cellular proteins. Both viruses have evolved elaborate 
ways of usurping cellular pathways for their own purposes, and it is surprising 
that, despite the close relation and high sequence conservation, HIV and SIV 
Envs show several differences in their trafficking properties. These differences 
will have to be taken into account, when SIV is used as a model for HIV 
infection and human AIDS.
This thesis provides insights into protein-protein interactions between the 
lentiviral Envs and cellular proteins and suggests intracellular trafficking 
pathways and targeting mechanisms. However, further research will be 
necessary to elucidate the details of these mechanisms and show their 
relevance for virus biology in vivo. A detailed knowledge of Env trafficking will 
eventually lead to a deeper understanding of how infectious viruses are 
formed, which is a prerequisite for viral pathogenesis. In addition, studies 
aimed at the cellular machinery necessary for HIV and SIV protein targeting as 
well as virus assembly may explain why different budding sites appear to be 
used in T cells and macrophages and show their importance for the progress 
of viral spread and AIDS.
Anti-retroviral drugs so far were predominately aimed at early steps of viral 
infection, targeting the viral enzymes or the viral entry process, and were 
mainly useful in inhibiting T cell infection. A detailed understanding of virus 
protein targeting and virus assembly will provide us with a range of potential 
new drug strategies, aiming at eradicating virus spread through interference 
with Env incorporation into virions and thereby preventing the formation of new 
infectious virions. Inhibiting the release of infectious virus may though prove
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difficult, if HIV assembles in a pre-existing cellular compartment, which is 
needed for degradative or secretory purposes by the cell (see section 8.2), 
potential targets therefore need to be carefully evaluated. However, if a cellular 
compartment is modified by the virus e.g. through recruitment of specific 
membrane proteins, a selective inhibition of virus budding may be possible. 
Alternatively, the targeting mechanisms for viral Env and also Gag proteins 
could be affected by rendering signal sequences on the viral proteins 
themselves non-functional through binding of site-specific drugs. Thus, in order 
to develop successful anti-viral strategies, a detailed understanding of the 
molecular mechanisms underlying the formation of infectious virus is required.
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